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High throughput screening techniques that are routinely used in modern drug 
discovery processes result in a higher prevalence of poorly water-soluble drugs. Such 
drugs often have poor bioavailability issues due to their poor dissolution and/or 
permeability to achieve sufficient and consistent systemic exposure, resulting in sub-
optimal therapeutic efficacies, particularly via oral administration. Alternative 
formulations and delivery routes are demanded to improve their bioavailability. 
Nanoparticulate formulations of poorly water-soluble drugs offer improved dissolution 
profiles. The physiology of the lung makes it an ideal target for non-invasive local and 
systemic drug delivery for poorly water-soluble drugs.  
In Chapter 2, a particle engineering process ultra-rapid freezing (URF) was 
utilized to produce nanostructured aggregates of itraconazole (ITZ), a BCS class II drug, 
 viii
for pulmonary delivery with approved biocompatible excipients. The obtained 
formulation, ITZ:mannitol:lecithin (1:0.5:0.2, w/w), i.e. URF-ITZ, was a solid solution 
with high surface area and ability to achieve high magnitude of supersaturation. An 
aqueous colloidal dispersion of URF-ITZ was suitable for nebulization, which 
demonstrated optimal aerodynamic properties for deep lung delivery and high lung and 
systemic ITZ levels when inhaled by mice. 
The significantly improved systemic bioavailability of inhaled URF-ITZ was 
mainly ascribed to the amorphous morphology that raised the drug solubility. The effect 
of supersaturation of amorphous URF-ITZ relative to nanocrystalline ITZ on 
bioavailability following inhalation was evaluated in Chapter 3. The nanoparticulate 
amorphous ITZ composition resulted in a significantly higher systemic bioavailability 
than for the nanocrystalline ITZ composition, as a result of the higher supersaturation that 
increased the permeation. 
In Chapter 4, pharmacokinetics of inhaled nebulized aerosols of solubilized ITZ 
in solution versus nanoparticulate URF-ITZ colloidal dispersion were investigated, under 
the hypothesis that solubilized ITZ can be absorbed faster through mucosal membrane 
than the nanoparticulate ITZ. Despite similar ITZ lung deposition, the inhaled solubilized 
ITZ demonstrated significantly faster systemic absorption across lung epithelium relative 
to nanoparticulate ITZ in mice, due in part to the elimination of the phase-to-phase 
transition of nanoparticulate ITZ. 
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Chapter 1: Inhaled Nanoparticles – A Current Review  
 
1.1 ABSTRACT 
The field of nanotechnology may hold the promise of significant improvements in 
the health and well being of patients, as well as in manufacturing technologies. The 
knowledge of this impact of nanomaterials on public health is limited so far. This paper 
briefly reviews the unique size-controlled properties of nanomaterials, their disposition in 
the body after inhalation, and the factors influencing the fate of inhaled nanomaterials. 
The physiology of the lung makes it an ideal target organ for non-invasive local and 
systemic drug delivery, especially for protein and poorly water-soluble drugs that have 
low oral bioavailability via oral administration. The potential application of pulmonary 
drug delivery of nanoparticles to the lungs, specifically in context of published results 
reported on nanomaterials in environmental epidemiology and toxicology is reviewed in 
this paper.  
 
1.2 OVERVIEW OF NANOMATERIALS 
In the current era of nanoscience, the use of nanotechnologies in commercial 
applications is increasing in many scientific disciplines, including electronics, sporting 
goods, tires, stain-resistant clothing, cosmetics, and medicine for diagnosis, imaging and 
drug delivery. 
 
'Nanoscience' and 'nanotechnologies' have been defined by the Royal Society and 
Royal Academy of Engineering [1, 2] as follows: 
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"Nanoscience is the study of phenomena and manipulation of materials at atomic, 
molecular and macromolecular scales, where the properties differ significantly from 
those at a larger scale"; likewise, "Nanotechnologies are the design, characterization, 
production and application of structures, devices and systems by controlling shape and 
size at nanometer scale".  
 
Nanomaterials, the building blocks for nanotechnology, are engineered materials 
with one or more components with at least one dimension measuring 100 nanometers or 
less. They include nanoparticles, nanofibers and nanotubes, composite materials and 
nano-structured surfaces. Nanoparticles, as a subset of nanomaterials, are currently 
defined as single particles with a diameter less than 100 nm. Agglomerates of 
nanoparticles can be larger than 100 nm in diameter but may be de-agglomerated with 
weak mechanical forces or by dispersing in a solvent. Nanofibers and nanotubes have two 
dimensions measuring less than 100 nm but the axial dimension can be much larger. 
 
1.3 CHARACTERISTICS OF NANOMATERIALS 
The main differentiating characteristic of nanomaterials is their size, which falls 
in the transitional zone between individual atoms or molecules and the corresponding 
bulk materials [3]. Size reduction can modify the physical and chemical properties of 
nanomaterials distinctively from their bulk and molecular counterparts. It is known that 
for a group of airborne particles with fixed mass (10 mg/m3) and unit density (1 g/cm3), 
as the particle size decreases to less than 100 nm, the number of particles increases 
exponentially along with the surface area, as shown in Figure 1.1. This allows a greater 
proportion of atoms or molecules to be orientated on the surface rather than within the 
interior of the material, hence allowing adjacent atoms and substances to interact more 
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readily. The surface-to-volume ratio determines the potential number of reactive groups; 
the intrinsic properties of materials at the nanosized level are emphasized compared to 
their larger bulk counterparts. The enhanced activities could be either beneficial (e.g. 
antioxidation, carrier capacity for drugs, increased uptake and interaction with biological 
tissues) or disadvantageous (e.g. toxicity, instability, induction of oxidative stress) 
depending on the intended use [4, 5].  
 
Independent of particle size, the charges carried by the materials in contact with 
cell membranes and the chemical reactivity of the materials play a dominant role when 
the particles react with other substances or tissues [6]. 
 
Due to the attractive properties of nanomaterials (summarized in Table 1.1.), such 
as high strength, conductivity, solubility, durability and reactivity, they have been used in 
a variety of applications, including fillers, opacifiers, catalysts, semiconductors, 
cosmetics, microelectronics, and drug carriers [4, 7]. However, as production and use of 
engineered nanomaterials have expanded, the potential impact to the environment and 
human health must be investigated and confirmed [8].  
 
Particle size and surface area of the nanomaterials are important characteristics 
from a toxicological viewpoint. Carbon black nanoparticles of similar mass and 
composition but with different specific surface areas (300 versus 37 m2/g) were studied. 
It was found that the biological effects, such as, inflammation, genotoxicity, and 
histology were related to surface area and not particle mass. Similar findings have been 
reported regarding tumorigenic effects of inhaled particles. It was shown that the tumor 
incidence correlated better with specific surface area than with particle mass [9, 10]. It is 
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recognized that biologically available surface area is probably the most critical parameter 
for the effects of the nanomaterials. Additionally, particle surface chemistry, 
biodegradability, number, shape, and solubility are all found to be significant factors in 
determining harmful biological effects [3, 11, 12]. 
 
Knowledge of the effects of nanomaterials on biological systems is limited due to 
the relative novelty of this technology, and little has been done to assess the risks of 
nanomaterials to biological systems. The current paradigm in environmental 
epidemiology is that adverse health effects of fine and ultrafine particulates, such as those 
found in air pollution and some workplaces, are driven by the ultrafine particle fraction, 
indicating that exposure to materials in the nano-size range could cause significant public 
health problems, such as pulmonary and cardiovascular diseases [13-15].  
 
1.4 THE LUNGS AS A DELIVERY TARGET FOR NANOMATERIALS 
The lungs, skin, and intestinal tract are in direct contact with the environment. 
These organs are likely to be a first port of entry for nanomaterials into the body. 
Epidemiological studies showed a positive correlation between increases in atmospheric 
particulate concentrations and the short term increases in morbidity and mortality [15, 
16]. Inhalation is the most significant exposure route for airborne nanoparticles [3, 4]. 
The lung consists of two functional parts, the airways (trachea, bronchi, and bronchioles) 
and the alveoli (gas exchange areas). The conducting zone consist of the first 16 
generations of airways comprised of the trachea (generation 0), which bifurcates into the 
two main stem bronchi, and subdivides into progressively smaller-diameter bronchi and 
bronchioles. The respiratory zone consists of all structures that participate in gas 
exchange and begins with the respiratory bronchioles [17]. The human lungs contain 
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about 2300 km of airways and 500 million alveoli [18]. The surface area of the human 
lungs is estimated to be approximately 75-140 m2 in adults [19-21]. The pseudostratified 
epithelia that constitute the barrier to absorption into the bloodstream are markedly 
different in airways and alveoli of the lungs. The airways are composed of a gradually 
thinning columnar epithelium, with the bronchial epithelium of 3-5 mm and bronchiolar 
epithelium of 0.5-1 mm in thickness [17, 22]. In the tracheo-bronchial region the 
epithelium is protected by a mucus layer [23]. Any particle deposited in this area is 
transported away from the lung by mucociliary clearance [24], or diffuse through the 
thick mucus to reach the epithelium cells. In contrast, the alveoli have a thin, single cell 
layer. The distance from the air in the alveolar lumen to the capillary blood flow is less 
than 400 nm. The large surface area of the alveoli and the intimate air-blood contact in 
this region make the alveoli less well protected against inhaled substances, such as 
nanoparticles, as compared to the airways [23]. 
 
1.5 DEPOSITION OF NANOMATERIALS IN THE RESPIRATORY TRACT 
There are three principal mechanisms that lead to pulmonary deposition: inertial 
impaction, gravitational sedimentation, and Brownian diffusion, as summarized in Table 
1.2. The inertial impaction occurs during the passage through the oropharynx and large 
conducting airways if the particles possess a mass median aerodynamic diameter 
(MMAD) more than 5 micron. When the MMAD of particles ranges from 1 to 5 microns, 
they are subject to sedimentation by gravitational force that occurs in smaller airways and 
respiratory bronchioles. Sedimentation is influenced by breath-holding. Particles with a 
MMAD of less than or equal to approximately 0.5 micron, they are deposited 
significantly by diffusion, based on the Brownian motion [23, 25, 26]. 
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The site, extent and efficacy of particle deposition after inhalation is influenced 
primarily by three factors (aerosol properties and physiology) during breathing: (a) 
particle/droplet size (diameter), density, surface properties, or shape (i.e. fibers) [27]; (b) 
anatomy of the upper and lower airways and the alveolar structure; (c) ventilatory 
parameters with impact on the particle deposition are breath pattern (including breath-
holding and presence of expiratory flow limitation), flow rates and tidal volume, 
determining the airflow velocity and the residence time in the respiratory tract [25, 28, 
29].  
 
Next to morphological characteristics and ventilation parameters, the particle size 
and geometry is most important [25]. The particle size is commonly referred to the 
aerodynamic diameter, which is a variable depending on the shape, density and size of 
the object. If aerosols contain different particles, the size distribution is usually 
characterized by MMAD, which is particularly important to determine whether the 
particles will be efficiently deposited deep into alveolar region [21, 30]. A successful 
deposition into deep lung requires the particles be small enough to avoid deposition by 
inertial impaction on upper airways and can pass through the lower airways, meanwhile 
be large enough to avoid exhalation [31, 32]. The optimal particle size for achieving 
delivery deep into alveolar region has been established to be an aerodynamic diameter 
between 1 and 3 microns [33]. In general, aerosol particles measuring less than 1 micron 
can be exhaled up to 80% after inspiration without being deposited, because of their low 
inertia [34, 35]. The deposition of particles in the lung; however, is bi-model and ultra 
fine particles (less than 100 nm) appear to settle effectively to the alveolar region with a 
fractional deposition of around 50%, as calculated with mathematical modeling of 
monodisperse particles after slow inhalation with a breath hold (see Figure 1.2.) [23, 33, 
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36]. This has been confirmed by controlled clinical studies evaluating deposition and 
effects of laboratory-generated ultra fine particles. High deposition efficiencies in the 
total respiratory tract of healthy subjects were found, and deposition was even greater in 
subjects with asthma or chronic obstructive pulmonary disease [37, 38]. 
  
Nanoparticle deposition in the respiratory tract is determined predominantly by 
diffusional displacement due to the thermal motion of air molecules interacting with 
particles in the inhaled and exhaled air streams [39, 40]. Depending on the particle size, 
shape and ventilation parameters, deposition occurs in all regions of the lung: the airways 
and the alveoli. With decreasing particle diameter below about 500 nm, the deposition 
increases in all regions of the lung because of the increasing diffusional mobility [33]. 
Nanofibers with a small diameter will penetrate deeper into the lungs, while very long 
fibers (more than 20 microns) are predominantly located in the upper airways [41, 42]. 
 
1.6 THE FATE OF INHALED NANOMATERIALS IN THE LUNG 
The fate of inhaled nanomaterials depends on regional distribution in the lung, 
because disposition within the lung is a complex function of the kinetics of absorption 
and non-absorptive clearance mechanisms [43]. Once nanomaterials are deposited onto 
the lining of the respiratory tract, they first contact the mucous layer within the airways or 
the surfactant lining fluid layer within the alveolar region. Airway mucus (about 5 
microns in depth) is a complex aqueous secretion of airways, comprising electrolytes, 
proteins, glycoproteins (e.g. mucins), and cell debris [44]. The components vary much 
depending on environmental and disease states. The surfactant lining layer (10-20 nm in 
thickness) that covers the alveolar surface is composed of 90% in weight of 
phospholipids and 10% in weight of specific proteins [45, 46]. Both airway and alveolar 
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surface liquids are coated with at least a monolayer of highly surface active lung 
surfactant, which are primarily water insoluble long chain phospholipids. They form 
liquid crystals but not micelles in aqueous media [22] to maintain the functions of the 
lungs: facilitation of gas exchange and prevention of alveoli collapse by reducing the 
lung air interface surface tension [47, 48]. 
 
It was found that regardless of the nature of the nanomaterials surfaces, they will 
be submersed into the lining fluids after their deposition [40]. Study of interactions 
between different nanoparticles and lung surfactant film indicated that the smaller the 
size of nanoparticle, the more can be incorporated into the surfactant film. However, the 
surface pressure of the surfactant film does not change significantly with the 
incorporation of nanoparticles, i.e. the size dependent incorporation of nanoparticles does 
not destabilize the lung surfactant film [49]. D-alpha-tocopheryl polyethylene glycol 
1000 succinate (TPGS) coated nanoparticles also do not destabilize the model surfactant 
film, suggesting potential application of nanoparticles to lungs [50].  
 
Once deposited within the lung lining fluid, there are separate biokinetics for lung 
absorption and non-absorptive clearances. The kinetics of dissolution of inhaled 
particulates determines whether the inhaled nanomaterials will dissolve in the epithelial 
lining fluid for lung absorption or whether such nanomaterials will undergo non-
absorptive clearances [51]. Inhaled nanomaterials that are either lipid soluble, or soluble 
in intracellular or extracellular fluids undergo chemical dissolution in situ. Low 
molecular weight hydrophobic molecules are thought to be rapidly absorbed (within 
seconds) by passive diffusion through the lung epithelial membrane [52]. The kinetics of 
diffusion in the alveoli is much faster than that of the small airways, mainly because lung 
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absorption mostly occurs from the air-side surface of the alveoli to the pulmonary 
capillaries. The alveoli has a thin monolayer (0.1- 0.4 micron) composed of extremely 
broad and thin Type I cells and small compact Type II cells, and a large surface area 
(more than 100 m2). Only a small portion of inhaled nanoparticles is absorbed from the 
tracheobronchial airways which have a much thicker layer of column-shaped epithelial 
cells (10–60 microns) and lower surface area (1– 2 m2) [29]. This is supported by Fick's 
law. Low molecular weight hydrophilic molecules can be absorbed by active transport 
via specific transporters, or by passing through the tight junctions [22]. The kinetics of 
active absorption should depend upon the lung-regional expression and functionality of 
receptors or transporters. It was recently reported that the absorption of large molecule 
immunoglobulins of the IgG class (150 kDa) might occur in the upper airways by 
receptor-mediated transcytosis of IgG [53, 54]. Solutes and soluble components may be 
eventually cleared into blood and lymphatic circulation. 
 
Inhaled nanomaterials that are insoluble in mucus and lining fluid, are not able to 
be rapidly absorbed, and may undergo physical translocation. This is different depending 
on lung region in which the nanoparticles have been deposited [4]. Immersion of the 
inhaled, slowly dissolving or insoluble nanomaterials in the fluid lining the lungs may 
enable them to be closely associated with epithelial cells and cells of the host-defense 
system for particle-cell interaction [40]. Subsequently, several post defense mechanisms, 
including the mucociliary escalator transport, phagocytosis by macrophages and 
endocytosis, are involved in the removal of deposited nanoparticles and to maintain the 
lung mucosal surfaces [55, 56].  
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The mucociliary escalator dominates clearance of nanoparticles from the upper 
airways. Nanoparticles that consist of slowly dissolving or insoluble materials in the 
airway mucus will be partly moved by action of the ciliated epithelial cells pushing the 
mucus along with the nanoparticles that deposited on the airway walls to the larynx, 
where they are swallowed to the gastrointestinal tract or excreted through the mouth [34]. 
The deposited nanoparticles may also be removed by coughing within 1–2 days [22]. 
However, Schurch et al. showed that mucus clearance can be overcome by nanoparticles, 
possibly due to rapid displacement of particles to the airway epithelium via surface 
energetics [39].  
 
Clearance of the slowly dissolving and insoluble nanoparticles from the alveoli is 
predominantly by macrophage phagocytosis and endocytosis [57]. The air-side surface of 
each of the 500 million alveoli in the human lungs is routinely monitored by 12–14 
alveolar macrophages in the lung lining fluid [18]. The uptake of deposited particles by 
alveolar macrophages depends on the particle size and composition of coating material. 
Particles of 1-3 microns in diameter are far better taken up than those of 6 microns by 
macrophages, which have cell diameters about 15–22 microns [58]. Particles of less than 
0.26 micron can escape from phagocytosis by macrophages [59]. Due to the small size, 
the chance of nanoparticles undergoing phagocytosis in the alveoli is much lower than 
micron sized particles. The remaining nanoparticles will interact with the non-phagocytic 
cells of the epithelium, and the endocytic events are regulated by clathrin-coated pits and 
caveolae, as well as scavenger receptors (e.g., scavenger receptor SR-A). It has been 
suggested that caveolae and coated pits preferentially transport small and large particles, 
respectively, but this needs to be further verified in vivo [60]. Caveolae are indentations 
of the plasma membrane lined with caveolin-1, and are abundantly expressed on lung 
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capillaries and type l alveolar cells. Macromolecules or particles of several nanometers in 
radii may be transported within caveolae from lung to blood [55, 60].  
 
Transport via pores, as suggested for lung-blood substance exchange, is another 
possible route of disposition of inhaled nanomaterials. Inspiratory expansion and 
expiratory contraction of lung alveoli may lead to the opening and closing of the 
caveolae. These openings measure between 40 to 100 nm in size and are thought to be 
involved in the transport of macromolecules, such as proteins, across the alveolar-
capillary barrier [22]. Additionally, a reactive nanomaterial surface will be able to initiate 
chemical interactions between nanoparticles and membranes by inducing lipid 
peroxidation at the interface, causing changes in membrane permeability and dynamics 
[5]. Thus, depending on size and surface reactivity, nanoparticles may be transported 
across cellular and sub-cellular membranes by different mechanisms. As a result most 
nanoparticles will be no longer retained as free particles on the epithelium as inhaled and 
deposited. 
 
1.7 SYSTEMIC TRANSLOCATION OF INHALED NANOMATERIALS 
Recently, it was reported that inhaled nanomaterials may also influence organs 
other than the lungs. Inhaled ultrafine technetium (99mTc) labeled carbon particles, which 
are very similar to the ultrafine fraction of actual pollutant particles, diffused into the 
systemic circulation of hamsters within 5 minutes. Nemmar et al. concluded that 
phagocytosis by macrophages and/or endocytosis by epithelial and endothelial cells may 
be responsible for particle-translocation to the blood, along with other mechanisms [61]. 
There are recent reports that inhaled nanoparticulates have been found in the brain, 
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probably traveling from the nasal nerves [62]. This suggests that nanoparticles may travel 
to sites away from the site of deposition in the lungs. 
 
However, no definite conclusion about the systemic translocation of inhaled 
nanoparticles can be drawn to date, based on the conflicting results of human and animal 
studies. It was reported that rapid translocation to the liver (more than 50%) of 13C-
labeled nanoparticles with a diameter of 26 nm occurred within 24 hours following 
inhalation in a rat model [42]. In another rat study, only less than 1%  iridium 
nanoparticles (15–20 nm in diameter) were found in secondary organs of rats, but the 
nanoparticles were distributed widely throughout the body to such organs as liver, spleen, 
kidneys, brain and heart [63]. Kato et al. [64] has provided morphological data showing 
that inhaled polystyrene particles are transported into the pulmonary capillary space, 
presumably by transcytosis; nevertheless, other research groups did not find any 
detectable particulates in the body other than the lungs [65, 66]. 
 
The variable results from extrapulmonary translocation of experimental 
nanoparticles may due to differences in the chemical composition, particle size, surface 
characteristics, labeling materials and experimental models reported in the different 
studies. Taken together evidence from the in vivo studies for alveolar translocation of 
inhaled nanomaterials, supports that this pathway exists in humans; however, the extent 
of extrapulmonary translocation is determined by characteristics of the nanomaterials. 
Systemic translocation of the inhaled nanomaterials could better explain the 
epidemiological findings of adverse cardiovascular effects found in communities with air 
pollution [67].  
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Inhaled nanoparticles may end up in systemic circulation and the lymphatic 
system once they reach the pulmonary interstitial sites following transcytosis across 
alveolar epithelial cells [4]. There is uncertainty regarding the real contribution of the 
lung's lymphatic pathway to systemic appearance following inhalation of nanoparticles. 
In the respiratory system, a vast network of lymphatic vessels drains both the airways and 
the alveolar regions and terminates in the hilar and mediastinal lymph nodes [68]. 
Lymphatic drainage is responsible for alveolar clearance of deposited drugs and 
particulates up to a certain particle diameter, i.e. 500 nm [69, 70]. In vivo 
pharmacokinetic studies of radiolabelled solid lipid nanoparticles (mean diameter of 200 
nm) revealed significant lymphatic uptake and a high rate of distribution in periaortic, 
axillar and inguinal lymph nodes after inhalation in rats [71]. For the deposited 
nanoparticles that are insoluble in the lining fluid of the lungs, they are taken up less 
efficiently by the macrophages [58]. The phagocytosed nanoparticles may be destroyed 
once within the lysosomes of phagocytic cells. Therefore it is evident that for the 
nanoparticles consisting of protein drug, macrophage engulfment usually means eventual 
digestion of the protein [72]. The nanoparticles sequestered by the macrophages may also 
be transported to regional lymph nodes and may subsequently migrate to systemic 
circulation. Particle-loaded macrophages were seen in pulmonary lymphatic vessels and 
in hilar lymph nodes of animals following instillation of particulates into the airways 
[68]. It has been shown that transfer of nanoparticles to the lymph nodes of the lung 
generally increases with increasing molecular weight greater than 10–20 kDa, whereas 
molecules less than 10 kDa are unlikely to be involved in this pathway [73]. The extent 
of elimination of inhaled nanoparticles from the different pathways is highly dependant 
on the nanomaterial characteristics (e.g., particle size, coating, surface charges), the 
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amount of inhaled nanoparticles, and potential degradation by lysosomal enzymes before 
transport to the lymphatic circulation.     
 
1.8 FACTORS INFLUENCING THE FATE OF NANOMATERIALS 
Clearance of inhaled nanoparticles from the lungs depends mainly on particle size 
and, by implication, on particle surface characteristics. It was reported following three 
months exposure of rats to ultrafine (~20 nm) and fine (~200 nm) titanium dioxide (TiO2) 
particles by inhalation, the ultrafine particles were cleared significantly more slowly,  and 
showed more translocation to interstitial sites and to regional lymph nodes as compared 
to the fine TiO2 particles [74]. Particles between about 20 and 50 nm in diameter may 
enter into the central nervous system and cells. In addition, alveolar macrophages on the 
surface of the lungs appear not be able to recognize particles of less than 70 nm as being 
“foreign”, thus allowing them to gain access to the pulmonary interstitium, and then 
capillary blood flow [75]. 
  
Particle shape may also interfere with the clearance mechanisms. Nanofibers 
measuring more than 20 microns in one axis are too long to be phagocytosed (fibers 
longer than the diameter of the alveolar macrophage) and will be cleared very slowly, 
staying in the lungs for months and possibly years. They induce a rather general non-
specific pulmonary inflammatory response, including release of chemokines, cytokines, 
reactive oxygen species, and other mediators, which can result in sustained inflammation 
and eventually fibrotic changes [3, 16]. 
 
Surface coating of nanoparticles was found to effect particle uptake. Albumin, 
lecithin, polysorbate 80, or peptide attachments can enhance nanoparticle uptake into 
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cells, whereas polyethylene glycol interferes with nanoparticle uptake into the liver [76]. 
Kato et al. administered intact or lecithin-coated insoluble polystyrene latex beads (240 
nm in diameter) intratracheally to rats using an air jet nebulizer. Scanning electron 
micrographs of the rat lungs showed that both lecithin-coated and uncoated beads were 
incorporated into alveolar macrophages. Some of the ingested beads in the alveolar 
macrophages were sequestered within lysosomes. Types I, and II alveolar epithelial cells 
and monocytes in the capillary lumen selectively incorporated only lecithin-coated beads. 
These findings suggest that alveolar epithelial cells can incorporate exogenous particles, 
which are then transferred from the alveoli to intravascular spaces by transcytosis. The 
interaction between cells and the lecithin-coated particles may involve cellular ligands to 
recognize the lecithin by virtue of its molecular charge or hydrophilicity. Also, as 
observed with lecithin, albumin coating of inhaled nanoparticles appeared to facilitate 
nanoparticle endocytosis [64]. 
 
Moreover, surface electrostatic charge is an important factor influencing the 
deposition of inhaled nanoparticles. Charged nanoparticles have higher deposition 
efficiencies as compared to neutrally charged nanoparticles. Moderately lipophilic 
compounds with a positive charge at physiological conditions, such as pentamidine and 
verapamil, are preferentially bound to lung tissue [77]. Polycationic macromolecules 
show a strong interaction with cell membranes in vitro. Three polycationic paint 
components exhibited considerable cytotoxicity (LD50 generally below 100 mg/ml for an 
incubation period of 20–24 hours) in primary cultures of rat and human type II 
pneumocytes, alveolar macrophages and human erythrocytes. The authors argued that the 
multiple positive charges play an important role in the toxic mechanism [78, 79]. It was 
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found that nanoparticles with polar surfaces showed different translocation rates across 
respiratory epithelium and into circulation in a hamster model [61]. 
 
1.9 POTENTIAL APPLICATIONS OF NANOMATERIALS IN DRUG DELIVERY  
Learning from environmental toxicology studies, nano-sized air pollutants, 
especially the spherical solid materials, easily enter the lungs and reach the alveoli, and 
subsequently are cleared from the lungs by different clearance mechanisms. However, 
due to their small size, nano-sized particles are not likely to be detected around the lung 
epithelial barriers. They will translocate into systemic circulation and target other organs. 
Since the definition for the cut-off size of airborne nanoparticles is the same as that of 
engineered nanoparticles (100 nm), they should share the same biokinetics upon 
inhalation into the lungs. Furthermore, the high surface-to-volume ratio of natural 
airborne and engineered nanomaterials renders them more reactive, even though they are 
inert as larger particles. Therefore any possible effects of the nanomaterials may be 
amplified once entering the body via inhalation. On the other hand, the extrapulmonary 
toxicity induced by inhaled nanosized air pollutants may also provide evidence for 
systemic delivery of nanosized pharmaceutical agents by inhalation, for the medicines not 
suitable for oral or parenteral administration to improve bioavailability and patient 
compliance. 
 
Due to rapid advances in nanotechnology and biotechnology, nanoparticles have 
been considered as an effective form for delivery, and have been studied extensively to 
deliver the new generation of protein-, gene-based macromolecular therapeutic agents 
into the body, since many of the components of living cells are constructed at the nano 
level, such as ribosomes, membrane transporters, receptors and cell signaling systems 
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[80]. Nanoparticles fall in the same size range of the biological entities; therefore they 
can readily interact with molecules on both the cell surface and within the cell [81, 82]. 
Furthermore, drugs that are deposited within the lungs in nanoparticulate form have a 
greater chance to escape from the clearance mechanisms by the lung defense systems, 
compared to micro particulate form [39, 58]. Thus, drug-bearing nanoparticles have the 
potential to deliver drugs efficiently to the epithelium, while avoiding unwanted 
mucociliary clearance. In the pharmaceutical area, most nanoparticles described in the 
literature for drug delivery are between 50 to 500 nm in diameter [83]. 
 
Nanoparticles are useful to deliver water insoluble drugs. Despite high potency, 
the effectiveness of water insoluble drugs can be severely limited because the solubility is 
too low to reach therapeutic systemic concentrations. However, when their size is 
reduced to nano level, the increased particle surface-to-volume ratio helps to enhance 
solubility and dissolution rate in an aqueous environment. Nanoparticulate forms of drug 
could have an enormous benefit by significantly improving systemic bioavailability 
(defined as the rate and extent of therapeutically active drugs reaching the systemic 
circulation) and allowing a more rapid onset of therapeutic action [84].  
 
The route of administration is as important as the drug itself for therapeutic 
success. Nano-based approaches to drug delivery are focused on crossing a particular 
physical barrier, such as the gastro-intestinal epithelium for absorption of 
macromolecules, blood–brain barrier; or on finding alternative and acceptable routes for 
the delivery of drugs expensive and vulnerable to the gastro-intestinal environment. 
Pulmonary delivery of drugs at the nano level is a non-invasive promising means to 
provide not only local lung effects but possibly high systemic bioavailability.  
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1.10 DELIVERY DEVICES  
Aerosols are an effective method to deliver therapeutic agents to the lungs. 
Nebulizers, metered dose inhalers (MDIs), or dry powder inhalers (DPIs) are commonly 
used to generate aerosols [85, 86]. Despite the above mentioned advantages of 
nanoparticles, the use of a drug-bearing nanoparticle itself for delivery to lungs is 
severely limited because their low inertia causes them to be exhaled after inspiration. 
Moreover, their small size leads to particle aggregation due to their high surface energy, 
making handling of nanoparticles very difficult [87]. Therefore, the drug-bearing 
nanoparticles require carriers with MMADs suitable for efficient pulmonary delivery.  
 
In contrast to the conventional micron sized particulate drug formulations for 
nebulizers, the drug-bearing nanoparticles in an aqueous colloidal dispersion are more 
easily incorporated into the “respirable percentage” of aerosolized droplets [88]. 
Therefore, more nanoparticles can be enveloped into the aerosol droplets and delivered to 
deep lung. For instance, assuming the particles are spherical, if the volume fraction of 
particles in the carrier solvent is 0.01, only about 1/100th of 3 μm carrier droplets will 
contain a 3 μm particle; whereas each carrier droplet would contain about ten 300 nm 
particles. Thus, nanoparticle colloidal dispersions, relative to microparticle dispersions, 
have the potential to increase the rate of drug absorption by promoting more uniform 
drug distribution throughout the alveoli [89, 90]. 
 
For pulmonary delivery of drug formulations in solid form, micron sized powder 
particles containing the drug-bearing nanoparticles were designed for deep lung delivery 
by using MDIs and DPIs. Sham et al. [91] developed a platform for aerosol delivery of 
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nanoparticles by preparing carbohydrate (e.g. lactose, mannitol) carrier particles 
containing nanoparticle clusters using spray drying technique. Carrier particles can be 
made with an appropriate MMAD to optimize alveolar deposition. Dispersion of the 
lactose carrier containing either gelatin or polybutylcyanoacrylate nanoparticles by a DPI 
showed a fine particle fraction (FPF; defined as the percentage of droplets with an 
aerodynamic diameter less than 4.7 μm) of about 40% and MMAD of 3 microns. Upon 
reaching the deep lung and contacting with the aqueous lining fluid of the lung 
epithelium, the carrier particles dissolved and released the nanoparticles. A novel type of 
effervescent carrier particle containing nanoparticles, with a MMAD suitable for deep 
lung delivery, was reported by Ely et al. [92]. Incorporation of effervescent technology 
into carrier particles adds an active release mechanism for the nanoparticles after 
pulmonary administration using DPI. Nanoparticles were observed to be distributed 
throughout the gas bubble that caused by the effervescent reaction when exposed to 
humidity. Another idea reported for pulmonary delivery of nanoparticles is forming 
trojan particles, which can be formed by incorporation of nanoparticles into a thin-walled 
micron sized large porous particles (LPPs) [31]. LPPs, characterized by geometric sizes 
larger than 5 microns and mass densities around 0.1 g/cm3 or less, offer advantage of 
higher aerosolization efficiency over conventional inhaled therapeutic aerosol particles 
[93]. In addition, LPPs with geometric diameters of 10–20 microns can penetrate deep 
into the lungs and avoid macrophage engulfment by virtue of their large size [93, 94]. 
The trojan particles reportedly have several attractive features: they are comprised solely 
of nanoparticles; they are readily redispersed as nanoparticles in solution, yet the trojan 
particles are readily dispersed as aerosols. By using these micron sized carriers to deliver 
nanoparticles to deep lung, benefits of aerosolization properties of micron particles and 
the drug release and delivery advantages of nanoparticles can be combined. 
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1.11 PULMONARY DELIVERY OF THERAPEUTIC NANOMATERIALS 
Drug loaded nanoparticles have the potential to be used for pulmonary delivery of 
therapeutics for treating lung diseases locally and exerting systemic actions. Delivery of 
therapeutic agents to the site of action for lung diseases may allow for efficient treatment 
of chronic lung infections, lung cancers, tuberculosis and other respiratory pathologies 
[95].  
 
In vivo studies have observed an accumulation of nanoparticles in tumor sites 
after intravascular administration [96], due to the leaky blood vessel structure of tumors. 
Such properties make nanoparticles a very attractive delivery vehicle for lung cancer 
treatment. Polysorbate 80 coated nanoparticles which were loaded with doxorubicin 
(DOX) have been developed to treat lung cancer. The nanoparticles were then 
incorporated into inhalable carrier particles by a spray-freeze-drying technique [97]. 
DOX-loaded nanoparticles had a particle size of 173±43 nm after re-dissolving the carrier 
particles. Cytotoxicity was assessed by incubated cultured monolayer of two lung cancer 
cell lines (H460 and A549) with DOX-nanoparticle (powder form) at the concentration of 
0.625 μg/mL for 24 h. The DOX-loaded nanoparticles showed enhanced cytotoxicity in a 
concentration dependent manner, compared to free DOX. This indicates that DOX-loaded 
nanoparticles are more effective than free drug. The enhanced activity of DOX-loaded 
nanoparticles resulted from the nanoparticles being more readily internalized by an 
endocytosis mechanism compared to a passive diffusion mechanism of DOX into cells. 
This study supports the approach of lung cancer treatment using nanoparticles as a drug 
delivery vector. The carrier particles containing DOX-loaded nanoparticles may be 
delivered by a dry powder inhaler. Development of inhalable nanoparticles loaded with 
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bioactive molecules is a new delivery platform which can allow targeting of lung specific 
diseases in the future. 
 
Solid lipid nanoparticles (SLN) are lipophilic particulates consisting of a spherical 
solid lipid matrix, and can be used as an efficient and non biotoxic drug carrier for drug 
delivery [98]. Recently, SLN have been proposed as carriers of either diagnosis or 
therapeutic reagents upon encapsulation of cytotoxic drugs. Videira et al. [71] prepared 
lipid nanoparticles using gliceryl behenate by a melt homogenization technique and 
radiolabelled with 99mTc using the lipophilic chelator D,L-hexamethylpropyleneamine 
oxime (HMPAO). Thus obtained SLNs have a mean diameter of 180-220 nm. 
Biodistribution studies were carried out following ultrasonic nebulization of an aqueous 
dispersion of the 99mTc-HMPAO-SLN and administration of the aerosols to rats by 
inhalation using a mask. Dynamic images were obtained up to 4 hours post-inhalation, 
and showed a significant uptake of the radiolabelled SLN into the lymphatic system after 
inhalation, and a high rate of distribution in periaortic, axillar and inguinal lymph nodes. 
The results revealed an important role of the lymphatic pathway in the uptake of inhaled 
nanoparticulates. This study suggested the possibility of pulmonary delivery of 
radiolebelled SLN as a lymphoscintigraphic agent and direct delivery of cytotoxic drugs 
to target lung cancer, which may metastasize through lymphatic drainage. 
 
In vivo pulmonary delivery of 5-fluorouracil (5-FU) in lipid-coated nanoparticles 
(LNPs) system to a hamster model was recently reported [99]. The 5-FU lipid-coated 
nanoparticles consisted of a core composed of 20% (w/w) 5- FU, 20% (w/w) FITC-
dextran, and 60% (w/w) poly- (glutamic acid) with a shell composed of 33% (w/ w) cetyl 
alcohol and 67% (w/w) tripalmitin. The cores measure 600 nm in diameter and the shells 
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measure 200 nm in thickness. The LNPs were suspended at 5 mg/mL in 0.01% Pluronic 
F68 aqueous solution and atomized into droplets using an ultrasonic driver. The produced 
droplets were dried and then directed into a nose-only rodent aerosol exposure chamber 
for inhalation by hamsters at a dose of 30 mg LNPs/kg body weight (1.5 mg 5-FU/kg 
body weight). The pharmacokinetics of the 5-FU lipid-coated nanoparticle and total 5-FU 
in the lung, trachea, larynx, esophagus, and serum was studied. It was found that effective 
local targeting as well as sustained efficacious concentrations of 5-FU in the expected 
tumor sites were achieved. The results suggest using 5-FU containing lipid-coated 
nanoparticles for treating squamous cell carcinoma of the lung. 
 
Besides the success in delivering macromolecules via inhalation to systemic 
circulation, the potential of pulmonary delivery of small molecule weight entities that 
encounter formidable biopharmaceutical challenges with conventional routes (e.g. oral) 
of administration was also explored. Itraconazole (ITZ), a poorly water soluble 
compound, has displayed low and erratic absorption following oral administration. It has 
been used for treating invasive fungal infections, which quite often gained entry to the 
body from lung, and may disseminate to the circulation in immune suppressed patients. 
Two formulations of amorphous nanoparticulate ITZ using polymers and surfactants as 
excipients were prepared by spray freezing into liquid (SFL) technology. One is designed 
for pulmonary delivery (ITZ-pulmonary). Eight milliliters of the aqueous colloidal 
dispersion of the ITZ-pulmonary nanoparticles (containing 200 mg of ITZ equivalent) 
was aerosolized by a micro pump nebulizer. The aerosols were administered to mice via 
inhalation exposure for 20 minutes at a dose of 30 mg/kg body weight of ITZ. The other 
(ITZ-oral) is for oral delivery [100]. The pharmacokinetic profiles of the two 
formulations were compared with the commercial product Sporanox® oral solution 
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(itraconazole/Janssen) after repeated dosing. ITZ-pulmonary achieved significantly 
greater (more than 10-fold) lung tissue concentrations compared to the Sporanox oral 
solution and ITZ-oral. There were no statistical differences between the two oral 
formulations. ITZ-pulmonary achieved significantly greater lung levels per unit serum 
concentration compared to the orally dosed ITZ compositions. High and sustained lung 
tissue concentrations were achieved via inhalation of an amorphous nanoparticulate ITZ-
pulmonary formulation while maintaining serum levels above the minimum lethal 
concentration of Aspergillus fumigatus. This study and other related research [101, 102] 
showed a paradigm of treating disseminated lung infection by pulmonary delivery of 
nanosized therapeutics to achieve both high lung local and sufficient systemic drug 
concentrations to effectively improve survival.  
 
Budesonide, another poorly water soluble drug has been prepared as a 
nanosuspension by high-pressure homogenization and delivered by nebulization [90]. 
This budesonide nanosuspension has a mean particle size about 500-600 nm, 99% of the 
nebulized aerosols were below 3 microns; and the nanosuspension also displayed long-
term stability without aggregation or particle growth occurring over the examined period 
of 1 year. The manufacturing technology is feasible to scale up. These features of the 
budesonide nanosuspension imply the potential of successful in vivo pulmonary 
application. However, it is regretted that no in vivo experiments were reported to study 
the pharmacokinetics and effects of the budesonide nanosuspension. 
 
1.12 CONCLUSIONS  
While nanotechnology provides great promises in healthcare, the potential risk 
imposed by natural and engineered nanomaterials to public health has also been of 
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concern.  This is due to their enhanced activity at the nano-scale. The potential of the 
lung as a natural entry route for systemic delivery of aerosols of macromolecules that are 
otherwise vulnerable to enzyme degradation in the gastrointestinal tract, and of water 
insoluble drugs, has been recognized in the pharmaceutical field. The integration of 
nanotechnology and pulmonary delivery of drug aerosols represents a new and exciting 
frontier for pharmaceutical dosage form design to increase bioavailability and patient 
compliance, as supported by the results of studies using nanoparticles as either diagnostic 
or therapeutic agents for lung and systemic diseases.  
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1.14 DISSERTATION OBJECTIVES AND OUTLINE 
High throughput screening techniques routinely used in modern drug discovery 
processes result in a higher prevalence of poorly water-soluble active pharmaceutical 
ingredient (API). Such APIs often have poor bioavailability issues due to their poor 
dissolution and/or permeability to achieve sufficient and consistent systemic exposure. 
Consequently it results in sub-optimal efficacy in patients, particularly via oral 
administration. Alternative formulations made by novel pharmaceutical technologies for 
improving the dissolution properties and thereby bioavailability of the poorly water-
soluble APIs are becoming increasingly important to modern drug delivery. Alternative 
delivery routes are also important to enhance drug bioavailability. The overall objective 
of this dissertation was to formulate, fully characterize nanoparticle formulations of 
poorly water-soluble drug through in vitro and in vivo tests. Formulations were produced 
and evaluated based on current needs of clinical use, with the aid of novel particle 
engineering techniques and well established animal models to evaluate the 
bioavailability.   
 
The use of nanotechnologies in commercial applications is increasing in many 
scientific disciplines. Chapter 1 reviews the unique size-controlled properties of 
nanomaterials, their disposition in the body after inhalation, and the factors influencing 
the fate of inhaled nanomaterials. The physiology of the lung makes it an ideal target 
organ for non-invasive local and systemic drug delivery, especially for protein and poorly 
water-soluble drugs. The potential application of pulmonary delivery of nanoparticle 
formulations of poorly water-soluble drugs is promising.  
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To improve the bioavailability of itraconazole (ITZ), an extremely poorly water-
soluble drug which suffers erratic absorption from oral formulations, a particle 
engineering process ultra-rapid freezing (URF) was utilized to produce nanoparticle 
formulation for pulmonary delivery in Chapter 2. Biocompatible and biodegradable 
excipients suitable for lung use were employed to make the nanostructured aggregates 
containing ITZ:mannitol:lecithin=1:0.5:0.2, w/w), i.e. URF-ITZ. In which ITZ was found 
to molecularly dispersed in the excipients as a solid solution with high surface area and 
ability to achieve high magnitude of supersaturation. Aqueous colloidal dispersion of 
URF-ITZ was suitable for nebulization, which demonstrated optimal aerodynamic 
properties for deep lung delivery. Single dose inhalation of the nebulized aerosols in mice 
using a whole body exposure dosing apparatus demonstrated high lung and systemic ITZ 
levels. 
 
The significantly improved systemic bioavailability of inhaled URF-ITZ was 
mainly ascribed to the amorphous morphology that raised the drug dissolution rate and 
saturation solubility. To evaluate the impact of supersaturation of amorphous relative to 
crystalline nanoparticulate formulations of ITZ on bioavailability via inhalation, a nano-
sized crystalline ITZ composition was made by wet milling process (i.e. Wet-milled ITZ) 
to compare the bioavailability with URF-ITZ following inhalation in Chapter 3. 
Dissolution tests revealed that URF-ITZ achieved 4.7-times higher extent of 
supersaturation than nanocrystalline Wet-milled ITZ. This was translated to 3.8-times 
higher systemic ITZ levels in rats following a single dose inhalation of the respective 
nebulized aerosols using a nose-only dosing apparatus. Engineering amorphous 




In Chapter 4, a 2-hydroxypropyl-β-cyclodextrin (HPβCD) solubilized ITZ 
solution (i.e., HPβCD-ITZ) suitable for pulmonary delivery by nebulization was made, to 
compare pharmacokinetics of inhaled nebulized aerosols of HPβCD-ITZ versus URF-
ITZ, under the hypothesis that solubilized ITZ could be absorbed faster through a 
mucosal membrane than the nanoparticulate ITZ.  Single dose inhalation of nebulized 
aerosols of HPβCD-ITZ solution and aqueous colloidal dispersion of URF-ITZ in mice 
produced similar ITZ lung depositions, but significantly faster systemic absorption of 
HPβCD-ITZ across lung epithelium than URF-ITZ. The faster absorption of solubilized 
ITZ across the lung mucosal surface may be due in part to the elimination of the phase-
to-phase transition. However, the nanoparticle URF-ITZ offered higher systemic 




Table 1.1. Unique features of nanomaterials [16]  
 
Size:  20-50 nm enters CNS 
         < 70 nm, able to escape defense system in vivo 
High Surface to mass ratio 
High strength, conductivity, solubility, durability and reactivity 
Catalytic promotion of reactions 
Ability to adsorb and carry other compounds 
Ability to escape defense system in vivo 
Ability to cross cellular and sub-cellular membranes 
Surface coating (e.g. lecithin,albumin) 
          -Enhance uptake by Type I/II pneumocytes 
          -Transcytosis across capillary 





Table 1.2. Mechanism of Aerosol Deposition [23, 33]  
 
Site                                    Size (μm) Mechanism Comment 
Large airways                  5-9 (slow inhalation) 
3-6 (fast inhalation) 
 Impaction  Most deposition in 
Segmental airways 
Smaller airways               1 - 5   Gravitational 
sedimentation  
 Improved with slow 
and deep breathe  
Respiratory bronchioles   1 - 3   Gravitational 
sedimentation  
 Improved with slow 
and deep breathe 













Figure 1.1. Relationship between particle size and number of molecules displayed on 
particle surface. The percentage of molecules displayed on the surface of the 
particles to the total molecules in the particles increases exponentially while 
particle diameter decreases in the range of 1-100 nm. At a particle diameter 
of 30 nm, about 10% of its molecules are displayed on the surface; whereas 
at 10 and 3 nm particle diameter, 20% and 50% of the total molecules in the 
particles may display on the surface, respectively. Increase the ratio of 
atoms or molecules on the surface to the total molecules of a material may 
enhance the chemical and biological properties of nanomaterials. The 
enhanced activities could be either beneficial (antioxidation, carrier capacity 
for drugs, increased uptake and interaction with biological tissues) or 
disadvantageous (toxicity, instability, induction of oxidative stress) 






Figure 1.2. The effect of particle size on the deposition of aerosol particles in the human 
respiratory tract following a slow inhalation and a 5-second breath hold. 
Larger particles deposit in the airways or mouth and throat, whereas 
smaller particles deposit in the alveolar region. Particles <1 μm can be 






Chapter 2: High Bioavailability from Nebulized Itraconazole 
Nanoparticle Dispersions with Biocompatible Stabilizers  
 
2.1 ABSTRACT 
A nebulized dispersion of amorphous, high surface area, nano-structured 
aggregates of itraconazole (ITZ):mannitol:lecithin (1:0.5:0.2 w/w) yielded improved 
bioavailability in mice.  The ultra-rapid freezing (URF) technique used to produce the 
nanoparticles was found to molecularly disperse the ITZ with the excipients as a solid 
solution. Upon addition to water, ITZ formed a colloidal dispersion suitable for 
nebulization, which demonstrated optimal aerodynamic properties for deep lung delivery 
and high lung and systemic levels when dosed to mice. The ITZ nanoparticles produced 
supersaturation levels 27 times the crystalline solubility upon dissolution in simulated 
lung fluid. A dissolution/permeation model indicated that the absorption of 3 μm ITZ 
particles is limited by the dissolution rate (BCS Class II behavior), while absorption is 
permeation limited for more rapidly dissolving 230 nm particles. The predicted 
absorption half-life for 230 nm amorphous ITZ particles was only 15 min, as a result of 
the small particle size and high supersaturation, in general agreement with the in vivo 
results. Thus, bioavailability may be enhanced, by decreasing the particle size to 
accelerate dissolution and increasing permeation with (1) an amorphous morphology to 
raise the drug solubility, and (2) permeability enhancers.   
 
2.2 INTRODUCTION  
Improving the bioavailability of active pharmaceutical ingredients (API), defined 
as the rate and extent of the API that reaches systemic circulation is a major goal of 
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pharmaceutical drug delivery. Enhancements in bioavailability may increase patient 
compliance. The effectiveness of poorly water soluble APIs can be severely limited when 
solubilities are too low to produce systemic therapeutic levels. Several strategies have 
been developed to improve the aqueous dissolution properties of poorly water soluble 
API formulations, including the use of surfactants, emulsification processes, solution 
based precipitation and solid state manipulation [1-6]. Amorphous particles may be 
designed to produce high levels of supersaturation relative to the solubility of the 
crystalline state [7].  Cryogenic technologies have been used to produce highly porous, 
amorphous, nanostructured particles with improved dissolution rates and high 
supersaturation drug levels relative to the solubility of the crystalline state for poorly 
water soluble APIs [8-10]. The Spray Freezing into Liquid (SFL) process forms a solid 
dispersion or solid solution composed of drug domains within a polymer matrix by 
spraying the drug/excipients solution directly into liquid nitrogen [8]. The URF particle 
engineering process utilizes rapid freezing of a drug/excipient solution onto a cryogenic 
substrate of desired thermal conductivity to obtain a solid dispersion/solution [10].  
 
 ITZ, a broad-spectrum antimycotic triazole has been used for both prophylaxis 
and treatment of invasive fungal diseases for the last two decades. ITZ is a poorly soluble 
weak base with a calculated log P of 6.2. Its aqueous solubility is estimated at 
approximately 1 ng/mL at neutral pH and approximately 4 μg/mL at pH 1 [11]. Given the 
high log P value, ITZ is classified as a class II drug according to the Biopharmaceutical 
Classification System (BCS) [12]. Sporanox® oral capsule and solution, ITZ preparations 
for oral administration on the market, show low oral absorption and considerably varied 
pharmacokinetics in immunocompromised patients,[13-15]. To treat invasive fungal 
infection, especially Aspergillus spp. infections in immunocompromised patients, ITZ 
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levels of greater than 0.5 μg/g of lung tissue, or 0.5 μg/mL of blood [16] is generally 
required.  
 
The design of rapidly dissolving drug nanoparticles offers potential improvements 
in therapeutic efficacy, stability, patient compliance, and safety [17, 18]. The route of 
administration is as important as the drug formulation for achieving therapeutic success 
[19-22]. Pulmonary delivery of a wide spectrum of drug substances, including 
proteins/peptides, nucleic acids, and antibiotics to the lungs can be highly effective for 
localized treatment or prophylaxis of pulmonary diseases, including lung infections, 
cystic fibrosis, and asthma [23]. Pulmonary delivery is a non-invasive route that 
facilitates deposition of large drug doses to the lungs, and offers the potential for high 
systemic absorption. Efficient systemic absorption is attributed to the lung’s large 
absorptive surface area, very thin diffusion path to the blood stream, elevated blood flow, 
relatively low metabolic activity, and the avoidance of hepatic first pass metabolism [24]. 
Particle size distribution and morphology have pronounced effects on all aspects of 
pulmonary drug delivery, including deposition in the respiratory tract, dissolution in the 
lung lining fluid and the clearance mechanism [25]. The particle size of aerosols is 
determined by the inhalation device and physicochemical properties of the drug 
formulation, such as viscosity and surface tension [26].  
 
Pulmonary drug delivery targeted to the alveoli is advantageous and critical for 
systemic absorption [27]. The concept of improving bioavailability of poorly water 
soluble APIs by pulmonary delivery of nanostructured aggregates has been recently 
reported in mouse models. Inhalation of a nebulized ITZ nanoparticle composition 
(ITZ:polysorbate 80:poloxamer 407 = 1:0.75:0.75 by weight ratio, prepared by SFL; 
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namely SFL-ITZ) by mice for 20 min produced relatively high drug concentrations in 
lung tissue and about one third the drug level in systemic circulation compared to 
Sporanox® solution administered orally at the same dose [28]. Nebulization of aqueous 
colloidal dispersions of amorphous cyclosporin A/polysorbate 80 nanoparticles into mice 
produced therapeutic lung levels and systemic concentrations below toxic limits [29].  
 
Inclusion of certain surface active excipients in pulmonary formulations may 
enhance bioavailability, but may also interfere with cell lipid bilayer membranes and thus 
raise long term safety concerns [30]. The objective of this study was to develop an ITZ 
nanoparticle dispersion for pulmonary delivery by nebulization that does not require the 
use of synthetic polymers and surfactants to achieve high supersaturation values in vitro 
and high bioavailability. Mannitol is a widely used excipient approved by the Food and 
Drug Administration (FDA) for inhalation purposes [31, 32]. Lecithin, currently FDA 
approved for pulmonary formulations, contains mainly dipalmitoylphosphatidylcholine 
(DPPC), the primary component of endogenous human lung surfactant [33]. We 
hypothesize that a high surface area nanostructured ITZ composition encompassing 
soluble, and/or biodegradable, and/or biocompatible materials such as mannitol and 
lecithin, ITZ:mannitol:lecithin = 1:0.5:0.2 (by weight ratio, namely URF-ITZ), can be 
inhaled by  nebulization to produce high supersaturation levels rapidly in the alveolar 
fluid. Pulmonary delivery of the nanostructured ITZ composition may provide not only 
local lung deposition, but possibly high systemic bioavailability with low toxicity.  
 
The URF-ITZ dry powder and its aqueous dispersion suitable for nebulization 
were characterized by a wide variety of techniques. A single dose 24-hour 
pharmacokinetic study was also performed in mice to assess the bioavailability of 
 44
nebulized URF-ITZ nanoparticle dispersion by inhalation and to explore the factors 
influencing the pharmacokinetic parameters. In order to better understand how particle 
size and solubility (supersaturation) may be designed to enhance absorption rates in the 
alveoli, a recently developed model of Tam et al. [29] was used to analyze the individual 
effects of dissolution. 
 
2.3 MATERIALS AND METHODS  
2.3.1 Materials 
The following materials were purchased: ITZ, micronized pharmacopeial grade 
(Hawkins Chemical, Minneapolis, MN); mannitol and polysorbate 80 (Spectrum 
Chemicals, Gardena, CA); lecithin, 1,4-dioxane (Fisher Scientific, Fair Lawn, NJ); 
diethanolamine (VWR International, West Chester, PA); acetonitrile (EM Industries Inc., 
Gibbstown, NJ). All organic solvents used were HPLC grade. Other reagents used were 
at least ACS grade.  
 
2.3.2 Preparation of nanostructured aggregate powder of ITZ using URF technology 
For a standard batch of the formulation, lecithin (118 mg) was dissolved in a 
mixture of 1,4-dioxane and purified water (65/35, v/v) co-solvent system (200 mL) using 
a magnetic stirrer. ITZ (588 mg) and mannitol (294 mg) were subsequently dissolved in 
the mixture, this provided a dissolved solids ratio of ITZ:mannitol:lecithin of 1:0.5:0.2 by 
weight. The solution was frozen using the URF apparatus [10, 34]. Briefly, the solution 
was applied to the cryogenic solid substrate (which was previously cooled to -70 ℃), 
whereby the solution was frozen rapidly. The resultant frozen solids were collected and 
lyophilized using a VirTis Advantage bench top tray lyophilizer (The VirTis Company, 
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Inc., Gardiner, NY, USA). The dry powder was stored in a desiccator under vacuum at 
room temperature. 
 
2.3.3 Preparation of physical mixture 
A physical mixture consisting of ITZ:mannitol:lecithin in the weight ratio of 
1:0.5:0.2 was mixed by geometric dilution and trituration using a ceramic mortar and 
pestle. 
 
2.3.4 Powder X-Ray Diffraction (XRD) 
The URF-ITZ powder, the physical mixture, the bulk ITZ and mannitol were 
examined by wide angle XRD. A Philips 1710 X-ray diffractometer with a copper target 
(CuKα1,λ = 1.54056 Å) and nickel filter (Philips Electronic Instruments Inc., Mahwah, 
NJ) was used to obtain the XRD patterns. The voltage was 40 kV and the current was 40 
mA. Samples were analyzed in the 2-theta range from 10 to 50° using a step size of 0.05 
2-theta degree with a dwell time of 2 sec. 
 
2.3.5 Scanning Electron Microscopy (SEM) 
SEM was used to evaluate the morphology of the samples. The samples were 
mounted onto an aluminum stage using conductive carbon tape. Samples were coated 
using a model K575 sputter coater (Emitech Products, Inc., Houston, TX) with 
gold/palladium for 20 sec in a high vacuum evaporator. SEM was performed using a 
Hitachi S-4500 field emission scanning electron microscope (Hitachi High-Technologies 
Corp., Tokyo, Japan) operating at an accelerating voltage of 10-15 kV. Images were 
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captured with Quartz PCI software (Quartz Imaging Corporation, Vancouver, BC, 
Canada). 
 
2.3.6 Scanning Transmission Electron Microscopy (STEM) 
The URF-ITZ powder was further characterized using STEM, by placing the dry 
powder on a Holey Carbon Support Film with 200 Mesh Copper Grids (Jed Pella, Inc., 
Redding, CA) and viewing on a JEOL 2010F transmission electron microscope (JEOL 
USA, Inc., Peabody, MA) equipped with an energy dispersive spectroscopy (EDS) 
detector for elemental characterization. 
 
2.3.7 Thermal Analysis  
Differential Scanning Calorimetry (DSC) of the URF-ITZ powder and each 
component was conducted using modulated temperature DSC (MTDSC), Model 2920 
(TA Instruments, New Castle, DE), equipped with a refrigerated cooling system. Dry 
nitrogen gas was used as the purge gas through the DSC cell at a flow rate of 40 mL/min. 
Samples were weighed to 10-15 mg in aluminum crimped pans, Kit 0219-0041 (Perkin-
Elmer Instruments, Norwalk, CT). The mass of the empty sample pan was matched with 
that of the empty reference pan within ±0.2 mg. Samples were heated at a ramp rate of  
10 ℃/min from -30 to 200 ℃ with a modulation temperature amplitude of 1 ℃/60 sec for 
all studies. Data was analyzed using TA Universal Analysis 2000 software (TA 
Instruments, New Castle, DE). Amorphous pure ITZ was prepared by the URF process as 
described above. Amorphous mannitol and lecithin were prepared by quench-cooling 
[35]. In brief, accurately weighed mannitol and lecithin powders were heated to 200 and 
150 ℃, respectively, in sealed aluminum DSC pans, the temperature was held for 15 min. 
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The samples were then quench-cooled in liquid nitrogen externally to the DSC 
instrument. DSC was conducted by placing back the samples to pre-cooled sample 
chamber (-50 ℃), and thermograms were recorded the same as with the other samples. 
 
2.3.8 True Density Measurements 
True density of ITZ, mannitol and lecithin was measured using an AccuPyc 1330 
helium pycnometer (Micrometrics; Norcross, GA). The samples were dried overnight. 
Upon measurement, the samples were purged 20 times with dry helium at 19.85 psi 
followed by six analytical runs at 19.85 psi. The equilibration rate was 0.0050 psi/min. 
Measurements were performed in triplicate. 
 
2.3.9 Particle Size Analysis by Laser Diffraction 
Particle size distribution, based on volume fraction, of the URF-ITZ powder, the 
physical mixture and bulk ITZ was measured by laser diffraction with a Malvern 
Mastersizer-S (Malvern Instruments, Ltd., Worcestershire, UK). To measure the particle 
size distribution, powder aliquots were dispersed in 5 mL purified water, sonicated, and 
the dispersions were added to the sample reservoir to produce light obscuration in the 
range of 10–15%. Bulk ITZ was dispersed in 5 mL of a 0.1% polysorbate 80 aqueous 
solution for pre-wetting due to its high hydrophobicity. Sonication was used during the 
measurement to break up the agglomerated particles. Values reported are the average of 
at least three determinations. 
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2.3.10 Brunauer-Emmett-Teller (BET) Specific Surface Area Analysis 
Specific surface area was measured using a Nova 2000 version 6.11 instrument 
(Quantachrome Instruments, Boynton Beach, FL). An aliquot of powder was added to a 
12-mm Quantachrome bulb sample cell and degassed overnight prior to analysis. The 
data was then analyzed using NOVA Enhanced Data Reduction Software (version 2.13). 
 
2.3.11 Dissolution Testing at Supersaturation Conditions 
Dissolution testing at supersaturated conditions was conducted in a USP 25 
dissolution apparatus model Vankel 7000 Dissolution Tester (Vankel Technology Group, 
Cary, NC) using 100 mL glass dissolution vessels and stirred with small paddles at 100 
rpm. Simulated lung fluid containing 0.02% DPPC (Davies and Feddah, 2003, Cook et 
al., 2005) at 37 ℃ was used as the dissolution medium. An equivalent of 100 μg ITZ in a 
colloidal dispersion (equal to 100-times of equilibrium solubility of crystalline ITZ (Ceq)) 
at 4 ℃ was added to the dissolution vessels (n = 6) within one second immediately after 
sonication. Aliquots of 2 mL of the dissolution media were taken at 5, 15, 30, 60, 120 and 
180 min. All samples were filtered through a 0.2 μm GHP Acrodisc filter (Pall 
Corporation, East Hills, NY), and diluted with acetonitrile for content analysis. The ITZ 
content was determined using a Shimadzu LC-10A high performance liquid 
chromatography (HPLC) system (Shimadzu Corporation, Columbia, MD) equipped with 
an Alltech InertsilTM ODS-2 5 μm, 150 mm × 4.6 mm, C-18 column (Alltech Associates, 
Inc., Deerfield, IL). The mobile phase was acetonitrile:water:diethanolamine (70:30:0.05) 
and it eluted the ITZ peak at approximately 5.5 min at 25 ℃ with a flow rate of 1 
mL/min. The ITZ absorbance was measured at a wavelength λmax of 263 nm.  
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2.3.12 In Vitro Aerosol Performance 
A colloidal dispersion of the URF-ITZ powder was prepared for nebulization by 
dispersing the powder in purified water (equivalent to 20 mg/mL ITZ) using 
ultrasonication in an ice bath. An aliquot (5 mL) of the dispersion was nebulized using an 
Aeroneb® Professional micropump nebulizer (Nektar Inc., Mountain View, CA) for 10 
min at an air flow rate of 28.3 L/min. The flow rate was maintained by a vacuum pump 
(MFG Corp., Benton Harbor, MI) and calibrated by a TSI mass flow meter, Model 4000 
(TSI Inc., St. Paul, MN). The in vitro deposition characteristics of the colloidal dispersion 
of URF-ITZ for nebulization, was investigated using an eight-stage Andersen cascade 
impactor (Thermo-Electron Corp., Symrna, GA). The cascade impactor was assembled 
and operated in accordance with USP General Chapter 601 to assess the drug delivered. 
After deposition onto the stages of the impactor, the mass deposited on each of the stages 
was collected and the total mass of drug on each stage was analyzed by HPLC. The 
aerosolization behavior was described in terms of total emitted dose (TED), mass median 
aerodynamic diameter (MMAD), geometric standard deviation (GSD), and percentage 
fine particle fraction (FPF; defined as the percentage of droplets with an aerodynamic 
diameter less than 4.7 μm).  
 
2.3.13 Stability Study 
The URF-ITZ powder was stored in desiccators under vacuum at room 
temperature, and the physical stability was assessed by XRD at 1, 3 and 12 months. 
 
The physical stability of the colloidal dispersion of URF-ITZ for nebulization was 
also investigated. The colloidal dispersion of URF-ITZ for nebulization was prepared as 
previously described. It was allowed to equilibrate at 25 ℃ for 15 min, and then was 
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quench frozen using excess liquid nitrogen. The colloidal dispersion was lyophilized, and 
the resultant powder was investigated by XRD. 
 
2.3.14 In Vivo Pulmonary Dosing of Mice 
Fourteen male ICR mice (Harlan Sprague Dawley, Inc., Indianapolis, IN) were 
dosed by inhalation of the nebulized colloidal dispersion of the URF-ITZ (equivalent to 
20 mg/mL ITZ) for 10 min in a whole-body dosing chamber as previously described 
(McConville et al., 2005). This restraint-free chamber was designed to hold up to 14 
mice. An Aeroneb Professional micropump nebulizer was situated at the inlet of the 
chamber, and the colloidal dispersion of the URF-ITZ was nebulized through the inlet 
into the chamber with an air flow rate of 1 L/min. Following exposure to the aerosol 
cloud, the mice were sacrificed by carbon dioxide asphyxiation at 0.5, 1, 2, 4, 6, 10, and 
24 h time points post dosing. Blood samples were taken by cardiac puncture, and the 
lungs were harvested. The study protocol was approved and conducted in accordance 
with the Institutional Animal Care and Use Committee (IACUC) guidelines at The 
University of Texas at Austin. 
 
2.3.15 Plasma and Lung Analysis  
Serum was separated by centrifugation at 3,000 g for 10 min in a 1.5 mL micro-
centrifuge tube using a Microfuge® 18 centrifuge (Beckman Coulter, Fullerton, CA). The 
serum and lung samples were stored at -20 ℃ until analyzed. The homogenized lung 
samples were prepared by adding 1 mL of normal saline to each of the harvested lung and 
homogenized using tip sonication on an ice bath. Drug levels in the calibration standards, 
serum and homogenized lung samples were analyzed as previously indicated [28]. 
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Briefly, to an aliquot of 250 μL serum or 250 μL of lung homogenate, 50 μL of 0.3 N 
barium hydroxide and 50 μL of 0.4 N zinc sulfate heptahydrate solutions were added and 
vortex mixed for 30 sec to precipitate water-soluble proteins. Acetonitrile (1 mL) 
containing 500 ng/mL ketoconazole as an internal reference standard was added to each 
sample followed by vortex mixing for 1.5 min. Each sample was then centrifuged at 
3,000 g for 15 min. The supernatant was transferred to a clean 1.5 mL micro-centrifuge 
tube and dried under a stream of nitrogen gas. Each sample was reconstituted with 250 
μL mobile phase (62% acetonitrile: 38% 0.05 M potassium phosphate monobasic buffer 
adjusted to pH 6.7 with NaOH) and analyzed by HPLC with an Alltech InertsilTM ODS-2 
5 μm, 250×4.6 mm, C-18 column protected by a C-18 guard column (5 μm, 7.5×4.6 mm) 
(Alltech Associates, Inc., Deerfield, IL). The injection volume was 100 μL, and the 
wavelength of absorption was 263 nm (λmax). The limit of detection and quantitation for 
ITZ was 10 ng/mL and 30 ng/mL, respectively. The column was maintained at 37 ℃ 
during the analysis. The ITZ peak eluted at approximately 18 min and the ketoconazole 
peak eluted at 9.3 min at a mobile phase flow rate of 1.0 mL/min.  
 
2.3.16 Pharmacokinetic Analysis 
Pharmacokinetic parameters for lung and serum were derived by 
noncompartmental and one-compartmental analysis, respectively. Pharmacokinetic 
parameters were estimated by standard methods. Cmax was the maximal concentration 
observed, Tmax was the time to Cmax, and they were obtained from the individual 
concentration-time curves. The K01 absorption and K10 elimination rate constants were 
determined by linear regression of the points of the log-linear plasma concentration 
versus time curve. The area-under-the-concentration-time curve from time zero to infinity 
(AUC0–∞) was determined by use of the linear trapezoidal rule with extrapolation to 
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infinity by using the K10 elimination rate constant.  The t1/2 was defined as 0.693/ rate 
constant K [36]. 
 
2.4 RESULTS  
2.4.1 Physicochemical Properties of URF–ITZ Powder 
The URF process was employed to make the nanostructured aggregate powder 
with an ITZ potency of 56%. ITZ is a highly crystalline hydrophobic molecule with a 
molecular weight of 705.64. The degree of crystallinity in the ITZ/excipient mixture has 
been shown to affect the solubility and dissolution rate of ITZ in the mixture [8]. The 
crystallinity of bulk ITZ, mannitol, URF-ITZ and the physical mixture were examined by 
XRD and the profiles are depicted in Figure. 1. The characteristic crystalline peaks for 
ITZ were found at 14.5, 17.6, 20.3, and 23.45 2-theta degrees, as seen in the bulk ITZ 
(purchased from the manufacturer) and physical mixture samples. The physical mixture 
of ITZ: mannitol: lecithin (1: 0.5: 0.2 ratio by weight) showed a qualitative reduction in 
crystalline intensity for both ITZ and mannitol. The URF-ITZ powder was amorphous as 
indicated by the absence of the characteristic crystalline peaks of ITZ and mannitol. 
 
From the SEM images, the bulk ITZ and the physical mixture were composed of 
large, compact crystals at the micron-scale, ranging up to about 5 μm in length (Figures 
2.2a, 2.2b). In contrast, a highly porous structure with more regularly shaped particles of 
the URF-ITZ powder was observed at higher magnifications in Figures 2.2c and 2.2d, 
displaying aggregated nanoparticles that formed a porous matrix. Closer inspection of the 
morphology by STEM demonstrated that the bridged, round shaped primary particles of 
the nanostructured aggregates were about 30-50 nm in diameter, as seen in Figure 2.3a. 
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2.4.2 Energy Dispersive Spectroscopy (EDS)---Elemental Characterization 
The ITZ molecule (C35H38Cl2N8O4) may be distinguished from other molecules 
present in the formulation due to the presence of two chlorine atoms; whereas mannitol 
contains only carbon, oxygen and hydrogen, and lecithin also contains phosphorus. 
Chlorine may be used as a marker to determine the distribution of ITZ molecules within 
the nanostructured aggregates. EDS was used to map the compositional distribution of 
the elements, including: carbon, oxygen and chlorine.  
 
Elemental distribution mapping for carbon, oxygen and chlorine contained in the 
nanoparticle aggregates of URF-ITZ scanned by EDS are presented in Figure 2.3c, d, e 
along with a STEM image of the scanned nanostructured aggregates in Figure 2.3b. 
Element distribution images showed colored dots, representing the presence of a 
particular chemical element, in contrast to the black background. It can be seen that the 
distribution of each element is consistent with the shape and density of the aggregated 
nanoparticles scanned, including the presence of the pores. 
 
2.4.3 Thermal Analysis 
MTDSC was carried out to study the thermal properties of the URF-ITZ powder 
and its individual components. The glass transition temperature (Tg) of URF pure ITZ (no 
excipients; 100% potency), quench-cooled mannitol and quench-cooled lecithin were 
59.6 ℃ (consistent with reports of [37, 38], 16.8 ℃ and 5.1 ℃, respectively, as shown in 
Figure 2.4 thermograms. The URF-ITZ powder (ITZ:mannitol:lecithin=1:0.5:0.2 ratio by 
weight) showed a single Tg at 44.5 ℃. The corresponding physical mixture only showed 
 54
one endothermic melting peak at 166.2 ℃. XRD was conducted on powders of the 
following compositions, and the results indicated that the URF pure ITZ (no excipients; 
100% potency) was amorphous, URF pure mannitol was crystalline, URF pure lecithin 
was amorphous, URF ITZ:mannitol = 1:0.5 (ratio by weight) was amorphous,  and URF 
mannitol:lecithin = 0.5:0.2 (ratio by weight) was partially crystalline (Figure 2.1). 
 
2.4.4 Particle Size Distribution 
The particle size distributions that measured by laser diffraction are shown in 
Table 2.1. The URF-ITZ powder showed a narrow size range with D50 and D90 (diameter 
at which the cumulative sample volume was under 50% and 90%, respectively) are less 
than 230 and 540 nm, respectively, compared to the corresponding values of 2.75 and 
5.10 μm in the corresponding physical mixture. 
 
2.4.5 Specific Surface Area and True Density 
The specific surface area of the URF-ITZ powder was 71.48 m2/g, in contrast to 
2.20 m2/g for the unprocessed bulk ITZ and 1.80 m2/g for the physical mixture. The URF 
process rendered the ITZ/excipients about 30-40 times greater surface area as compared 
to that of the bulk ITZ and the physical mixture, as seen in Table 2.1. 
 
True density of ITZ, mannitol and lecithin were determined to be 1.37, 1.50, 1.10 
g/cm3, respectively, by helium pycnometry.  
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2.4.6 Supersaturation Dissolution Study  
The maximum concentration of dissolved ITZ in simulated lung fluid was 
determined under supersaturated conditions (100-times Ceq). The results are shown in 
Figure 2.5. The Ceq in simulated lung fluid was about 10 ng/mL after shaking at 37 ℃ for 
3 days with excess ITZ present. The URF-ITZ powder showed a value of the measured 
concentration of dissolved ITZ (C ) versus Ceq (C/Ceq) of 22-times at 5 min in simulated 
lung fluid and the highest value of 27-times at 15 min. The supersaturated ITZ 
concentration gradually decreased to about 7-times at 3 h. The physical mixture 
demonstrated about 2-times the measured C/Ceq at 15 and 30 min, and gradually 
decreased and reached a plateau at Ceq value after 2 h in the simulated lung fluid. The 
cumulative extent of supersaturation was calculated as the area-under-the-
supersaturation-curve (AUSC), which was 25,000 and 2,500 ng·min/mL for URF-ITZ 
and the corresponding physical mixture, respectively. 
 
2.4.7 In Vitro Aerosol Performance 
The aerodynamic particle size of the colloidal dispersion of URF-ITZ for 
nebulization, with an equivalent of 100 mg ITZ in 5 mL, is summarized in Table 2.2. The 
TED was 52.97 mg out of 100 mg ITZ available for nebulization. The FPF was 66.96% 
with a fine particle dose (amount of aerosol droplets entering the impactor less than      
4.7 μm, TED × FPF, indication of the dose delivered to the deep lung) delivered at a rate 
of 3.55 mg/min. The MMAD of the atomized droplets was 2.38 μm with a GSD of 2.56, 
which is suitable for deep lung delivery.  
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2.4.8 Stability Study 
The crystallinity of the URF-ITZ powder was monitored using XRD and the 
results are depicted in Figure 2.1. There was no characteristic crystalline peak of ITZ or 
mannitol detected by XRD after storage for up to 12 months, indicating the powder 
retained its amorphous morphology when stored at room temperature and protected from 
humidity. 
 
Additionally as a simulation for the period of the URF-ITZ powder dispersion to 
be nebulized, the absence of characteristic crystalline peaks confirmed that the URF-ITZ 
in the colloidal dispersion remained amorphous over the nebulization time period. 
 
2.4.9 Single Dose, 24-h Pharmacokinetic Study in Mice  
Mice inhaled the single dose aerosols of the nebulized URF-ITZ colloidal 
dispersion for 10 min. ITZ concentrations versus time in the blood and lung samples of 
the single dose 24-h pharmacokinetic study are presented in Figure 2.6. The 
pharmacokinetic parameters are listed in Table 2.3. In the lung samples, the Cmax was 
21.19 μg/g (wet lung tissue) at 0.5 h post dosing. The t1/2 was 7.4 h and the Kelimination rate 
constant was 0.093 h-1, which may explain the ITZ lung level was maintained at         
2.16 μg/g (wet lung weight) for up to 24 h. In serum, based on a one-compartmental 
analysis, the Cmax was 1.64 μg/mL at 2 h after dosing. The K01 absorption and K10 elimination 
rate constants were 0.757 and 0.195 h-1, respectively. The t1/2 k01 and t1/2 k10 were 0.92 and 




2.5.1 Characterization of URF-ITZ and Comparison to SFL-ITZ 
Pulmonary delivery of the nebulized colloidal dispersion of nanostructured 
aggregates of URF-ITZ dramatically improved bioavailability compared to the previously 
reported formulation of SFL-ITZ, more specifically a faster absorption rate, shorter Tmax, 
almost double the Cmax in lung tissue, and 10-times higher Cmax in blood were observed 
[28]. Both of the formulations were tested in the same animal model according to 
identical dosing apparatus and procedures.  Further work would be needed to characterize 
the in vitro properties of the SFL-ITZ dispersions in order to understand these differences 
in bioavailability. 
 
Both SFL and URF processes were able to create submicron particles of drug 
domains within a polymer matrix due to rapid freezing of a co-dissolved drug and 
excipient mixture [8, 9, 39]. Solid dispersions are systems in which drug particles are 
homogeneously distributed throughout a solid matrix. A solid solution results when the 
drug is molecularly dispersed throughout a solid matrix [40]; here, the particle size of the 
drug has been reduced to its absolute minimum without any crystalline drug domains 
[41]. Solid dispersions or solid solutions of poorly water soluble drugs have greatly 
enhanced extents and rates of dissolution, due to increased exposure area of drug to the 
dissolution media and higher Gibbs free energy of the amorphous versus crystalline states 
[6, 42]. This leads to significantly improved bioavailability and therefore is of interest to 
pharmaceutical formulation scientists.  
 
In this study, powder XRD, MTDSC and EDS were used to differentiate between 
a solid dispersion and solid solution. Based on the MTDSC results, a single Tg for the 
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URF-ITZ powder was observed between the Tgs of the amorphous pure ITZ and 
mannitol. The modified Gordon–Taylor equation for ternary systems [43]  was used to 







=   (1) 
where w1, w2, and w3 are the weight fractions of lecithin, mannitol and ITZ, respectively, 
and Tg1, Tg2 and Tg3 are the corresponding glass transition temperatures. K is a constant 
calculated by  
K1= ρ1Tg1/ρ2Tg2, K2= ρ2Tg2/ρ3Tg3 (2) 
where ρ1, ρ2, and ρ3 are the corresponding true densities. The predicted Tg’ of 42.3 ℃, 
agrees closely with the measured Tg of  44.5 ℃ for the URF-ITZ powder.  
 
The XRD pattern indicated that URF processed pure mannitol was partially 
crystalline; whereas ITZ:mannitol=1:0.5 and ITZ:mannitol:lecithin=1:0.5:0.2 (URF-ITZ) 
were completely amorphous. Absence of crystallinity of the drug or complete absence of 
a drug peak (either in DSC or XRD) indicates that the composition is a solid solution 
[44]. The partial crystallization of the mannitol by URF and lyophilization may be 
expected from its low Tg of 16.8 ℃. Kim et al. also reported similar results and difficulty 
in obtaining amorphous mannitol freeze-dried powder [35]. ITZ may retard mannitol 
crystallization from the glassy state, which is expected from a miscible polymer pair. 
Lecithin itself is in an amorphous form. Mannitol and lecithin may plasticize the 
extremely hydrophobic ITZ in the URF-ITZ powder leading to improved wettability, 
though also reduction of its Tg.   
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Moreover, EDS was performed to analyze the distribution of ITZ in the 
drug/excipient matrix by mapping elemental distributions. Theoretically, the ratios of the 
main elements (carbon, oxygen, chlorine) at any given area should be constant if ITZ, 
mannitol and lecithin formed a solid solution. EDS is capable of highly selective spatial 
resolution of chemistry, from volumes as small as 1 μm3 [45]. The qualitative elemental 
distribution images suggest a generally homogenous distribution of ITZ in the scanned 
aggregated nanoparticles of URF-ITZ. Based on MTDSC, XRD, and EDS results, the 
components of the URF-ITZ composition are fully miscible and dispersed in each other 
at the molecular level. Thus, the URF-ITZ powder is primarily a solid solution formed by 
the immobilization of molecularly dispersed ITZ and excipients (mannitol, lecithin) on a 
timescale of milliseconds during the URF process [10, 46].  
 
2.5.2 Role of the surfactant and mannitol 
In the URF-ITZ composition, the soy lecithin is an accepted excipient for aerosol 
inhalation [32]. It is acceptable in the lung as the biocompatible and biodegradable 
substance, i.e. phosphatidylcholine (PC) comprises an estimated 70-80% of the naturally 
occurring pulmonary surfactant pool [47]. Besides playing an important role in improving 
the wettability of the nanoparticles containing ITZ, it may also enhance the absorption of 
ITZ across the lung epithelium. Phospholipids are known to penetrate cell membranes, 
decrease bilayer stability, and thereby induce changes in the cytoskeleton that can affect 
tight junctions and accelerate paracellular passage of drugs [48-50]. Codrons et al. [51] 
reported that incorporation of DPPC into a dry powder formulation of parathyroid 
hormone for pulmonary administration produced a high systemic bioavailability of 34% 
in rats. DPPC has also been shown to increase absorption of insulin via pulmonary 
delivery and enhance the hypoglycemic effect in rats relative to free insulin, when 
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formulated as an admixture or in liposomes [52, 53]. The addition of very small amounts 
of exogenous DPPC may transiently alter local PC concentrations [54], and/or accelerate 
the surfactant turnover process, leading to enhanced penetration of the drug molecules 
through the lung alveolar cells into the systemic circulation [52].  
 
In the present study, the high systemic absorption of ITZ following pulmonary 
dosing may be attributed partially to the inhaled exogenous PC, as well as the small 
particle size. The PC from lecithin may facilitate both dissolution and permeation, via 
dilated pulmonary epithelial tight junctions. Thus, the selection of lecithin as an excipient 
in the URF-ITZ composition offers the potential of marked improvement in absorption, 
without adding toxicity to the formulation. Moreover, the presence of the surfactant in the 
ITZ nanoparticle formulations is important to stabilize the dispersion and aid in wetting 
upon deposition in the lungs. Nanoparticles have high surface energies, due to the high 
surface-to-volume ratio and tend to agglomerate. Wettability of the URF-ITZ powder is 
critical for forming dispersions in the aqueous medium prior to nebulization. Mannitol 
was chosen as the second excipient in the URF-ITZ composition, to improve wetting of 
the URF-ITZ powder by introducing water into the matrix to aid dissolution. 
Once the drug is deposited in the aqueous lining fluid in the lung, the mannitol 
may quickly dissolve, resulting in a porous drug matrix. Lecithin will initially swell, 
causing stress relaxation of the matrix and allowing water ingress before it dissolves. 
These processes will help stabilize the ITZ from aggregation and precipitation during 
dissolution.  
 
The URF process dramatically increased the surface area of the nanostructured 
aggregates of URF-ITZ to about 40 times that of the corresponding physical mixture for 
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dissolution. Additionally, the thinner diffusion boundary layer for the smaller particle 
size raises the dissolution rate [55, 56]. Furthermore, the degree of crystallization of 
undissolved ITZ in the particles upon exposure to the lung fluid is reduced by the rapid 
dissolution of the high surface area nanoparticles relative to microparticles, as examined 
in detail elsewhere [6]. A combination of increased intrinsic solubility and reduced 
chance to crystallize of undissolved ITZ in the media may provide an explanation for the 
URF-ITZ to produce supersaturation values more than 20-times Ceq in simulated lung 
fluid.  
 
2.5.3 Deposition of the nanoparticles containing ITZ  
It is generally accepted that aerosol droplets with aerodynamic diameters between 
1-5 μm can be delivered into the alveolar lumen after inhalation [57]. Furthermore, the 
aerosol diameter of aqueous droplets produced by nebulizers may readily be tuned to this 
optimal size range [27]. Nanoparticles may be distributed more uniformly throughout  the 
nebulized droplets than microparticles [58, 59]. For instance, if the volume fraction, f, of 
particles in the solvent is 0.01, then only about 1/100 of 3 μm carrier droplets will contain 
a 3 μm particle.  In contrast each carrier droplet would contain about twenty-two 230 nm 







f/NN =   (3) 
Thus, the rate of drug absorption may be increased for nanoparticle relative to 
microparticle colloidal dispersions, by promoting more uniform drug distribution 
throughout the alveoli [60, 61].  More specifically, for a 32.5 μg drug/g lung dose (chosen 
based on the ITZ Cmax recovered from lung tissue at t=0.5 h and the corresponding blood 
concentration given in Figure 2.6.) delivered as 3 μm drug particles, only 1 in 75 alveoli 
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are estimated to receive a particle. However, approximately 30 drug particles are 
deposited in each alveolus when the same dose is delivered as 230 nm drug particles.   
 
2.5.4 Absorption of ITZ as a function of the composition and particle morphology 
A drug in an amorphous state will possess a higher intrinsic solubility than in its 
crystalline state [6, 62-64]. The URF-ITZ powder was shown to be an amorphous solid 
solution by DSC, XRD, and elemental mapping analysis. Furthermore, the exposure of 
ITZ molecules to the dissolution medium is maximized in the high surface area particles, 
as the soluble mannitol and lecithin dissolve in the lung lining fluid. The dispersed ITZ 
molecules are then available as free molecules to form a supersaturated solution [41]. 
After deposition of the inhaled ITZ nanoparticles in the lung lining fluid, the rate and 
extent of dissolution influence the permeation rate of ITZ through the lung epithelium to 
reach systemic circulation.  
 
The effects of particle size, dissolution rate, extent of supersaturation and 
permeability on absorption of poorly water soluble drugs in the lungs were examined 
with a model reported recently [29]. The Noyes-Whitney equation describes the 
dissolution rate of ITZ spherical nanoparticles.  The permeate concentration was assumed 
to be zero as the drug concentration in the blood may be assumed to be insignificant 
compared to that in the alveolar fluid and thus the permeation is irreversible [65]. The 
thickness of the human alveolar membrane (100-200 nm) is small versus the diameter of 
the alveolus (300 μm) [27, 66] and thus planar coordinates are appropriate. Consider a 
material balance on the fluid surrounding a drug particle in the alveolar fluid as shown in 
Figure 2.7. The accumulation of dissolved drug in the fluid of a single alveolus C is given 
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by the inlet flow from particle dissolution and the depletion by an outlet flow from drug 











where Np is the number of drug particles deposited in each alveolus, D is the 
diffusion coefficient of the drug, P is the permeability, and V and A are the volume and 
surface area, respectively, of an annular layer of lung fluid in a single alveolus adjacent to 
the epithelium (Figure 2.7.). Absorption half-lives were determined as the time when 
Mpermeated/M0 = 0.5 or likewise, r3/ r03 = 0.5. It is instructive to consider the two boundary 
conditions for absorption: purely dissolution limited and purely permeation limited. For 
purely dissolution limited absorption (P = ∞ and C → 0), the absorption half-life 







50 ≈  (5) 





t =  (6) 
where AAlv = A for planar geometry.   
    
The Wilke-Chang equation was used to estimate a D= 5.26 × 10-6 cm2/s [67] for 
ITZ. A P value of 5.61 × 10-5 cm/s was chosen based on experimental ITZ permeabilities 
in intestinal membranes [68]. Common permeabilities of poorly water soluble drugs with 
similar molecular sizes in lung cell cultures range between 10-6-10-4 cm/s [69]. The 
number of drug particles deposited in the lungs was calculated from an estimated drug 
dose and the average particle volume. The drug dose, or the total mass of drug deposited 
in the lungs, was approximated to be 5.8 µg (32.5 µg/g wet lung tissue) based on the lung 
tissue Cmax (21.2 μg/g) and the corresponding blood concentration (492 ng/mL) from the 
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single-dose pharmacokinetic study. The number of alveoli in a mouse was estimated to be 
~2.25 ×107, calculated using an alveolar surface area of 680 cm2 [70] and alveolus 
diameter of 31 μm [71] for mice. Total alveolar fluid volume was estimated to be 8.3 μL, 
based on a human alveolar surface fluid volume of 15 mL [66, 72] and the ratio of human 
lung to mouse lung weight.   
 
Figure 2.8. shows the predicted absorption half-lives for particles ranging from 50 
nm to 3 μm in diameter for a wide equilibrium solubility range, from 10 ng/mL to 10 
μg/mL. Particle sizes between 50-230 nm are representative of URF-ITZ particles, as 
determined by STEM images (Figure 2.3a) and light scattering results (Table 2.1.), 
whereas a particle size of 3 µm is typical of particles traditionally delivered to the lungs 
(Courrier et al., 2002). The t50 for a crystalline 3 micron ITZ particle (Csat=10 ng/mL) 
was estimated to be 200 h (Figure 2.8G), far too slow to be appropriate for therapy. In 
contrast, t50 values for the amorphous 230 nm particles were only 14.7 min, which would 
be consistent with the kinetics for the studies with mice in Figure 2.6.  
 
The t50 values are shown for purely dissolution limited absorption (diamonds, 
infinite permeability) and purely permeation limited absorption (asterisks, C = Csat). For 
permeation limited absorption, t50 does not change with particle size for the 50 and 230 
nm particles as predicted from eq. 6. However, it is much larger for a 3 μm particle 
deposited in an alveolus because of the larger Mo. Based on in-vivo lung and blood levels, 
only 1 in 67 alveoli would be estimated to receive a 3 μm drug particle compared to about 
30 particles per alveolus for a 230 nm particle. For the 230 nm particles, the smaller Mo 
resulting from the more uniform distribution of particles throughout all of the alveoli is a 
major benefit, as it produces smaller t50 values relative to microparticles. 
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For all three Csat values with 3 μm particles, the absorption rate is strongly limited 
by the dissolution rate as expected for a BCS Class II drug. Thus, the t50 decreases orders 
of magnitude with an increase in Csat by 1000 fold, which increases the driving force for 
particle dissolution. Interestingly, the absorption became much more permeability limited 
than dissolution rate limited for the 230 nm particles, no longer exhibiting BCS Class II 
behavior, for all three Csat values. For the high surface area 50 nm particles, the 
dissolution rate limited t50 was about two orders of magnitude shorter than the permeation 
limited value. With the extremely rapid dissolution rates relative to permeation, 
absorption times remained fairly constant versus particle diameter for sub-230 nm 
particles, at a given equilibrium solubility (Figure 2.8A-F).   
Despite the high dissolution rate for the 230 nm crystalline particles, the t50 value 
was still undesirably long because of the effect of the low Csat on the permeability. The t50 
was reduced markedly by an increase in Csat for the amorphous URF-ITZ. Yet a further 
improvement in permeation rates may be achieved by incorporating permeability 
enhancers. In fact, the increased systemic absorption rate of  URF-ITZ over SFL-ITZ 
[28], despite the similar particle sizes, may be explained by the incorporation of lecithin 
in the URF-ITZ formulation, a known permeation enhancer. As a result, an order of 
magnitude increase in Cmax was achieved in circulation (URF-ITZ: 1.64 μg/mL serum 
versus SFL-ITZ: 0.12 μg/mL) in a shorter time (Tmax of URF-ITZ: 2 h versus SFL-ITZ: 
5.35 h) as well as a higher absorption rate of ITZ from lung to blood compared to the 




Amorphous ITZ particles were made by the ultra-rapid freezing process with 
FDA approved biodegradable and biocompatible excipients to achieve a mean diameter 
of 230 nm, a large surface area of 71 m2/g, and a wettable surface. The particles dissolved 
rapidly in simulated lung fluid to produce supersaturation levels up to 27-times of Ceq for 
the crystalline form. Nebulized aqueous colloidal dispersions of the ITZ nanoparticles 
exhibited aerodynamic characteristics suitable for deep lung delivery. An in vivo single 
dose 24-h pharmacokinetics study of the nebulized ITZ nanoparticle dispersion 
demonstrated substantial lung deposition and systemic absorption with blood levels 
reaching a peak of 1.6 μg/mL serum in 2 h.  
 
To investigate the mechanism of drug absorption in the alveolar epithelium, a 
dissolution/permeation model was used to elucidate the effects of particle size and 
solubility. ITZ microparticles (3 μm) exhibited BCS Class II behavior for poorly soluble 
drugs with high permeabilities, where the absorption was influenced strongly by the 
dissolution rate. However, for 230 nm particles, the dissolution became sufficiently fast 
such that the concentration in the alveolar fluid reached saturation, and consequently, the 
absorption became permeation limited.  Therefore, a microparticle formulation with BCS 
Class II behavior, may exhibit a completely different kind of behavior when reformulated 
at the nanoscale. 
 
Four strategies were used to raise the bioavailability. The aqueous nebulized 
droplets were optimized to deposit the drug in the deep lungs. The decrease in particle 
size (increase in surface area) enhanced the dissolution rate as well as the uniformity of 
the distribution of drug dose among the alveoli. The increase in Csat with the formation of 
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an amorphous polymorph, raised the driving force for permeation through the alveolar 
membrane. The fourth and final approach was to raise the membrane flux with lecithin, a 
known permeation enhancer. For the permeation limited absorption of the 50-230 nm 
URF-ITZ nanoparticles, the presence of lecithin may have contributed to the enhanced 
systemic levels observed in the in-vivo results. Pulmonary delivery of the ITZ 
nanoparticle aerosols offers the potential to treat invasive fungal infections more 
effectively in patient populations that have poor prognosis. 
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Table 2.1. Particle size distributions and specific surface areas (SSA) of URF-ITZ (URF 
processed ITZ:mannitol:lecithin = 1:0.5:02) powders, Physical Mixture 
(physical mixture of ITZ:mannitol:lecithin = 1:0.5:02) and bulk ITZ. 
 
Particle Size (μm) 
Samples D(v, 0.1) D(v, 0.5) D(v, 0.9) SSA (m2/g) 
URF-ITZ  0.09 0.23 0.54 71.48 
Physical Mixture 1.45 2.75 5.1 1.80 









Table 2.2. Cascade impaction data for URF-ITZ (URF processed ITZ:mannitol:lecithin = 
1:0.5:02) powder, aerosolized using the Aeroneb® Professional micropump 
nebulizer at an air flow-rate of 28.3 L/min for 10 min. 
Total Emitted Dose (mg) 52.97 
Fine Particle Fraction (%) 66.96 
Fine Particle Dose  (mg/min) 3.55 
Mass Median Aerodynamic Diameter (MMAD) (µm) 2.38 







Table 2.3. Pharmacokinetic parameters for lung deposition and serum concentration in 
male outbred ICR mice (25 g) after inhalation of nebulized URF-ITZ (URF 
processed ITZ: mannitol: lecithin = 1: 0.5: 02) nanoparticles dispersion 
following single dose administration.  
 
 SFL-ITZ* URF-ITZ 
Pharmacokinetic parameter Lunga Serumb Lunga Serumb 
Cmax (μg/g) 13.4 0.12 21.19 1.64 
Tmax (h) 1 5.35 0.5 2 
t1/2 K01 (h)  3.73  0.92 
t1/2 K10 (h) 5.5 3.7 7.44 3.55 
K01 absorption (h-1)  0.186  0.76 
K10 elimination (h-1) 0.13 0.188 0.093 0.2 
AUC0–24 (μg·h/mL)    126.74 5.53 
AUC0–∞ (μg·h/mL) 85.8 1.69 149.94 5.60  
 
* Data of SFL-ITZ were adapted from [28] for comparison purposes. 
a Based on non-compartmental analysis of the lung tissue concentrations versus time. 
b Calculated based on one-compartmental analysis of the serum concentrations versus     








































Figure 2.1. X-ray powder diffraction patterns (from the top to bottom): micronized bulk 
mannitol, Physical Mixture (physical mixture of ITZ:mannitol:Lecithin = 
1:0.5:0.2), URF-ITZ (URF processed ITZ:mannitol:Lecithin = 1:0.5:0.2), 
URF processed lecithin, ITZ, mannitol, ITZ:mannitol = 1:0.5 (ratio in 
weight), mannitol:lecithin = 0.5 :0.2 (ratio in weight), respectively, re-
lyophilized powder from a fast frozen colloidal dispersion of the URF-ITZ 
(20 mg ITZ/mL) after sitting at room temperature for 15 min, URF-ITZ 
powders after stored in desiccators under vacuum at room temperature for 1, 
3 and 12 months, respectively, micronized bulk ITZ. 
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Figure 2.2. SEM images of (a) Bulk ITZ at a magnification of 5k (b) Physical Mixture of 
ITZ: mannitol: Lecithin = 1: 0.5: 0.2 at a magnification of 5k (c) URF-ITZ 
(URF processed ITZ: mannitol: Lecithin = 1: 0.5: 0.2) at a magnification of 
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Figure 2.3. (a) STEM image of nanoparticles of URF-ITZ (URF processed 
ITZ:mannitol:Lecithin = 1:0.5:0.2). (b) STEM image of nanoparticles of 
URF-ITZ at a higher magnification for elemental analysis by area scan using 
energy dispersive spectroscopy.  The particles within the pink frame were 
scanned for elemental distribution. (c) Carbon atoms distribution in the 
scanned nanoparticles (d) Oxygen atoms distribution in the scanned 







Figure 2.4. DSC profiles of (a). URF processed pure ITZ, (b). Quench-cooled mannitol, 
(c). Quench-cooled lecithin, (d). URF-ITZ (ITZ:mannitol:lecithin = 
1:0.5:0.2 ratio in weight), (e). Physical mixture of ITZ:mannitol:lecithin = 



















Figure 2.5. Dissolution profiles of URF-ITZ (URF processed ITZ: mannitol: Lecithin = 
1: 0.5: 0.2) and Physical Mixture (ITZ: mannitol: Lecithin = 1: 0.5: 0.2) in 
simulated lung fluid (pH=7.4) at supersaturation conditions (e.g. 100-times 
equilibrium solubility of crystalline ITZ was added) using 100-mL vessels 























































Figure 2.6. Serum concentration and lung deposition of ITZ in male outbred ICR mice 
after inhalation of nebulized URF-ITZ (URF processed ITZ: mannitol: 
Lecithin = 1: 0.5: 0.2, ratio by weight) colloidal dispersion by single dose 
administration (an equivalent dose exposure of 100 mg/kg by aerosolization 
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Figure 2.7. Schematic of material balance used in dissolution/permeation model.  The 
concentration of dissolved drug in the alveolar fluid of a single alveolus, C, 
is given by the inlet flow from particle dissolution and the depletion by an 








Figure 2.8. Predicted absorption half lives (time for 50% of drug to dissolve and permeate 
through lung epithelium) for various particle sizes and solubilities. The 
values are also shown for purely dissolution limited absorption (diamonds, 
infinite permeability) and purely permeation limited absorption (asterisks, 
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Chapter 3: Comparison of the Bioavailability of Amorphous versus 




The effect of supersaturation on bioavailability of inhaled nebulized aerosols is 
compared for amorphous versus crystalline nanoparticulate dispersions. The 
nanocrystalline formulations of itraconazole (ITZ) were made using wet milling (i.e. 
Wet-milled ITZ), whereas nano-structured aggregates (ITZ:mannitol:lecithin =1:0.5:0.2, 
weight ratio) were made using an ultra-rapid freezing process (i.e. URF-ITZ). Dissolution 
tests revealed the extent of supersaturation was 4.7-times higher for URF-ITZ versus 
Wet-milled ITZ, though their dissolution rates were similar. The aerodynamic 
performances of both aqueous colloidal dispersions were comparable and suitable for 
deep lung delivery. Single-dose 24-hr pharmacokinetic studies were conducted in 
Sprague-Dawley rats following inhalation of the nebulized colloidal dispersions 
(equivalent to 20 mg ITZ/mL dispersion in 5 mL) using a nose-only dosing apparatus. 
Lung depositions following inhalation were similar for both compositions. In systemic 
circulation, Wet-milled ITZ and URF-ITZ achieved Cmax of 50.4 and 177.5 ng/mL at 2.7 
and 4 hr, and AUC0–24 of 662 and 2543 ng·hr/mL, respectively, based on one-
compartmental analysis. Pulmonary delivery of the nanoparticulate amorphous ITZ 
composition resulted in significantly higher systemic bioavailability than for the 
nanocrystalline ITZ composition, as a result of the higher supersaturation that increased 
the permeation of ITZ.   
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3.2 INTRODUCTION  
Modern drug discovery processes, which routinely use high throughput screening 
techniques, appear to result in a higher prevalence of lead compounds with increased 
molecular weight and lipophilicity [1, 2]. Such drug molecules pose challenges to 
formulate therapeutically effective products for clinical use, since they often have poor 
bioavailability issues due to their poor dissolution or poor permeability to achieve 
sufficient and consistent systemic exposure. Consequently this results in sub-optimal 
efficacy in patients, particularly when delivered via the oral administration [3, 4].  
 
To address the issues of low aqueous solubility, solubilization and micronization 
have commonly been used to increase dissolution rate and thereby oral bioavailability of 
such drugs. Attempts to solubilize and stabilize these drugs using salt formation [5], co-
solvents [6], micellar solutions [7], or inclusion complexes with cyclodextrins [8] have 
been of limited success. The increased amount of excipients required to formulate the 
poorly water-soluble drugs may potentially increase side effects, resulting in low patient 
compliance. Alternatively, invasive dosage forms such as parenteral formulations have to 
be developed to address the challenges being presented. However, with even less 
pharmaceutically acceptable excipient options, increased solubilization of drug is 
practically limited [9].  
 
For the means of micronization, although particle size reduction of the poorly 
water-soluble drugs increases their dissolution rate by increasing drug surface area, it 
does not increase equilibrium solubility. Often for drugs with very low aqueous 
solubility, the achieved increase in dissolution rate is limited and insufficient to provide 
significant enhancement of bioavailability [3].  
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However, drug particles in the 100 nm range dissolve more quickly and to a 
greater extent (i.e., higher equilibrium solubility) than micronized drug particles, as 
described by the Noyes-Whitney and Ostwald-Freundlich equations [10]. Both particle 
dissolution kinetics and solubility are size dependent. Thus, the dissolution of drug 
nanoparticles in vivo is usually accompanied by an increase in bioavailability [11, 12]. 
On the other hand, the potential for increased Van der Waals interactions and electrostatic 
attraction between ultrafine particles can reduce the effective surface area for dissolution 
and therefore counteract improvements in bioavailability [13]. Colloidal dispersions of 
drug nanocrystals with a typical mean particle size between 200 and 500 nm and 
stabilized by a suitable stabilizer (i.e. nanosuspension) [4], have therefore been developed 
as an alternative approach.  
 
The effectiveness of nanosuspensions of poorly water-soluble drugs in enhancing 
bioavailability has been proved in animal models and clinical trials with various 
administration routes, including oral [14, 15], pulmonary [16-18], ocular [19, 20] and 
parenteral delivery due to their particle size sufficiently small to be injected intravenously 
[21-23]. Among these, of particular interest is inhalation delivery, because of the 
following advantages of this noninvasive delivery route: (1) potential for high systemic 
absorption with an enormous absorptive surface area of approximately 100 m2, very thin 
diffusion path to the blood stream and rich vasculature that facilitate rapid delivery of 
large drug doses; (2) targeted lung local action with reduced systemic side effects relative 
to other routes of administration, and (3) relatively low metabolic activity and avoidance 
of hepatic first-pass metabolism [24, 25].  
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Several studies predicted, from thermodynamics, the potential impact of 
polymorphs on bioavailability based on in vitro dissolution profiles and/or thermal 
analysis for oral delivery [26-28]. The amorphous form of a drug has a higher 
thermodynamic chemical potential than its crystalline counterpart [29]. The higher 
thermodynamic activity of the drug can produce supersaturated solutions [28, 30], 
thereby providing an opportunity to enhance absorption and bioavailability. In most 
experimental studies, supersaturation values of micron sized particles are less than 5-
times Ceq, despite predictions from calorimetric measurements of the heat capacity (used 
to determine the free energy) that they can be much larger [26, 31]. Significantly higher 
supersaturation values approaching 100 were achieved for amorphous nanoparticles 
relative to microparticles, as the microparticles crystallize in the solid state before they 
dissolve and produce high supersaturation [32]. The experimental supersaturation values 
approached the large values calculated from the heat capacity glassy solid measured by 
DSC [28], unlike previous studies with microparticles where supersaturation values are 
typically below 5.   
 
Amorphous nanostructured formulations of poorly water-soluble drugs for 
pulmonary delivery have also been developed to enhance therapeutic effectiveness [33, 
34].  Vaughn et al. reported that inhaled aerosols in mice of a nebulized ITZ amorphous 
nanoparticulate composition (ITZ: polysorbate 80: poloxamer 407 = 1:0.75:0.75 by 
weight ratio, prepared by Spray Freezing into Liquid technology; namely SFL-ITZ) for 
20 min, achieved a lung tissue Cmax of 13.4 μg/g wet lung weight and an AUCinf of     
99.7 μg·hr/mL, and a serum Cmax of 0.12 μg/mL [35]. Inhalation of another ITZ 
nanostructured composition (ITZ: poloxamer 407: polysorbate 80 = 1: 0.16: 0.13 by 
weight ratio, prepared by Evaporative Precipitation into Aqueous Solution technology; 
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namely EPAS-ITZ) which had a crystalline morphology, in the same mouse model 
produced a high lung Cmax of 16.8 μg/g wet lung weight and an AUCinf of 85.8 μg·hr/mL, 
but no systemic ITZ level was reported [36]. Despite the similar lung depositions of 
inhaled ITZ, in a subsequent prophylaxis study using a mouse model of invasive 
pulmonary aspergillosis, the nebulized aerosols of SFL-ITZ led to higher survival than 
for EPAS-ITZ for both short (8 days) and long-term survival (20 days) [37]. This 
improvement in survival may have resulted from a higher supersaturation of ITZ in the 
lung fluid for the amorphous SFL-ITZ, compared to crystalline EPAS-ITZ formulation.  
 
To our knowledge, so far no study has assessed the effects of amorphous versus 
crystalline nanoparticulate formulations of a poorly water-soluble drug on in vivo 
bioavailability following lung delivery. In the present study, we evaluate the impact of 
the in vitro solubility advantage of amorphous versus crystalline nanoparticulate 
formulations of poorly water-soluble drug on bioavailability following pulmonary 
administration. We hypothesize that the supersaturation produced by inhaled amorphous 
nanoparticles of a poorly water-soluble drug will produce a higher systemic absorption 
and thereby enhanced bioavailability, relative to the nanocrystalline counterpart. ITZ was 
chosen as a model poorly water-soluble drug, because of its extremely high lipophilicity, 
i.e. an estimated aqueous solubility of about 1 ng/mL at neutral pH and a calculated 
octanol/water partition coefficient (Clog P) value of 6.2 [38]. A nano-sized crystalline 
ITZ composition was made by wet ball milling process (i.e. Wet-milled ITZ). The 
amorphous nano-structured aggregates of ITZ composition (ITZ: mannitol: lecithin =1: 
0.5: 0.2 by weight ratio) with a large, wettable surface made by ultra-rapid freezing 
process (i.e. URF-ITZ) was reported previously [34]. We compare both the 
physiochemical properties in vitro and the bioavailability after inhalation in rats. Given 
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that pulmonary delivery has become an increasingly attractive route of application for 
poorly water-soluble drugs, the ability to provide greater insight into formulation design 
for improved bioavailability will be of widespread interest.  
 
3.3 MATERIALS AND METHODS 
3.3.1 Materials 
The following materials were purchased: ITZ, micronized B.P. grade (Hawkins 
Chemical, Minneapolis, MN); mannitol and lecithin (Spectrum Chemicals, Gardena, 
CA); 1,4-dioxane and acetonitrile (Fisher Scientific, Fair Lawn, NJ); diethanolamine 
(VWR International, West Chester, PA). All organic solvents used were HPLC grade. 
Other reagents used were at least of ACS grade.  
 
3.3.2 Preparation of Crystalline ITZ Nanoparticulates and Amorphous 
Nanostructured Aggregate of ITZ  
The crystalline ITZ nanoparticulates were prepared by wet ball milling in a 
ceramic jar with Zirconia grinding media (1/2" Radius end cylinder) (U.S. Stoneware, 
East Palestine, OH). Three grams of the commercially available ITZ powder (mean 
particle size of 5 μm in diameter, 100% < 17.7 μm) was added 15 mL of purified water 
and milled at 100 rpm 20 °C under nitrogen gas for 10 days. Thus obtained slurry was 
combined with several successive washings of the ceramic jar and milling media using 
purified water to make a dispersion of the milled ITZ; which was then quickly frozen by 
dripping into liquid nitrogen and lyophilized to obtain dry powder by using a VirTis 
Advantage bench top tray lyophilizer (The VirTis Company, Inc., Gardiner, NY, USA). 
Thus obtained Wet-milled ITZ dry powder was stored in a desiccator under vacuum 
(~15% relative humidity) at room temperature.  
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Amorphous nanostructured aggregate URF-ITZ powder was prepared using the 
ultra-rapid freezing (URF) technology, as described previously [34]. In brief, lecithin was 
dissolved in a mixture of 1, 4-dioxane and purified water (65/35, v/v) co-solvent system 
using a magnetic stirrer. Mannitol and ITZ were subsequently dissolved in the mixture, in 
a weight ratio of ITZ:mannitol:lecithin = 1:0.5:0.2. The solution was rapidly frozen after 
applied to the URF apparatus that pre-cooled to about −70 °C [39]. The frozen solids 
were collected, lyophilized and stored the same as described above.  
 
3.3.3 Scanning Electron Microscopy (SEM) 
SEM was used to evaluate the morphology of the samples. The samples were 
mounted onto an aluminum stage using conductive carbon tape. Samples were coated 
using a model K575 sputter coater (Emitech Products, Inc., Houston, TX) with 
gold/palladium for 20 sec in a high vacuum evaporator. SEM was performed using a 
Hitachi S-4500 field emission scanning electron microscope (Hitachi High-Technologies 
Corp., Tokyo, Japan) operating at an accelerating voltage of 10-15 kV. Images were 
captured with Quartz PCI software (Quartz Imaging Corporation, Vancouver, BC, 
Canada). 
 
3.3.4 Powder X-Ray Diffraction (XRD) 
The crystallinity of the dried powders of Wet-milled ITZ and URF-ITZ were 
examined by wide angle XRD. A Philips 1710 X-ray diffractometer with a copper target 
(CuKa1,λ = 1.54056 Å) and nickel filter (Philips Electronic Instruments Inc., Mahwah, 
NJ) was used to obtain the XRD patterns. Dried powder was pressed onto a glass slide to 
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from a level surface. Samples were analyzed in the 2-theta range from 10 to 50° using a 
step size of 0.05 2-theta degree with a dwell time of 2 sec. 
 
3.3.5 Modulated Temperature Differential Scanning Calorimetry (MTDSC) 
Thermal properties of the powder samples were investigated using a TA 
Instruments Model 2920 DSC (New Castle, DE), equipped with a refrigerated cooling 
system. Dry nitrogen gas was used as the purge gas through the DSC cell at a flow rate of 
40 mL/min. Samples were weighed to 10-15 mg in aluminum crimped pans (Kit 0219-
0041, Perkin-Elmer Instruments, Norwalk, CT). The mass of the empty sample pan was 
matched with that of the empty reference pan within ±0.2 mg. Samples were heated at a 
ramp rate of 10 ℃/min from 0 to 200 ℃ with a modulation temperature amplitude of 1 
℃/60 sec. Data was analyzed using TA Universal Analysis 2000 software (TA 
Instruments, New Castle, DE).  
 
3.3.6 Particle Size Analysis  
Particle size distribution, based on volume fraction, of the colloidal dispersions of 
Wet-milled ITZ and URF-ITZ was measured by static light scattering with a Malvern 
Mastersizer-S (Malvern Instruments, Ltd., Worcestershire, UK). The colloidal dispersion 
of URF-ITZ (equivalent to 20 mg ITZ/mL) was prepared by dispersing an aliquot of 
URF-ITZ powder (~ 170 mg) in 5 mL purified water by sonication on an ice bath. The 
colloidal dispersion of Wet-milled ITZ was prepared by dispersing an aliquot of Wet-
milled ITZ powder (~ 100 mg) in 5 mL aqueous solution containing 1% mannitol and 
0.4% lecithin to make the compositions same as the URF-ITZ dispersion. To measure the 
particle size distribution, the respective dispersion was then diluted with about 500 mL of 
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purified water to produce light obscuration in the range of 10–15%. Values reported are 
the average of at least three measurements. 
 
3.3.7 Brunauer-Emmett-Teller (BET) Specific Surface Area Analysis 
Specific surface area was measured using a Nova 2000 version 6.11 instrument 
(Quantachrome Instruments, Boynton Beach, FL) with nitrogen as the adsorbate gas. An 
aliquot of powder was added to a 12-mm Quantachrome bulb sample cell and degassed 
for a minimum of 8 hr prior to analysis. Six points were taken over a range of relative 
pressures from 0.05 to 0.35. The data was then analyzed with the BET equation using 
NOVA Enhanced Data Reduction Software (version 2.13). 
 
3.3.8 Dissolution Testing Under Supersaturated Conditions 
Dissolution testing at supersaturated conditions was conducted in a USP 25 
dissolution apparatus model Vankel 7000 Dissolution Tester (Vankel Technology Group, 
Cary, NC) using 100 mL glass dissolution vessels and stirred with small paddles at 100 
rpm. Simulated lung fluid containing 0.02% dipalmitoylphosphatidylcholine [40, 41] was 
used as the dissolution medium and pre-heated to 37 ℃. Aliquots of the URF-ITZ and 
Wet-milled ITZ colloidal dispersions (equivalent of 80 μg ITZ, equal to 100-times of the 
equilibrium solubility (Ceq) of crystalline ITZ) were added to the dissolution vessels (n = 
6), respectively, within one second immediately after preparation. Aliquots of 2 mL of 
the dissolution media were taken at 5, 15, 30 min, 1, 2, 3, 6, 12 and 24 hr. The samples 
were immediately filtered through a 0.2 μm GHP Acrodisc filter (Pall Corporation, East 
Hills, NY), and diluted with acetonitrile for content analysis. The ITZ content was 
quantified using a Shimadzu LC-10A high performance liquid chromatography (HPLC) 
 95
system (Shimadzu Corporation, Columbia, MD) equipped with an Alltech InertsilTM 
ODS-2 5 μm, 150 mm × 4.6 mm, C-18 column (Alltech Associates, Inc., Deerfield, IL). 
The mobile phase was acetonitrile:water:diethanolamine (70:30:0.05) and it eluted the 
ITZ peak at approximately 5.5 min at 25 ℃ with a flow rate of 1 mL/min. The ITZ 
absorbance was measured at a wavelength λmax of 263 nm. The supersaturation levels are 
reported as the drug concentration divided by the crystalline equilibrium solubility. 
Supersaturation was plotted versus time and area-under-the-supersaturation-curve 
(AUSC) was calculated by the linear trapezoidal rule.  
 
3.3.9 In Vitro Aerosol Performance 
An aliquot (5 mL) of the colloidal dispersions of the Wet-milled ITZ and URF-
ITZ (equivalent to 20 mg/mL ITZ) were nebulized using an Aeroneb® Professional 
micropump vibrating mesh nebulizer (Nektar Inc., Mountain View, CA) for about 10 
min. The in vitro deposition characteristics of the colloidal dispersions of Wet-milled ITZ 
and URF-ITZ for nebulization, was investigated using an eight-stage Andersen cascade 
impactor (Thermo-Electron Corp., Symrna, GA). The cascade impactor was assembled 
and operated in accordance with USP General Chapter 601 to assess the drug delivered. 
The flow rate of the nebulized aerosols was maintained by a vacuum pump (MFG Corp., 
Benton Harbor, MI) that was calibrated by a TSI mass flowmeter (Model 4000, TSI Inc., 
St. Paul, MN) to an air flow rate of 28.3 L/min. After deposition onto the stages of the 
impactor, the mass deposited on each of the impactor pieces was collected and the total 
mass of drug was quantified by HPLC. The aerosolization behavior was described in 
terms of total emitted dose (TED), mass median aerodynamic diameter (MMAD), 
geometric standard deviation (GSD), and percentage fine particle fraction (FPF; defined 
as the percentage of droplets with an aerodynamic diameter less than 4.7 μm). The 
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MMAD and GSD were obtained by plotting the cumulative mass found on the stages of 
the impactor as a function of the logarithm of the impactor stage cut-off diameter.  
 
3.3.10 In Vivo Pulmonary Dosing of Rats 
With approval and in accordance with the Institutional Animal Care and Use 
Committee (IACUC) guidelines at The University of Texas at Austin, in vivo studies 
were conducted using jugular vein pre-catheterized CD® IGS Sprague-Dawley rats 
(Charles River Laboratories, Inc., Wilmington, MA), weighing 275 to 325 grams. 
Throughout the study the rats were housed individually, subjected to 12 h -12 h light and 
darkness cycles, with access to food and water ad libitum. The catheters were flushed 
daily with heparinized normal saline. After acclimatization for 3 days, eight rats in each 
formulation group were dosed by inhalation of the nebulized colloidal dispersions of the 
Wet-milled ITZ or URF-ITZ (equivalent to 20 mg/mL ITZ), respectively, for 10 min in a 
nose-only dosing apparatus, as shown in Figure 3.1. An Aeroneb® Professional 
micropump nebulizer was situated at the inlet of the dosing tube, and the nebulized drug 
aerosols went through the dosing tube with an air flow rate of 1 L/min. Following 
exposure to the aerosol cloud, serial blood samples (approximately 0.3 mL each) were 
withdrawn through the jugular vein catheter at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 
hr post dosing and placed into a pre-heparinized microcentrifuge tube. Equal volumes of 
saline were replaced after each sampling. Two rats in each dosing group were sacrificed 
immediately upon finishing inhalation to harvest the lungs for determining the lung 
deposition of the inhaled drug. The lungs of the other rats were harvested at 24 hr upon 
completing blood sampling.  
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3.3.11 Plasma and Lung Analysis  
Plasma was separated by centrifugation at 3,000 g for 10 min in a 1.5 mL micro-
centrifuge tube using a Microfuge® 18 centrifuge (Beckman Coulter, Fullerton, CA). The 
plasma and lung samples were stored at -80 ℃ until HPLC analysis. The lung 
homogenates were prepared by adding 1 mL of normal saline to a portion of about 0.5 g 
of the harvested lung and using a homogenizer (Omni International, Marietta, GA) in an 
ice bath. Drug levels of the calibration standards, plasma, and homogenized lung samples 
were analyzed using the following procedures. Briefly, to an aliquot of 250 μL plasma or 
250 μL of lung homogenate, 50 μL of 0.3 N barium hydroxide, and 50 μL of 0.4 N zinc 
sulfate heptahydrate solutions were added and vortex mixed for 30 sec to precipitate 
water-soluble proteins. Acetonitrile (1 mL), containing 500 ng/mL ketoconazole as an 
internal reference standard, was added to each sample followed by vortex mixing for    
1.5 min. Each sample was then centrifuged at 3,000 g for 15 min. The supernatant was 
transferred to a clean 1.5 mL micro-centrifuge tube and dried under a stream of nitrogen 
gas. Each sample was reconstituted with 250 μL mobile phase (62% acetonitrile: 38% 
0.05 M potassium phosphate monobasic buffer adjusted to pH 6.7 with NaOH) and 
analyzed by HPLC with an Alltech InertsilTM ODS-2 5 μm, 250 × 4.6 mm, C-18 column 
protected by a C-18 guard column (5 μm, 7.5×4.6 mm) (Alltech Associates, Inc., 
Deerfield, IL). The injection volume was 100 μL, and the wavelength of absorption was 
263 nm (λmax). The limit of detection and quantitation for ITZ was 10 ng/mL and           
30 ng/mL, respectively. The column was maintained at 37 ℃ during the analysis. The 
ITZ peak eluted at approximately 18 min, and the ketoconazole peak eluted at 9.3 min at 
a mobile phase flow rate of 1.0 mL/min.  
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3.3.12 Pharmacokinetic and Statistical Analysis 
Plots of the log concentration of ITZ in plasma versus time exhibited a first-order 
absorption phase and a first-order elimination phase. A one-compartmental model for 
extravascular administration was therefore selected to assess the pharmacokinetic 
parameters of ITZ in rat plasma using WinNonlin Professional Version 2.1 (Pharsight 
Corporation, Mountain View, CA). All results are presented as mean±SD. Student’s t 
tests were conducted using SigmaPlot version 7 (Systat Software, Inc., Chicago, IL), to 
determine the significance between the two dosing groups. For all tests, statistical 
significance was defined by p < 0.05. 
 
3.4 RESULTS AND DISCUSSION   
3.4.1 Physicochemical Properties of Wet-milled ITZ and URF-ITZ Formulations  
3.4.1.1 Morphology and Particle Size Distribution 
In the widely used wet milling process, comminution continually fractures drug 
crystals to reduce the particle size. The efficiency depends upon the nature of the 
grinding medium, the wetting of the solid, and the hardness of the drugs [42]. In the 
present study, because of the limited achievable rolling speed of the mill and hardness of 
ITZ, it took 10 days to reduce the particle size from an average size of 5 μm (100% < 
17.7 μm) to nano-size level. The low solubility of ITZ may be advantageous in suppressing 
crystal growth during and after the milling process, and the hardness (i.e. the high melting point) 
may favor comminution. From the SEM image in Figure 3.2(a), Wet-milled ITZ was 
composed of fractured, irregular shaped particles with various sizes, ranging from about 
150 to 600 nm in length. This is consistent with a report that NanoCrystals of 
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beclomethsaone dipropiante can be prepared by ball milling a 5% w/w drug suspension in 
2.5% PVA over a day, resulting in a mean size of 267 nm [42].   
 
In contrast with Wet-milled ITZ, URF-ITZ powder exhibited a highly porous 
structure with more regularly round-shaped particles as shown in Figure 3.2(b).  The 
SEM displayed aggregated nanoparticles that formed a porous matrix. Both the milling 
and URF process dramatically reduced ITZ particles to nano-size range compared to bulk 
micron-sized ITZ particles shown in Figure 3.2(c). 
 
With the particle size reduction, the specific surface area of the Wet-milled ITZ 
and URF-ITZ powder were found to be 38.6 and 31.7 m2/g, respectively, which 
correspond to effective particle diameters of 150 and 190 nm (Table 3.1), assuming the 
particles were monodisperse and in spherical shape. The surface area of the bulk particles 
of  2.20 m2/g was 15 times smaller. 
 
However, the particle size distribution analysis using static laser light scattering 
showed D(v, 0.5) and D(v, 0.9) (diameter at which the cumulative sample volume was 
under 50% and 90%, respectively) values of 0.57 and 1.22 μm, respectively, for Wet-
milled ITZ in colloidal dispersion (Table 3.1). This value is larger than that inferred from 
the measured surface area and SEM. Though the primary particle size of Wet-milled ITZ 
is ~190 nm from the surface area, the potential for increased Van der Waals interactions 
and electrostatic attraction between ultrafine particles can lead to aggregates ranging 
from loose flocculates to completely fused particles [13]. It is possible that some of the 
primary particles formed aggregates that were detected by static light scattering. 
Nevertheless, over 80% of the particles had a diameter of 1 micron or less.  
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In comparison, the URF-ITZ colloidal dispersion showed a narrow and smaller 
range with D(v, 0.5) and D(v, 0.9)  of 0.25 and 0.59 μm, respectively. The stable and 
relatively uniform particle sizes resulted from the rapid nucleation during ice formation in 
URF and arrested growth as the solution freezes as discussed previously [34]. 
 
3.4.1.2 Crystalline State Evaluation 
From the XRD diffraction profiles in Figure 3.3, ITZ exhibited intense 
characteristic crystalline peaks at 14.35, 17.46, 20.31, and 23.41 2-theta degrees, as seen 
in the micron-sized bulk ITZ (as purchased from the manufacturer). The XRD patterns of 
Wet-milled ITZ were found to be superimposable to the spectra of the micronized 
crystalline ITZ but with smaller peak heights. Reducing particle size can result in XRD 
peak broadening and halo formation, due to lost long-range crystalline order, without 
complete transition to an amorphous form [43]. It was also reported that XRD profiles of 
asulacrine nanocrystals with a mean particle size of 130 nm made by high pressure 
homogenization were not affected, with similar peak intensities as for micron-sized drug 
[22]. The XRD patterns of nanocrystal therefore seem material-specific and are related to 
the crystalline microstructure (crystal size, micro-strain and defects) of individual 
substances [43]. Therefore, the reduction in XRD peak intensity of Wet-milled ITZ is 
most likely due to particle size reduction.  
 
For XRD of URF-ITZ powder in Figure 3.3, broad, diffuse haloes were present 
with an absence of the characteristic crystalline peaks, indicating a highly amorphous 
morphology [29]. The crystallinity was examined further with MTDSC as shown in 
Figure 3.4. The URF-ITZ powder exhibited a glass transition at around 50 ℃, one 
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exothermic recrystallization peak, and finally a single endothermic melting peak at 165.7 
℃. These results further confirmed the amorphous nature of URF-ITZ seen by XRD. In 
contrast, an exothermic peak was not present for Wet-milled ITZ, but only a single 
endothermic peak at 163.4 ℃, corresponding to the melting of ITZ.  However, the 
melting peak of Wet-milled ITZ was not as sharp as for bulk ITZ and shifted slightly.   
 
Milling processes may generate amorphous domains on the particle surface [44]. 
Despite the long time period for milling the ITZ, the crystallinity was high and the 
amorphous content undetectable according to the XRD and DSC results.  
 
3.4.2 Supersaturation of Wet-milled ITZ and URF-ITZ Colloidal Dispersions in 
Simulated Lung Fluid 
Dissolution of the ITZ colloidal dispersions in simulated lung fluid with pH 7.4 at 
37 ℃ was conducted under supersaturated conditions (100-times Ceq equivalent ITZ were 
added) as shown in Figure 3.5. The Ceq in simulated lung fluid was measured to be 10 
ng/mL after shaking at 37 ℃ for 3 days with excess crystalline ITZ present. For the URF-
ITZ, C/Ceq reached 22-times at 5 min and a maximum value of about 26-times at 15 and 
30 min. The supersaturation levels gradually decreased to about 7-times at 2 hr, and 5-
times at 24 hr. In contrast, the supersaturation for Wet-milled ITZ only reached about 3-
times the measured C/Ceq at 30 min, fell to about 2-times at 6 hr and then gradually 
declined to about unity, the equilibrium ratio at 24 hr. The cumulative extent of 
supersaturation was calculated as the AUSC, which was 1785 and 383 ng·hr/mL for 
URF-ITZ and Wet-milled ITZ, respectively. The much larger Csat at various times and 
AUSC for the amorphous URF-ITZ have the potential to enhance bioavailability of this 
poorly water soluble drug. 
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Formation of a high energy amorphous or semicrystalline state can increase the 
predicted solubility, in many cases up to 100 times that of its crystalline form [26, 31]. 
The URF-ITZ formulation has been previously identified to be a solid solution of ITZ 
molecularly dispersed in mannitol and lecithin matrix [34]. Once the solid solution was 
exposed to the aqueous simulated lung fluid, the excipients dissolved very rapidly and the 
high surface area ITZ domains quickly supersaturated the dissolution medium. Because 
of the maximal achievable surface area for dissolution obtained by solid solution [45], the 
dissolution rate and Csat value of URF-ITZ colloidal dispersion could be much higher 
than the nanocrystalline ITZ colloidal dispersion upon added to a dissolution medium. 
The elevated Csat value of URF-ITZ might therefore be responsible for the 4.7-times 
higher amount of solvated ITZ molecules in the simulated lung fluid than Wet-milled 
ITZ.  
 
The driving force for dissolution depends on the drug solubility within a given 
environment (i.e. lung fluid) Csat and the concentration gradient between Csat at the 
particle surface and C in the bulk solution phase. Particle dissolution is governed by 
several factors that can be described by the Noyes-Whitney equation:  
dM/dt = AD(Csat -C)/h 
where dM/dt is the fraction of mass dissolved per unit time, A is the surface area available 
for dissolution, D is the diffusion coefficient, and h is the thickness of the diffusion 
boundary layer. Nanoparticles often dissolve more quickly due to the extensive 
enhancement in surface area, the smaller h which is proportional to the particle diameter 
and the higher Csat because of particle curvature according to the Kelvin equation [46-48]. 
The nano-sized URF-ITZ and Wet-milled ITZ both dissolved rapidly and reached a 
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maximum concentration within 30 min, as well as supersaturation relative to equilibrium 
solubility of the micronized ITZ. The D value was the same for both formulations, and 
the the available surface areas A were similar. Also the h values which are closely related 
to particle size [49] were similar. Thus the higher dissolution rate for the amorphous ITZ 
is due to the higher Csat  values.  
 
3.4.3 In Vitro Aerosol Performance of Wet-milled ITZ and URF-ITZ Aqueous 
Colloidal Dispersions 
Pulmonary drug delivery targeted to the alveoli is advantageous and critical for 
systemic absorption [50], as the distance from the air in the alveolar lumen to the 
capillary blood flow is less than 400 nm [51]. The efficacy of pulmonary delivery of drug 
to the deep lung is largely determined by the particle size distribution of aerosol droplets 
[52]. The inhaled aerosol should possess a narrow range of aerodynamic diameters 
between 1-5 micron to pass through the filter of the mouth and throat to be effectively 
delivered inside the lung [25]. The aerodynamic particle size of the nebulized colloidal 
dispersions of Wet-milled ITZ and URF-ITZ for inhalation, with an equivalent of 100 mg 
ITZ in 5 mL, is summarized in Table 3.2. The TED of Wet-milled ITZ and URF-ITZ 
were 51.73 and 56.40 mg out of 100 mg ITZ available for nebulization, respectively. 
Their corresponding FPF were 47.28 and 54.39% with the respective fine particle dose 
(defined as the amount of aerosol droplets entering the impactor less than 4.7 μm, TED × 
FPF, indication of the dose delivered to the deep lung) delivered at a rate of 2.45 and 3.07 
mg/min. The MMAD of the atomized droplets of Wet-milled ITZ and URF-ITZ colloidal 
dispersions were 2.78 and 2.36 μm with GSD of 3.06 and 2.66, respectively, which are 
suitable for deep lung delivery.  
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In this study, the aerodynamic diameter is goverened by the easily controllable 
nebulization of the aqueous droplets, which contain much smaller dispersed particles of 
drug. It was reported that the Aeroneb® Professional micropump nebulizer produced an 
aqueous mist of fine droplets with sizes ranging between 1 and 4 μm [36]. Nanoparticles 
with a diameter of less than 1 μm are more easily incorporated in the respirable 
aerosolized droplets with MMAD of 1–5 μm [53, 54]. Furthermore, the viscosities of the 
colloidal dispersions are similar to those of the water. The low viscosity facilitates the 
formation of small and uniform droplets [55]. Since both URF-ITZ and Wet-milled ITZ 
colloidal dispersions contain submicron particles, the aerodynamic performance of the 
nebulized fine aerosol droplets is similar to that of pure water.   
 
3.4.4 Pharmacokinetics of Inhaled Wet-milled ITZ and URF-ITZ in Rats 
With the same compositions and comparable in vitro aerodynamic performance of 
the nebulized aerosols of Wet-milled ITZ and URF-ITZ colloidal dispersions, their in 
vivo performance was subsequently explored in a rat model. Rats were exposed nose-only 
to a single dose aerosols of the nebulized colloidal dispersions (equivalent to 100 mg of 
ITZ total), respectively, for about 10 min. Drug concentration profiles in lung tissue and 
blood following a single inhalation dose are presented in Figures 3.6 and 3.7. Upon 
completing inhalation of the nebulized compositions (0 hr post dosing), 12.28±0.60 and 
11.01±4.26 μg/g wet lung weight of ITZ were found deposited in lungs from Wet-milled 
ITZ and URF-ITZ dosing groups, respectively. At 24 hr post dosing, these values were 
562±443 and 455±237 ng/g wet lung weight, respectively.  
 
Once deposited in the lungs, the nanoparticles underwent dissolution in the lung 
lining fluid to release free ITZ molecules for lung local action or were further absorbed 
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through lung alveolar epithelium to systemic circulation. The corresponding 
pharmacokinetic parameters in blood are summarized in Table 3.3. In plasma, based on a 
one compartmental analysis, the Cmax for Wet-milled ITZ and URF-ITZ dosing group 
were 50.4 and 177.5 ng/mL at 2.7 and 4.0 hr after dosing, respectively. The AUC0–24 of 
Wet-milled ITZ and URF-ITZ were 662 and 2543 ng⋅hr/mL, respectively. In URF-ITZ 
dosing group, after reaching the Cmax, a plateau of the high ITZ level was maintained 
from 2.5 to 6 hr, similar to a sustained release profile. At all the sampling time points, the 
ITZ levels in rats inhaled URF-ITZ were significantly higher than those inhaled Wet-
milled ITZ. 
 
Despite the comparable lung deposition levels of the inhaled aerosols of the two 
ITZ colloidal dispersions, the cumulative ITZ concentrations absorbed into blood from 
rats was about 3.8-times higher for the URF-ITZ versus Wet-milled ITZ. From Fick’s 
first law, the systemic absorption rate of a drug from the lung epithelium is given by P × 
A × C, where P is membrane permeability, A is the available surface area over which the 
drug is spread, C is the drug concentration in the lung lining fluids. The drug 
concentration in blood is assumed to be insignificant compared to the lung concentration 
and the transfer from lung to blood is irreversible [56]. For the Wet-milled ITZ and URF-
ITZ colloidal dispersions, many factors were fairly constant include the composition, 
aerodynamic performance, lung depositions, total drug dose, permeability and absorption 
area. The absorption has been shown to be permeation limited for both amorphous and 
crystalline ITZ nanoparticles of the sizes on the order of 200-600 nm with a combined 
dissolution/permeation material balance in the lung fluid [34]. Here the dissolution is 
essentially instantaneous relative to the permeation. In this case, the flux of ITZ into 
systemic circulation would be directly proportional to the dissolved concentration Csat. 
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This prediction was observed in the current study. The 3.8-times larger AUC of URF-ITZ 
in the systemic circulation versus Wet-milled ITZ was on the same order as the 4.7-times 
larger supersaturation level (thermodynamic activity) measured in the in vitro dissolution 
test.  
 
The biopharmaceutical consequences of solubility differences of polymorphs are 
directly related to the solubility difference [57]. It was reported that polymorphs of 
chloramphenicol palmitate with a measured solubility ratio of about 4.0 induced about 6-
times difference in Cmax in human after oral administration [58]; whereas no significant 
difference in pharmacokinetics was observed after a single oral dose of polymorphs of 
mefenamic acid with measured solubility ratio of about 1.3 [57]. Therefore, to achieve 
clinically meaningful biopharmaceutical consequences of solubility differences, the 
solubility ratios need to be about two fold higher [26]. Compared to the crystalline 
counterpart, the formation of significantly higher levels of supersaturation offered by 
amorphous formulations of drugs with poor/erratic bioavailability, enhances total drug 
absorption (AUC) and Cmax while reducing tmax as observed for oral [59, 60], topical [61] 
and pulmonary [62] administrations. The use of amorphous form of poorly water-soluble 
drugs has widened the window of achievable pharmacokinetic performance enormously.  
 
3.4.5 Lung Clearance of the Deposited Nanoparticles Containing ITZ 
In addition to influencing aerosol deposition and dissolution in the lung lining 
fluid, particle size distribution and morphology also may influence the clearance 
mechanism [44, 63]. The lungs have very efficient clearance mechanisms for foreign 
particles. The MMAD of Wet-milled ITZ and URF-ITZ aerosols favor deposition in the 
deep lung, bypassing the mucociliary clearance in the airways. Compared to Wet-milled 
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ITZ, the deposited amorphous URF-ITZ nanoparticles dissolve more quickly upon 
exposure to the lung lining fluid. Furthermore the rapid dissolution may minimize 
crystallization of undissolved particles of URF-ITZ in the lung fluid, which would 
otherwise lower the supersaturation [64, 65]. The more rapid dissolution and resulting 
higher supersaturation with minimal time for crystallization of undissolved solid results 
in reduced clearance of URF-ITZ relative to Wet-milled ITZ particles by the lung defense 
system.  These factors favor the observed significantly enhanced bioavailability of URF-
ITZ. 
 
For those deposited particles have not completely dissolved, they would mainly 
be cleared from the alveoli via endocytosis by epithelial and endothelial cells, and 
phagocytosis by macrophages [66, 67]. The efficiency of clearance of the inhaled 
particles is size-dependent. Alveolar macrophages preferentially uptake particles of 
approximately 1 to 3 μm in diameter [25, 68]. Phagocytosis of 1 μm particles has been 
observed as early as 15 min after nebulization [69]. Furthermore, 30–60% of 1–3 μm 
particles have been observed to be phagocytosed 2–4 h post intra-tracheal instillation, 
with complete pulmonary clearance of particles within 24 h [70]. After 24 hr post 
inhalation the ITZ levels in the lung were similar for the URF-ITZ and Wet-milled ITZ, 
even though the former was absorbed at a level of ~4 times higher.  Thus the much larger 
amount of unabsorbed Wet-milled ITZ particles must have been cleared by the lung 
defense system. The aggregates of the Wet-milled ITZ of 590 nm in mean diameter 
measured by light scattering are more vulnerable to uptake by macrophage clearance than 
the smaller URF-ITZ particles, so that ITZ levels in lung at 24 hr post inhalation were 




For an aqueous colloidal dispersion of amorphous nanoparticulate ITZ, rapid 
dissolution produced a supersaturation ~4.7-times larger than for a dispersion of 
crystalline nanoparticulates made by wet milling with the same composition and similar 
particle surface area. The aerodynamic diameters for both dispersions were suitable for 
deep lung delivery by nebulization, and similar to values produced for pure water. 
However, the increase in the systemic bioavailability for the amorphous versus crystalline 
dispersion of about 3.8 was approximately the same as the increase in supersaturation 
measured in vitro in the simulated lung fluid. The experimentally observed similarity in 
the values of bioavailability and supersaturation would be predicted for a permeability 
controlled model, where dissolution is very rapid, as suggested previously [34]. The high 
supersaturation, favored by rapid dissolution of amorphous nanoparticles, prior to particle 
clearance or crystallization favors the high permeability into the bloodstream.  Pulmonary 
delivery of amorphous nanoparticle formulations of extremely poorly water-soluble 
drugs, especially for high-dose drugs (e.g. ITZ), is thus beneficial for both local and 
systemic therapy.  
 
3.6 ACKNOWLEDGEMENTS 
This material is supported in part by the STC Program of the National Science 
Foundation under Agreement No. CHE987664. We would like to thank Mr. Kevin 
O’Donnell for his assistance with animal study.   
 
3.7 REFERENCES  
 
 109
1. C.A. Lipinski. Drug-like properties and the causes of poor solubility and poor 
permeability. Journal of Pharmacological and Toxicological Methods. 44:235-249 
(2000). 
 
2. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney. Experimental and 
computational approaches to estimate solubility and permeability in drug 
discovery and development settings. Adv Drug Deliver Rev. 23:3-25 (1997). 
 
3. R.H. Muller, C. Jacobs, and O. Kayser. Nanosuspensions as particulate drug 
formulations in therapy Rationale for development and what we can expect for the 
future. Adv Drug Deliver Rev. 47:3-19 (2001). 
 
4. V.B. Patravale, A.A. Date, and R.M. Kulkarni. Nanosuspensions: a promising 
drug delivery strategy. J Pharm Pharmacol. 56:827-840 (2004). 
 
5. S. Agharkar, S. Lindenbaum, and T. Higuchi. Enhancement of Solubility of Drug 
Salts by Hydrophilic Counterions - Properties of Organic Salts of an antimalarial 
Drug. J Pharm Sci. 65:747-749 (1976). 
 
6. K. Amin, R.M. Dannenfelser, J. Zielinski, and B. Wang. Lyophilization of 
polyethylene glycol mixtures. J Pharm Sci. 93:2244-2249 (2004). 
 
7. V.P. Torchilin. Micellar nanocarriers: Pharmaceutical perspectives. Pharmaceut 
Res. 24:1-16 (2007). 
 
8. R.A. Rajewskiand V.J. Stella. Pharmaceutical applications of cyclodextrins. 2. In 
vivo drug delivery. J Pharm Sci. 85:1142-1169 (1996). 
 
9. R. Liu. Water-insoluble drug formulation, CO Interpharm Press, Englewood, 
2000. 
 
10. D.J.W. Grantand H.G. Brittian. Physical Characterisation of Pharmaceutical 
Solids, Marcel Dekker, New York, 1995. 
 
11. R.J. Hintzand K.C. Johnson. The Effect of Particle-Size Distribution on 
Dissolution Rate and Oral Absorption. Int J Pharm. 51:9-17 (1989). 
 
12. P. Borm, F.C. Klaessig, T.D. Landry, B. Moudgil, J. Pauluhn, K. Thomas, R. 
Trottier, and S. Wood. Research strategies for safety evaluation of nanomaterials, 
part V: role of dissolution in biological fate and effects of nanoscale particles. 
Toxicol Sci. 90:23-32 (2006). 
 
13. N. Blagden, M. de Matas, P.T. Gavan, and P. York. Crystal engineering of active 
pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug 
Deliver Rev. 59:617-630 (2007). 
 110
 
14. G.G. Liversidgeand K.C. Cundy. Particle-Size Reduction for Improvement of 
Oral Bioavailability of Hydrophobic Drugs .1. Absolute Oral Bioavailability of 
Nanocrystalline Danazol in Beagle Dogs. Int J Pharm. 125:91-97 (1995). 
 
15. R. Mauludin, R.H. Muller, and C.M. Keck. Development of an oral rutin 
nanocrystal formulation. Int J Pharm. 370:202-209 (2009). 
 
16. P.C. Chiang, J.W. Alsup, Y.R. Lai, Y.D. Hu, B.R. Heyde, and D. Tung. 
Evaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary 
Drug Delivery. Nanoscale Research Letters. 4:254-261 (2009). 
 
17. C. Jacobsand R.H. Muller. Production and characterization of a budesonide 
nanosuspension for pulmonary administration. Pharmaceut Res. 19:189-194 
(2002). 
 
18. W.K. Kraft, B. Steiger, D. Beussink, J.N. Quiring, N. Fitzgerald, H.E. Greenberg, 
and S.A. Waldman. The pharmacokinetics of nebulized nanocrystal budesonide 
suspension in healthy volunteers. Journal of Clinical Pharmacology. 44:67-72 
(2004). 
 
19. M.A. Kassem, A.A.A. Rahman, M.M. Ghorab, M.B. Ahmed, and R.M. Khalil. 
Nanosuspension as an ophthalmic delivery system for certain glucocorticoid 
drugs. Int J Pharm. 340:126-133 (2007). 
 
20. R. Pignatello, C. Bucolo, P. Ferrara, A. Maltese, A. Puleo, and G. Puglisi. 
Eudragit RS100 (R) nanosuspensions for the ophthalmic controlled delivery of 
ibuprofen. European Journal of Pharmaceutical Sciences. 16:53-61 (2002). 
 
21. K. Peters, S. Leitzke, J.E. Diederichs, K. Borner, H. Hahn, R.H. Muller, and S. 
Ehlers. Preparation of a clofazimine nanosuspension for intravenous use and 
evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. 
Journal of Antimicrobial Chemotherapy. 45:77-83 (2000). 
 
22. S. Ganta, J.W. Paxton, B.C. Baguley, and S. Garg. Formulation and 
pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for 
intravenous delivery. Int J Pharm. 367:179-186 (2009). 
 
23. J.E. Kipp. The role of solid nanoparticle technology in the parenteral delivery of 
poorly water-soluble drugs. Int J Pharm. 284:109-122 (2004). 
 
24. A.L. Adjeand P.K. Gupta. Inhalation Delivery of Therapeutic Peptides and 
Proteins. In A.A.F. Mahmoud (ed.), Parasitic Lung Diseases, Marcel Rcel Dekker 
Inc., New York, 1997, pp. 89-125. 
 
 111
25. H.M. Courrier, N. Butz, and T.F. Vandamme. Pulmonary drug delivery systems: 
recent developments and prospects. Crit Rev Ther Drug Carrier Syst. 19:425-498 
(2002). 
 
26. B.C. Hancockand M. Parks. What is the true solubility advantage for amorphous 
pharmaceuticals? Pharmaceut Res. 17:397-404 (2000). 
 
27. B.C. Hancockand G. Zograf. Characteristics and significance of the amorphous 
state in pharmaceutical systems. J Pharm Sci. 86:1-12 (1997). 
 
28. M.E. Matteucci, M.A. Miller, R.O. Williams, and K.P. Johnston. Highly 
Supersaturated Solutions of Amorphous Drugs Approaching Predictions from 
Configurational Thermodynamic Properties. Journal of Physical Chemistry B. 
112:16675-16681 (2008). 
 
29. L.R. Hildenand K.R. Morris. Physics of amorphous solids. J Pharm Sci. 93:3-12 
(2004). 
 
30. G.V. Betageriand K.R. Makarla. Enhancement of dissolution of glyburide by 
solid dispersion and lyophilization techniques. Int J Pharm. 126:155-160 (1995). 
 
31. P. Gupta, G. Chawla, and A.K. Bansal. Physical stability and solubility advantage 
from amorphous celecoxib: The role of thermodynamic quantities and molecular 
mobility. Molecular Pharmaceutics. 1:406-413 (2004). 
 
32. M.E. Matteucci, B.K. Brettmann, T.L. Rogers, E.J. Elder, R.O. Williams, and 
K.P. Johnston. Design of potent amorphous drug nanoparticles for rapid 
generation of highly supersaturated media. Molecular Pharmaceutics. 4:782-793 
(2007). 
 
33. J.M. Tam, J.T. McConville, R.O. Williams, 3rd, and K.P. Johnston. Amorphous 
cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. 
Journal of pharmaceutical sciences:DOI 10.1002/jps.21367 (2008). 
 
34. W. Yang, J. Tam, D.A. Miller, J. Zhou, J.T. McConville, K.P. Johnston, and R.O. 
Williams. High bioavailability from nebulized itraconazole nanoparticle 
dispersions with biocompatible stabilizers. Int J Pharm. 361:177-188 (2008). 
 
35. J.M. Vaughn, J.T. McConville, D. Burgess, J.I. Peters, K.P. Johnston, R.L. 
Talbert, and R.O. Williams, 3rd. Single dose and multiple dose studies of 
itraconazole nanoparticles. Eur J Pharm Biopharm. 63:95-102 (2006). 
 
36. J.T. McConville, K.A. Overhoff, P. Sinswat, J.M. Vaughn, B.L. Frei, D.S. 
Burgess, R.L. Talbert, J.I. Peters, K.P. Johnston, and R.O. Williams. Targeted 
 112
high lung concentrations of itraconazole using nebulized dispersions in a murine 
model. Pharmaceutical Research. 23:901-911 (2006). 
 
37. B.J. Hoeben, D.S. Burgess, J.T. McConville, L.K. Najvar, R.L. Talbert, J.I. 
Peters, N.P. Wiederhold, B.L. Frei, J.R. Graybill, R. Bocanegra, K.A. Overhoff, 
P. Sinswat, K.P. Johnston, and R.O. Williams. In vivo efficacy of aerosolized 
nanostructured itraconazole formulations for prevention of invasive pulmonary 
aspergillosis. Antimicrob Agents Ch. 50:1552-1554 (2006). 
 
38. J. Peeters, P. Neeskens, J.P. Tollenaere, P. Van Remoortere, and M.E. Brewster. 
Characterization of the Interaction of 2-hydroxypropyl-beta-cyclodextrin with 
itraconazole at pH 2, 4, and 7. J Pharm Sci. 91:1414-1422 (2002). 
 
39. K.A. Overhoff, J.D. Engstrom, B. Chen, B.D. Scherzer, T.E. Milner, K.P. 
Johnston, and R.O. Williams, 3rd. Novel ultra-rapid freezing particle engineering 
process for enhancement of dissolution rates of poorly water-soluble drugs. Eur J 
Pharm Biopharm. 65:57-67 (2007). 
 
40. R.O. Cook, R.K. Pannu, and I.W. Kellaway. Novel sustained release 
microspheres for pulmonary drug delivery. Journal of Controlled Release. 104:79-
90 (2005). 
 
41. N.M. Daviesand M.R. Feddah. A novel method for assessing dissolution of 
aerosol inhaler products. International journal of pharmaceutics. 255:175-187 
(2003). 
 
42. T.S. Wiedmann, L. DeCastro, and R.W. Wood. Nebulization of 
NanoCrystals(TM): Production of a respirable solid-in-liquid-in-air colloidal 
dispersion. Pharmaceut Res. 14:112-116 (1997). 
 
43. Z. Deng, S. Xu, and S. Li. Understanding a relaxation behavior in a nanoparticle 
suspension for drug delivery applications. Int J Pharm. 351:236-243 (2008). 
 
44. A.H.L. Chow, H.H.Y. Tong, P. Chattopadhyay, and B.Y. Shekunov. Particle 
engineering for pulmonary drug delivery. Pharmaceutical Research. 24:411-437 
(2007). 
 
45. C. Leunerand J. Dressman. Improving drug solubility for oral delivery using solid 
dispersions. European Journal of Pharmaceutics and Biopharmaceutics. 50:47-60 
(2000). 
 
46. P. Borm, F.C. Klaessig, T.D. Landry, B. Moudgil, J. Pauluhn, K. Thomas, R. 
Trottier, and S. Wood. Research strategies for safety evaluation of nanomaterials, 
part V: role of dissolution in biological fate and effects of nanoscale particles. 
Toxicological Sciences. 90:23-32 (2006). 
 113
 
47. M.T. Crisp, C.J. Tucker, T.L. Rogers, R.O. Williams, 3rd, and K.P. Johnston. 
Turbidimetric measurement and prediction of dissolution rates of poorly soluble 
drug nanocrystals. J Control Release. 117:351-359 (2007). 
 
48. M.E. Matteucci, M.A. Hotze, K.P. Johnston, and R.O. Williams. Drug 
nanoparticles by antisolvent precipitation: Mixing energy versus surfactant 
stabilization. Langmuir. 22:8951-8959 (2006). 
 
49. A.P. Tinke, K. Vanhoutte, R. De Maesschalck, S. Verheyen, and H. De Winter. A 
new approach in the prediction of the dissolution behavior of suspended particles 
by means of their particle size distribution. Journal of pharmaceutical and 
biomedical analysis. 39:900-907 (2005). 
 
50. H.M. Courrier, N. Butz, and T.F. Vandamme. Pulmonary drug delivery systems: 
Recent developments and prospects. Critical Reviews in Therapeutic Drug Carrier 
Systems. 19:425-498 (2002). 
 
51. R. Altiereand D. Thompson. hysiology and pharmacology of the airways. In A. 
Hickey (ed.), Inhalation aerosols—Physical and biological basis for therapy 
Marcel Dekker, Inc., New York, 1996, pp. 85–138. 
 
52. T.B. Martonenand I.M. Katz. Deposition Patterns of Aerosolized Drugs within 
Human Lungs - Effects of Ventilatory Parameters. Pharmaceut Res. 10:871-878 
(1993). 
 
53. L.A. Dailey, T. Schmehl, T. Gessler, M. Wittmar, F. Grimminger, W. Seeger, and 
T. Kissel. Nebulization of biodegradable nanoparticles: impact of nebulizer 
technology and nanoparticle characteristics on aerosol features. Journal of 
Controlled Release. 86:131-144 (2003). 
 
54. O.N. McCallion, K.M. Taylor, M. Thomas, and A.J. Taylor. Nebulization of 
fluids of different physicochemical properties with air-jet and ultrasonic 
nebulizers. Pharmaceutical Research. 12:1682-1688 (1995). 
 
55. B.Y. Shekunov, P. Chattopadhyay, D. Yim, D. Cippola, and B. Boyd. 
Formulation and in vitro performance of drug-lipid nanosuspensions for 
pulmonary delivery, Conference on Respiratory Drug Delivery, Boca Raton, 
Florida, 2006, pp. 609-612. 
 
56. J.S. Pattonand P.R. Byron. Inhaling medicines: delivering drugs to the body 
through the lungs. Nature reviews. 6:67-74 (2007). 
 
57. A.J. Aguiarand J.E. Zelmer. Dissolution behavior of polymorphs of 
chloramphenicol palmitate and mefenamic acid. J Pharm Sci. 58:983-987 (1969). 
 114
 
58. A.J. Aguiar, J. Krc, Jr., A.W. Kinkel, and J.C. Samyn. Effect of polymorphism on 
the absorption of chloramphenicol from chloramphenicol palmitate. J Pharm Sci. 
56:847-853 (1967). 
 
59. K. Yamashita, T. Nakate, K. Okimoto, A. Ohike, Y. Tokunaga, R. Ibuki, K. 
Higaki, and T. Kimura. Establishment of new preparation method for solid 
dispersion formulation of tacrolimus. Int J Pharm. 267:79-91 (2003). 
 
60. D.A. Miller, J.T. McConville, W. Yang, R.O. Williams, 3rd, and J.W. McGinity. 
Hot-melt extrusion for enhanced delivery of drug particles. Journal of 
pharmaceutical sciences. 96:361-376 (2007). 
 
61. V. Sanna, E. Gavini, M. Cossu, G. Rassu, and P. Giunchedi. Solid lipid 
nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in-
vitro characterization, ex-vivo and in-vivo studies. J Pharm Pharmacol. 59:1057-
1064 (2007). 
 
62. P. Sinswat, K.A. Overhoff, J.T. McConville, K.P. Johnston, and R.O. Williams. 
Nebulization of nanoparticulate amorphous or crystalline tacrolimus - Single-dose 
pharmacokinetics study in mice. European Journal of Pharmaceutics and 
Biopharmaceutics. 69:1057-1066 (2008). 
 
63. W. Yang, J.I. Peters, and R.O. Williams. Inhaled nanoparticles - A current review. 
Int J Pharm. 356:239-247 (2008). 
 
64. M.E. Matteucci, B.K. Brettmann, T.L. Rogers, E.J. Elder, R.O. Williams, 3rd , 
and K.P. Johnston. Design of Potent Amorphous Drug Nanoparticles for Rapid 
Generation of Highly Supersaturated Media. Molecular pharmaceutics. 4:782-793 
(2007). 
 
65. M.E. Matteucci, J.C. Paguio, M.A. Miller, R.O. Williams, and K.P. Johnston. 
Highly Supersaturated Solutions from Dissolution of Amorphous Itraconazole 
Microparticles at pH 6.8. Molecular Pharmaceutics. 6:375-385 (2009). 
 
66. K. Donaldson, V. Stone, C.L. Tran, W. Kreyling, and P.J. Borm. Nanotoxicology. 
Occupational and environmental medicine. 61:727-728 (2004). 
 
67. A. Nemmar, H. Vanbilloen, M.F. Hoylaerts, P.H. Hoet, A. Verbruggen, and B. 
Nemery. Passage of intratracheally instilled ultrafine particles from the lung into 
the systemic circulation in hamster. American journal of respiratory and critical 
care medicine. 164:1665-1668 (2001). 
 
68. W.G. Kreyling, M. Semmler, F. Erbe, P. Mayer, S. Takenaka, H. Schulz, G. 
Oberdorster, and A. Ziesenis. Translocation of ultrafine insoluble iridium particles 
 115
from lung epithelium to extrapulmonary organs is size dependent but very low. J 
Toxicol Environ Health A. 65:1513-1530 (2002). 
 
69. P. Forsgren, J. Modig, B. Gerdin, B. Axelsson, and M. Dahlback. Intrapulmonary 
Deposition of Aerosolized Evans Blue-Dye and Liposomes in an Experimental 
Porcine Model of Early Ards. Ups J Med Sci. 95:117-136 (1990). 
 
70. H.Y. Zhou, Y.L. Zhang, D.L. Biggs, M.C. Manning, T.W. Randolph, U. 
Christians, B.M. Hybertson, and K.Y. Hg. Microparticle-based lung delivery of 
INH decreases INH metabolism and targets alveolar macrophages. J Controlled 








Table 3.1. Particle size distributions, specific surface areas (SSA) and the calculated 
particle sizes based on SSA of Wet-milled ITZ (wet milling processed pure 
ITZ) and URF-ITZ (URF processed ITZ:mannitol:lecithin = 1:0.5:02) 
powders.  
            
Particle Size (μm) 





Wet-milled ITZ 0.16 0.57 1.22 31.7 0.19 





Table 3.2. Cascade impaction data for nebulized aerosols of Wet-milled ITZ colloidal 
dispersion (ITZ:mannitol:lecithin = 1:0.5:0.2, weight ratio) and URF-ITZ 
colloidal dispersion (ITZ:mannitol:lecithin = 1:0.5:0.2, weight ratio) 
(equivalent to 100 mg of total ITZ), using the Aeroneb Professional 
micropump nebulizer at an air flow rate of 28.3 L/min for 10 min. 
 
  Wet-milled ITZ  URF-ITZ  
Total Emitted dose (mg) 51.73 56.40 
Respirable Fraction# (%) 74.54 72.95 
Fine Particle Fraction* (%) 47.28 54.39 
Available Dose  (mg/min) 3.86 4.11 
Mass Median Aerodynamic Diameter (MMAD) (µm) 2.78 2.36 
Geometric Standard Deviation (GSD) 3.06 2.66 
 
# Defined as the % mass of drug in aerosol droplets < 9 µm 






Table 3.3. Pharmacokinetic parameters for plasma ITZ concentration in rats after a single 
dose inhalation of nebulized aerosols of Wet-milled ITZ colloidal dispersion 
(ITZ:mannitol:lecithin = 1:0.5:0.2, weight ratio) and URF-ITZ colloidal 
dispersion (ITZ:mannitol:lecithin = 1:0.5:0.2, weight ratio).  
 
Pharmacokinetic 
parameters Wet-milled ITZ URF-ITZ 
Cmax (ng/mL) 50.4 177.5 
Tmax (hr) 2.7 4 
K01 absorption (/hr) 0.98 0.55 
K10 elimination (/hr) 0.09 0.08 
T1/2 absorption (hr) 0.71 1.27 
T1/2 elimination (hr) 7.82 8.16 

















Figure 3.1. Picture of the nose-only dosing apparatus for rodents 
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a.                                                                     b.                                                                 
   
c. 
    
 
 
Figure 3.2. SEM images of (a) Wet-milled ITZ (wet milling processed pure ITZ) powder 
at a magnification of 20k (b) URF-ITZ (URF processed 
ITZ:mannitol:lecithin = 1:0.5:0.2, weight ratio) powder at a magnification 
of 20k (c) bulk ITZ as received at a magnification of 10k. 
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Figure 3.3. X-ray powder diffraction patterns (from the top to bottom): Wet-milled ITZ 
(wet milling processed pure ITZ), URF-ITZ (URF processed 









Figure 3.4. DSC profiles of bulk ITZ, Wet-milled ITZ (wet milling processed pure ITZ) 
powder and URF-ITZ (URF processed ITZ:mannitol:lecithin = 1:0.5:0.2, 






















Figure 3.5. Dissolution profiles of Wet-milled ITZ colloidal dispersion 
(ITZ:mannitol:lecithin = 1:0.5:0.2, weight ratio) and URF-ITZ colloidal 
dispersion (ITZ:mannitol:lecithin = 1:0.5:0.2, weight ratio) in simulated 
lung fluid (pH=7.4) at supersaturation conditions (i.e. 100-times 
equilibrium solubility of micronized crystalline ITZ was added) using 100-



































Figure 3.6. Lung deposition of ITZ in rats at 0 and 24 hr post inhalation of a single-dose 
nebulized aqueous Wet-milled ITZ colloidal dispersion 
(ITZ:mannitol:lecithin = 1:0.5:0.2, weight ratio) and URF-ITZ colloidal 
dispersion (ITZ:mannitol:lecithin = 1:0.5:0.2, weight ratio). Data are 








































Figure 3.7. Plasma concentration of ITZ in rats after a single-dose inhalation of nebulized 
aqueous Wet-milled ITZ colloidal dispersion (ITZ:mannitol:lecithin = 
1:0.5:0.2, weight ratio) and URF-ITZ colloidal dispersion 
(ITZ:mannitol:lecithin = 1:0.5:0.2, weight ratio). Data are presented as 
Mean±SD, n=6.  
* p < 0.05, ** p < 0.01 
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Chapter 4: In Vitro Characterization and Pharmacokinetics in Mice 
following Pulmonary Delivery of Itraconazole as a Cyclodextrin 
Solubilized Solution  
 
 
4.1 ABSTRACT  
This study aims to make a 2-hydroxypropyl-β-cyclodextrin (HPβCD) solubilized 
itraconazole (ITZ) solution (i.e., HPβCD-ITZ) suitable for pulmonary delivery by 
nebulization, and compare the pharmacokinetics of inhaled nebulized aerosols of 
HPβCD-ITZ versus a colloidal dispersion of an ITZ nanoparticulate formulation (i.e., 
URF-ITZ). Solid state characterizations of lyophilized HPβCD-ITZ by differential 
scanning calorimetry (DSC), Fourier Transform Infrared Spectroscopy (FTIR), and X-ray 
photoelectron spectroscopy (XPS) indicated the formation of dynamic inclusion 
complexes between ITZ and HPβCD. Nebulized aerosols of both HPβCD-ITZ and a 
colloidal dispersion of URF-ITZ were confirmed suitable for deep lung delivery. Single 
doses of the nebulized aerosols (equivalent to 5.3 mg ITZ/mL in 5 mL) in mice produced 
similar ITZ lung depositions and pharmacokinetic profiles, with ITZ lung levels of 
approximately 4 μg/g wet lung weight upon completion of nebulization and remained 
above 0.5 μg/g at 24 hr. HPβCD-ITZ demonstrated faster systemic absorption of ITZ 
across lung epithelium than URF-ITZ, with Tmax values of 1.5 and 3.0 hr, and AUC0–∞ of 
2513 and 3717 ng·hr/mL, respectively. The fast absorption of solubilized ITZ across lung 




The incidence of invasive fungal infections has continued to increase over the last 
decade especially among high risk patients including those undergoing chemotherapy, 
solid organ or hematopoietic stem cell transplantation, and patients in intensive care units 
[1, 2]. The azole antifungals, which inhibit lanosterol 14-α-demethylase resulting in 
reductions in ergosterol within the fungal cell membrane, are a mainstay in the treatment 
of invasive fungal infecitons. Itraconazole (ITZ) is an appealing antifungal triazole for 
both prophylaxis and treatment in neutropenic and other immunocompromised patients, 
because of its broad spectrum of activity and enhanced potency against commonly 
occurring fungal pathogens including Candida and Aspergillus species [3].  
 
ITZ has a well-defined correlation between its in vitro minimal inhibitory 
concentration (MIC) activity and clinical performance in the treatment of candidiasis [4]. 
For susceptible organisms (MIC < 0.125 μg/ml), 89% of patients are cured clinically 
when ITZ plasma concentration is greater than 0.5 μg/mL. For Aspergillus sp. infections 
in immunocompromised patients, ITZ trough levels greater than 0.5 μg/g in lung tissue, 
or greater than 0.5 μg/mL in blood [5] are generally required. However, being classified 
as a Biopharmaceutical Classification System (BCS) class II compound, ITZ is 
practically insoluble in water (estimated aqueous solubility is approximately 1 ng/mL at 
neutral pH and 6 μg/mL at pH 1) [6]. The low solubility presents significant challenges in 
formulating sufficiently bioavailable dosage forms of ITZ, irrespective of routes of 
administration. A number of formulation approaches have been assessed in order to 
improve the pharmaceutical performance of ITZ [7], such as solubilization in surfactants 
to form self-emulsifying drug delivery systems [8, 9], solid state manipulation using 
particle engineering technologies [10-12], and formation of drug/cyclodextrin (CD) 
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inclusion complexes. Among these formulation approaches, the first to be 
commercialized was Sporanox® oral capsules, in which ITZ is molecularly dispersed with 
hydroxypropylmethylcellulose forming a solid solution [6]. However, the oral 
bioavailability is low, with erratic absorption influenced by food intake [13]. An 
alternative oral solution (Sporanox®, ITZ/HPβCD inclusion complex containing 10 
mg/mL of ITZ and 400 mg/mL of HPβCD) further increased bioavailability to about 30% 
higher than the capsule formulation  [14]. However, the significant gastrointestinal 
adverse effects caused by HPβCD, including osmotic diarrhea [15], led to limited patient 
acceptance. Newer formulations and/or delivery systems of ITZ with greater therapeutic 
efficacy and lower toxicity are still in demand.  
  
The lungs are often the primary port of entry into the body and site of infection 
for many life-threatening opportunistic fungi in immuno-compromised patients [16]. 
However, pulmonary infections may not respond well to systemic therapy with oral 
dosage forms due to insufficient drug diffusion into pulmonary tissues and lumen [17]. 
An increase in the amount of drug doses intended to compensate for poor diffusion may 
lead to systemic toxicity. Delivering antifungal drugs as aerosols by the pulmonary route 
allows high drug concentrations targeted directly at the site of infection, while 
minimizing potential systemic toxicity.  
 
Production of drug-loaded nanoparticles such as nanosuspensions for the poorly-
water soluble drugs is an alternative and promising approach to overcome their low 
aqueous solubilities and the consequential low bioavailabilities [18]. Moreover, drug-
loaded nanoparticles have the potential to be used for pulmonary delivery of therapeutics 
for treating lung diseases locally as well as for systemic actions. Pulmonary delivery of 
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nanoparticle formulations of poorly water-soluble drugs showed promising results in 
several in vitro investigations [19, 20], in vivo studies [21], and in a clinical trial of a 
nebulized nanocrystal suspension of budesonide (75–300 nm) [22].  
 
Nanoparticle formulations of ITZ for deep lung delivery have been designed and 
prepared by particle engineering technologies in our laboratory, namely evaporative 
precipitation of aqueous solution (EPAS) [23] and spray freezing into liquid (SFL) [24]. 
Single and multi dose inhalation of nebulized aerosols of these ITZ nanoparticle colloidal 
dispersions with a suitable aerodynamic diameter for deep lung delivery, demonstrated 
therapeutically effective ITZ concentrations in mouse lung, superior to the Sporanox® 
oral solution [25, 26]. In addition, the inhaled ITZ formulations demonstrated 
prophylactic effects against invasive pulmonary aspergillosis in murine models [27, 28]. 
 
A novel nanostructured ITZ solid solution formulation, URF-ITZ 
(ITZ:mannitol:lecithin=1:0.5:0.2, weight ratio) was recently developed using the ultra-
rapid freezing (URF) technology [29]. Inhalation of nebulized URF-ITZ aqueous 
colloidal dispersion, containing the same amount ITZ loading as the previously reported 
ITZ pulmonary formulations on the same murine model [25], produced significantly 
enhanced lung drug deposition and more than 10-fold higher ITZ level in the systemic 
circulation. The improved bioavailability was mainly attributed to the smaller nano-
scaled particle size (primary particles of 30-50 nm in diameter), and the presence of 
lecithin, which had facilitated permeation of ITZ through the lung epithelium [30].  
 
CDs have been reported to facilitate faster systemic absorption and improved 
bioavailability of poorly water-soluble drugs after pulmonary administration of aerosols 
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or solutions as compared to equipotent alternative formulations or routes of 
administration [31, 32]. A recent study reported that pulmonary delivery of a nebulized 
Vfend® I.V. aqueous solution of voriconazole (a triazole analog of ITZ) solubilized with 
sulfobutylether-β-cyclodextrin (SBEβCD) to rodents, attained a high lung deposition and 
a high systemic peak drug level within 30 min, similar to the intravenous administration 
profile [33]. The presence of the solubilized form of voriconazole molecules in a 
SBEβCD aqueous solution was thought to contribute to the rapid and complete 
absorption, and high systemic drug concentrations following pulmonary administration.  
 
Based on the results of the bioavailability studies of inhaled nanoparticulate ITZ 
and CD-solubilized voriconazole formulations, we hypothesized that inhalation of an 
effectively solubilized form of poorly-water soluble drug could lead to faster absorption 
through the lung mucosal epithelium as compared to the nanoparticulate form, which 
requires a drug dissolution process prior to absorption. Our aims were two-fold: (1) to 
prepare and characterize a CD solubilized ITZ solution formulation suitable for 
pulmonary delivery by nebulization; (2) to investigate the pharmacokinetic profiles of the 
inhaled aerosol of the CD solubilized form of ITZ compared to a nanoparticulate 
colloidal dispersion of this triazole in mice following nebulization in a whole-body 
exposure dosing apparatus. 
 
4.3 MATERIALS AND METHODS 
4.3.1 Materials 
Crystalline ITZ (micronized pharmacopeial grade) was purchased from Hawkins 
Chemical (Minneapolis, MN, USA). Hydroxyitraconazole was purchased from BDG 
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Synthesis (Wellington, New Zealand). Mannitol and lecithin (NF grade) were from 
Spectrum Chemicals (Gardena, CA). 2-hydroxypropyl-β-cyclodextrin (HPβCD) was 
kindly provided by Roquette America Inc. (Keokuk, IA). 1,4-dioxane, acetonitrile, and 
diethanolamine were purchased from Fischer Chemicals (Gibbstown, NJ, USA). All 
organic solvents used were of HPLC grade. Other chemicals utilized in this study were at 
least of ACS grade. Blank mice serum for chromatography analysis method validation 
was supplied by Invitrogen (Camarillo, CA, USA). 
 
4.3.2 Preparation of Nanostructured Aggregates Powder of ITZ Using URF 
Technology 
The amorphous nanostructured aggregate powder URF-ITZ, was prepared using 
URF technology as described previously [29]. In brief, ITZ, mannitol, and lecithin (in a 
weight ratio of 1:0.5:0.2) were dissolved in a mixture of 1,4-dioxane and purified water 
(65/35, v/v) co-solvent system. The solution was then applied to the cryogenic solid 
substrate (which was previously cooled to -70 °C) of the URF apparatus. The rapidly 
frozen solids were collected and lyophilized using a VirTis Advantage bench top tray 
lyophilizer (The VirTis Company, Inc., Gardiner, NY, USA). The resultant dry powder 
was stored in a desiccator under vacuum at room temperature. Amorphous pure ITZ was 
also prepared by the URF process as described above. 
 
4.3.3 Characterization of HPβCD and HPβCD-ITZ Solutions  
A series of concentrations of HPβCD solutions in purified water were prepared. 
Viscosity of the solutions was measured using a Cannon-Fenske Routine viscometer 
(Cannon Instrument Company, State College, PA, USA) at 25 °C.  
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Considering the osmolarity of the formulation to be delivered to the lungs, a 
sodium chloride (NaCl) solution in water with the proper osmolarity, was used to prepare 
the HPβCD solutions. The osmolality of the HPβCD-ITZ solution was measured by the 
freezing point depression method using a μOsmette Micro Osmometer (Precision 
Systems Inc., Natick, MA). 
 
The pH of the filtrates of the dispersions of ITZ in HPβCD was determined using 
an Orion 350 PerpHecT® Advanced Benchtop pH Meter (Thermo Fisher Scientific, 
Waltham, MA).  
 
4.3.4 Solubility Studies 
To study solubility differences between crystalline and amorphous ITZ in 
HPβCD, excess amounts of micronized crystalline ITZ or amorphous pure ITZ were 
added to 5 mL of 15% HPβCD in purified water. A 2-min sonication by a probe sonicator 
(Branson Sonifier 450, Danbury, CT) was used to facilitate the dispersion of the powders 
into the aqueous phase. The formed dispersions were then shaken at 100 rpm, at 25 °C 
for up to 2 days. Aliquots of 200 μL of the suspension were withdrawn at 0, 0.5, 1, 2, 3, 
5, 8, 24, 48 hr. All samples were filtered through 0.2 μm GHP Acrodisc syringe filters 
(Pall Corporation, East Hills, NY) and appropriately diluted with a solvent mixture of 
acetonitrile:water (70:30, v/v) for content analysis. The ITZ content was determined 
using a Shimadzu LC-10A high performance liquid chromatography (HPLC) system 
(Shimadzu Corporation, Columbia, MD) equipped with an Alltech InertsilTM ODS-2       
5 μm, 150 mm × 4.6 mm, C-18 column (Alltech Associates, Inc., Deerfield, IL). The ITZ 
peak was eluted at approximately 5.5 min using a mobile phase consisting of 
acetonitrile:water:diethanolamine (70:30:0.05, v/v/v) at a flow rate of 1 mL/min, column 
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temperature of 25 °C, and an absorption wavelength λmax of 263 nm. Values reported are 
the average of three measurements. 
 
4.3.5 Preparation of Solid State ITZ-HPβCD Inclusion Complex  
Aliquots of the ITZ in 15% HPβCD dispersion were sampled at 24 hr after 
dispersion and equilibration at room temperature, and filtered through 0.2 µm Acrodisc 
filters (Pall Corporation, East Hills, NY). The filtrates (designated as HPβCD-ITZ 
solution) were frozen and then lyophilized using the VirTis Advantage bench top tray 
lyophilizer (The VirTis Company, Inc., Gardiner, NY, USA) to obtain dry powders.  
 
4.3.6 Preparation of Physical Mixture 
A physical mixture consisting of micronized crystalline ITZ and HPβCD powder 
was prepared by gently mixing ITZ and HPβCD powders for 5 min using a spatula in a 
glass mortar to obtain a homogeneous blend at the same weight ratio as the lyophilized 
HPβCD-ITZ inclusion complex, based on the equilibrium solubility of ITZ per mL of 
15% HPβCD solution. 
 
4.3.7 Thermal Analysis  
All the powders were dried in desiccator for at least one day before thermal 
analysis. Differential scanning calorimetry (DSC) of the lyophilized HPβCD-ITZ dry 
powder, physical mixture, and each pure component was conducted using modulated 
temperature DSC (MTDSC), Model 2920 (TA Instruments, New Castle, DE), equipped 
with a refrigerated cooling system. Dry nitrogen gas was used as the purge gas through 
the DSC cell at a flow rate of 40 mL/min. Samples weighing 10-15 mg in crimped 
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aluminum pans (Kit 0219-0041, Perkin-Elmer Instruments, Norwalk, CT) were used. The 
mass of the empty sample pan was matched with that of the empty reference pan within 
±0.2 mg. Samples were heated at a ramp rate of 10 °C/min from 0 to 250 °C with a 
modulation temperature amplitude of 1 °C /60 sec for all studies. Data was analyzed 
using the TA Universal Analysis 2000 software (TA Instruments, New Castle, DE).  
 
4.3.8 Fourier Transform Infrared Spectroscopy (FTIR) 
ITZ, HPβCD, physical mixture powders, and the lyophilized HPβCD-ITZ dry 
powder were analyzed by FTIR to evaluate potential interactions. The samples were 
prepared by weighing approximately 4 mg of the material for analysis, homogenously 
dispersing in dried KBr of about 300 mg using a mortar and pestle, and compressing the 
powder under vacuum with a compression force of 10 tons using a 13 mm diameter 
round flat face punch for three minutes to produce a pellet compacts. The sample was 
placed in the IR light path and the IR spectra were recorded using a Thermo Mattson 
Infinity Gold FTIR with Spectra-Tech Thermal ARK module from 400 to 4000 cm-1 in 
transmission mode equipped with a KBr beamsplitter and DTGS detector having a 
resolution of 1 cm-1.   
 
4.3.9 X-ray Photoelectron Spectroscopy (XPS) 
XPS analysis was performed on the lyophilized powder comprised of 
HPβCD/ITZ inclusion complexes sampled at 1, 24 and 48 hr after dispersion, as well as 
physical mixture in order to verify the amount of ITZ present on the powder surfaces. 
The XPS measurements were conducted with an AXIS HS photoelectron spectrometer 
(Kratos Analytical, UK) equipped with a monochromated Al Kα x-ray source (hν = 
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1486.6 eV) operating at 10 kV and 15 mA (150 W). The vacuum in the sample chamber 
was maintained below 10-7 torr during analysis. The analysis area was approximately      
1 mm2. For each sample, a take-off angle of the photoelectrons perpendicular to the 
sample holder was used throughout. The data for the atomic surface composition were 
converted into molecular surface composition under the assumptions that all molecular 
species on the surface are present in “patches” with a depth of at least the depth of 
analysis (~5 nm for the powders), and the surface can be regarded as linear combination 
of the different molecular species.  
 
4.3.10 Aerosol Particle Size Analysis Using a Cascade Impactor  
The colloidal dispersion of URF-ITZ powder was prepared for nebulization by 
dispersing the powder in purified water using ultrasonication in an ice bath. An aliquot  
(5 mL) of the URF-ITZ colloidal dispersion and HPβCD-ITZ aqueous solution were 
nebulized using an Aeroneb® Professional micropump nebulizer (Nektar Therapeutics, 
San Carlos, CA) with an air flow rate of 28.3 L/min. The characterization of aerodynamic 
droplet size distribution was conducted according to the guidelines in USP 30 Section 
601 [34].  
 
Aerodynamic droplet size distributions were determined using a USP Apparatus 1 
non-viable eight-stage cascade impactor (Thermo-Anderson, Symrna, GA) with a spacer 
to quantify total emitted dose (TED) from the nebulizer output, mass median 
aerodynamic diameter (MMAD), geometric standard deviation (GSD), and percentage 
fine particle fraction (FPF; defined as the percentage of droplets with an aerodynamic 
diameter less than 4.7 μm). Fiberglass filters (81 mm diameter) (ThermoFisher Scientific, 
Franklin, MA) were set atop each impactor plate to absorb the aerosolized suspensions 
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and prevent overload of the plates. Each stage was rinsed with a known volume of the 
washing solution (acetonitrial/water=70/30, v/v). Each filter was placed in a separate 
container with a known volume of the washing solution and sonicated for 30 min to 
dissolve ITZ. Samples were filtered using 0.2 μm GHP Acrodisc syringe filters prior to 
quantification of drug contents using HPLC. 
 
4.3.11 Single-dose Pulmonary Administration to Mice  
Male outbred ICR (Institute for Cancer Research) mice (Harlan Sprague Dawley, 
Inc., Indianapolis, IN) weighing 25–28 g were acclimated in a whole-body dosing 
chamber as previously described [26] for 20 min/day for 2 days prior to dosing. This 
restraint-free chamber was designed to hold up to 14 mice. An Aeroneb® Professional 
micropump nebulizer was fitted at the inlet of the chamber, and the aerosols were 
delivered through the inlet into the chamber with an air flow rate of 1 L/min. Nebulized 
aerosols of HPβCD-ITZ solution and URF-ITZ colloidal dispersion were inhaled by the 
mice for approximately 18 min in the whole-body dosing chamber. Following exposure 
to the aerosol cloud, six mice were euthanized by carbon dioxide narcosis at 0, 0.5, 1, 1.5, 
2, 3, 4, 6, 10, and 24 hr post dosing. Samples taken immediately upon completion of 
aerosolization were assigned to the zero time point. Blood samples were taken by cardiac 
puncture, and the lungs were collected following exsanguination. The study protocol was 
approved and conducted in accordance to the Institutional Animal Care and Use 
Committee (IACUC) guidelines at The University of Texas at Austin. Throughout the 
study the animals were maintained in accordance with the American Association for 
Accreditation of Laboratory Animal Care guidelines.  
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4.3.12 Chromatographic Analysis  
Whole blood samples were centrifuged at 3000 g for 15 min to obtain the serum. 
Serum samples and whole lungs were stored at -80°C until assayed. Lungs were thawed 
and homogenized with 1 mL of purified water using an Omni Ruptor 250 ultrasonication 
homogenizer (Omni International, Marietta, GA) with power output setting at 40 and 
pulser at 60.  
 
Calibration standards, serum, and homogenized lung samples were analyzed as 
described previously [29]. Briefly, serum samples of 250 µL were transferred to clean    
2-mL microcentrifuge tubes. To each microcentrifuge tube, 50 µL of 0.3 N barium 
hydroxide and 50 µL 0.4 N zinc sulfate heptahydrate solutions were added and vortex 
mixed for 30 sec to precipitate water-soluble proteins.  Acetonitrile (1 mL) containing 
about 500 ng/mL voriconazole as an internal standard was added to each sample followed 
by vortex mixing for 1.5 min.  Samples were then centrifuged at 3000 g for 15 min. The 
supernatant from each vial was transferred to a clean 1.5 mL centrifuge tube and dried in 
an aluminum heating block (70 °C) under a stream of nitrogen gas. The samples were 
reconstituted with 250 μL mobile phase (0.05 M phosphate buffer, pH 6.7: acetonitrile = 
38:62, v/v), vortex mixed for 1 min, and centrifuged at 6000 g for 5 min. An aliquot of 
150 µL was pipetted into HPLC vial spring inserts and analyzed using Shimadzu HPLC 
system with an Alltech InertsilTM ODS-2 5 μm, 250 × 4.6 mm, C-18 column connected to 
a C-18 guard column (5 μm, 7.5×4.6 mm) (Alltech Associates, Inc., Deerfield, IL) 
maintained at 37 °C.  The voriconazole, hydroxyitraconazole (HyITZ) and ITZ peaks 
were eluted at approximately 5.3, 8.5 and 18.2 min, respectively, at a flow rate of 1 
mL/min, injection volume of 100 μL, and an absorption wavelength of 225 nm. The limit 
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of detection and quantification for HyITZ and ITZ were 10 ng/mL and 30 ng/mL, 
respectively. 
  
4.3.13 Pharmacokinetic Analysis  
Pharmacokinetics of 24-hr lung and serum was assessed for the pulmonary 
delivery of nebulized aerosols of HPβCD-ITZ aqueous solution and URF-ITZ colloidal 
dispersion to mice. A noncompartmental model was used to determine pharmacokinetic 
profiles for the ITZ concentrations in lung tissue using WinNonlin Professional Version 
2.1 (Pharsight Corporation, Mountain View, CA). Using this method of analysis, Tmax 
and Cmax were determined directly from the empirical data; area under the plasma 
concentration-time curve (AUC) was calculated by the linear trapezoidal rule. Plots of the 
log concentration of ITZ and HyITZ in serum versus time revealed a first-order 
absorption phase and a first-order elimination phase. A one-compartmental analysis was 
therefore used. The K10 elimination rate constants were determined by linear regression of 
the points of the log-linear plasma concentration versus time curve. The K01 absorption rate 
constants were determined by residual method. The t1/2 was defined as 0.693/rate constant 
K.  
  
4.3.14 Statistical Analysis  
Drug concentrations in lung tissue and serum were presented as mean with 
standard deviation (SD) (n = 6) at each sampling time point. The data were statistically 
analyzed by one-way Analysis of Variance (ANOVA) followed by Tukey’s post hoc 
analysis using OriginPro 7.5 (OriginLab Corporation, Northampton, MA), and Microsoft 
Excel 2003. A p-value of < 0.05 was considered as statistically significant.  
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4.4 RESULTS AND DISCUSSION 
To improve the bioavailability resulting from poor water solubility, CDs and their 
derivatives have been used as a means to increase aqueous solubility. CDs are 
characteristic of a truncated cone shape with a hydrophilic exterior surface and a 
nonpolar cavity interior [35]. This structure allows CDs to form non-covalent host–guest 
dynamic inclusion complexes with drug molecules of proper sizes and polarities, leading 
to enhanced apparent aqueous solubility, dissolution rate, chemical stability, and 
bioavailability [36, 37].  
 
Having a external and internal diameters of 1.53 nm and 0.78 nm, respectively, 
βCD provides the right fit for ITZ molecule, as the cavity internal diameter is comparable 
to the dimensions of substituted phenyl groups which contribute to the lipophilicity of 
ITZ and other azoles [15]. HPβCD and SBEβCD are chemically modified βCD with 
enhanced aqueous solubility and safety profiles, and there is a vast experience of use in 
pharmaceutical applications [38]. Despite their safety profiles, pharmaceutical dosage 
forms should contain as little CD as possible. Moreover, to make an ITZ solution with 
acceptable amount of CD for nebulization, enhancement of the complexation capacity of 
the chosen CD is of practical importance. HPβCD and SBEβCD were therefore tested in 
this study to select a more efficient complexing agent for solubilizing ITZ.  
 
4.4.1 Solubility Studies and In Vitro Solution Characterization  
The phase solubility studies of ITZ in various concentrations of CDs and 
derivatives at different pHs have been extensively investigated and reported in literature 
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[39, 40]. For pulmonary delivery systems, it is crucial that the formulations are 
physiologically compatible with the lungs. Our preliminary experiments found that 
higher equilibrium solubility of ITZ can be achieved in HPβCD as compared to SBEβCD 
solutions at neutral pH conditions. This result is consistent with other reports 
investigating interactions between CDs and antifungal azoles [40, 41]. HPβCD was 
therefore chosen as the functional excipient to formulate ITZ in our study due to its 
stronger solubilizing.  
 
The viscosity of the CD-containing solution is a barrier for pulmonary 
administration by the Aeroneb® Professional micropump nebulizer. In order to aerosolize 
the ITZ-CD formulation completely within a reasonable dosing duration, it is necessary 
to find a suitable HPβCD concentration for the nebulizer. As can be seen from Figure 
4.1., viscosity of HPβCD solutions increases along with its concentrations. Greater than 
30 min and approximately 17 min were required to nebulize 5 mL of 20% and 15% w/v 
HPβCD solutions with measured viscosities of 1.40 and 1.19 cP, respectively. The 15% 
w/v HPβCD solution was selected to formulate the ITZ nebulization solution, to be 
comparable with the URF-ITZ formulation which takes about 10 min to nebulize 5 mL of 
the dispersion. 
 
The equilibrium solubility of crystalline ITZ was significantly enhanced from      
1 ng/mL  in water [6] to 0.15 mg/mL in 15% w/v HPβCD aqueous solution in this study, 
which was in agreement with the work of Brewster et al. [40]. Despite the significant 
increase of ITZ concentration in HPβCD aqueous solution, the complexation efficiency 
was low, and was limited by the allowed amount of HPβCD in this formulation. To 
further increase complexation efficiency of ITZ, amorphous pure ITZ, which has a higher 
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intrinsic solubility than its crystalline counterpart [42], was employed to make the ITZ 
inclusion complex with HPβCD. As shown in Figure 4.2., a concentration of 5.4 mg/mL 
of ITZ was achieved immediately after dispersing amorphous ITZ in 15% HPβCD 
solution, presumably due to the supersaturation rendered by the amorphous state. 
Compared to crystalline ITZ, amorphous pure ITZ brought about a 34-times increase in 
equilibrium solubility in 15% w/v HPβCD solution. An equilibrium level of 5.3 mg/mL 
was attained at 2 hr and was maintained up to 24 hr as a mixed effect of HPβCD-ITZ 
inclusion complex formation, supersaturation stabilized by HPβCD via nucleation, and 
crystal growth inhibition [43]. At 48 hr, the ITZ concentration decreased slightly to 4.6 
mg/mL, which could be attributed to precipitation of supersaturated ITZ in the system.  
 
Osmolarity is one of the important parameters to be considered for physiological 
compatibility of pulmonary formulations. Sodium chloride (NaCl) was used to adjust the 
osmolarity of HPβCD aqueous solutions. The filtered HPβCD-ITZ solution that was 
sampled at 24 hr containing 5.3 mg/mL of ITZ, 150 mg/mL of HPβCD and 0.54 mg/mL 
of NaCl was found to be isotonic with an osmolality ranging from 290 to 310 mOsm/kg 
and a measured pH of 6.8. The lung lining fluid was reported to be either isotonic or 
slightly hypotonic and slightly acidic (pH 6.9) relative to plasma [44], hence the good 
compatibility of the HPβCD-ITZ solution with the lung fluid was evident. With 
considerably high levels of dissolved ITZ and a physiological pH value, the HPβCD-ITZ 
isotonic solution was shown to be suitable for in vivo dosing as solubilized form of ITZ. 
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4.4.2 Solid State Analysis of Inclusion Complexes 
4.4.2.1 DSC 
DSC is used in pharmaceutical area to establish the identity and purity of solid-
state systems and detect interaction of the components. Incorporation of a guest molecule 
in CD cavity can cause disappearance or shifting of its melting, boiling and sublimation 
points [45]. The thermograms of the pure components, physical mixture and lyophilized 
powder of HPβCD-ITZ are presented in Figure 4.3. Micronized crystalline ITZ 
demonstrated a single, defined endotherm at 171.9 °C, corresponding to its melting point. 
The thermogram of pure HPβCD powder exhibited a broad endothermic peak between 
50-120 °C, corresponding to the dehydration of HPβCD [46], since βCD did not produce 
any peaks of interest when examined by DSC [47]. In the physical mixture, the 
characteristic melting peak of ITZ appeared at 168.3 °C but with much lower intensity 
due to the dilution by HPβCD, indicating the absence of significant drug–cyclodextrin 
interactions. For the dry powder of HPβCD-ITZ, no appreciable endothermic event 
associated with the melting of ITZ was observed, suggesting the formation of true 
inclusion complexes between ITZ molecules and HPβCD at a weight ratio of 5.3: 150 
(molar ratio of 1:12). 
 
4.4.2.2 FTIR analysis 
FTIR spectra of pure ITZ, pure HPβCD, physical mixture (ITZ: HPβCD= 5.3: 
150, weight ratio), and lyophilized dry powder of HPβCD-ITZ are presented in        
Figure 4.4. The characteristic bands of pure ITZ occurred at 3126 and 3069 cm−1 due to 
absorption of the NH2 groups; at 2962 cm−1 due to CH2 stretching and the large peak at 
1698 cm−1 due to C=O stretching. The wave numbers observed at 1609 and 1425 cm−1 
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were assigned to the C=N and C-N bonds respectively. The bands at 1510 and 1451 cm−1 
are due to C-H deformation. These characteristic bands are consistent with previous 
reports [48]. The fingerprint region (1400-600 cm−1) contains a large number of bands 
characteristic of vibration within the molecule. Changes in the FTIR spectra such as shift 
of characteristic bands, disappearance or reduction in intensity, and appearance of new 
bands might be related to possible drug-CD interaction and/or amorphization of the 
product [49].  
 
The spectral pattern of the physical mixture corresponds to the sum of the band 
positions of the FTIR spectra of both ITZ and HPβCD although the intensity of the ITZ 
bands are low due to the low weight ratio of ITZ. The results indicated no or minor 
interaction between ITZ and HPβCD molecules in the physical mixture. In contrast, the 
spectra of the dry powder of HPβCD-ITZ demonstrated complete smoothing of the ITZ 
characteristic bands that were seen in the physical mixture spectra. Additionally, 
smoothing was evident for bands situated between wave numbers of 1170-1010 cm−1 as 
compared to those of the pure HPβCD and physical mixture, indicating interactions 
occurring in the HPβCD-ITZ dry powder. 
 
4.4.2.3 XPS analysis  
XPS is a surface sensitive technique used to probe the elemental composition of 
the surfaces with an analysis depth of less than 100 Å [50]. ITZ molecule 
(C35H38Cl2N8O4) is distinguished from HPβCD molecules (empirical formula:         
C42H70-nO35(C3H7)n) present in the HPβCD/ITZ systems due to the presence of two 
chlorine atoms and eight nitrogen atoms in the ITZ molecule, which can be used as 
probing markers. As βCD has an external diameter of 1.53 nm and internal diameter of 
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0.78 nm, encapsulated ITZ in its cavity can not be detected by XPS but ITZ molecules 
situated on the outside surface can be probed by its elemental markers.  
 
The atomic concentration (%) of carbon, oxygen, nitrogen and chlorine on the 
surface of the lyophilized dry powders of HPβCD/ITZ inclusion complex sampled at 1, 
24 and 48 hr after dispersing amorphous ITZ in 15% HPβCD as well as the physical 
mixture are presented in Table 4.1. The detection of 4.99% nitrogen and 0.65% chlorine 
on the surface of the physical mixture demonstrated the presence of free ITZ molecules. 
A decrease in chlorine and nitrogen content is observed in the HPβCD/ITZ inclusion 
complex sampled at 1 hr, suggesting that considerable portion of ITZ molecules hidden 
from the surface. In the HPβCD/ITZ inclusion complexes sampled at 24 and 48 hr, 
chlorine and nitrogen were no longer quantifiable, suggesting the majority of the ITZ 
molecules in the systems were encapsulated inside the HPβCD cavities and also possibly 
within micelles formed by HPβCD aggregation [51]. XPS data provided evidence of 
interactions between ITZ and HPβCD molecules by ruling out the existence of free, 
unencapsulated ITZ molecules from the powder surface.  
 
Based on the solid state characterizations by DSC, FTIR and XPS, it can be 
concluded that in the HPβCD-ITZ solution sampled at 24 hr, the majority of ITZ 
molecules were encapsulated, forming dynamic inclusion complexes. ITZ molecules 
inside the CD cavities were in equilibrium with free ITZ molecules in the solution. The 
focus of this study is the in vivo pharmacokinetic profiles following pulmonary 
administration of solubilized ITZ molecules as compared to ITZ nanoparticles. In 
consideration of the time to attain and maintain a high concentration of ITZ in solution, 
and based on the observations from the solubility studies and solid state characterizations, 
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the filtrate sampled at 24 hr from the amorphous ITZ dispersion in 15% HPβCD isotonic 
solution (ITZ:HPβCD=5.3:150 by weight ratio) was selected as the solubilized ITZ 
solution for in vivo dosing.  
 
4.4.3 Aerodynamic Particle Size Analysis  
HPβCD-ITZ solution and URF-ITZ colloidal dispersion (equivalent to 5.3 mg/mL 
of ITZ) as depicted in Figure 4.5. were aerosolized using an Aeroneb® Professional 
micropump nebulizer. The aerodynamic particle size distributions of the nebulized 
aerosols were measured using the 8-stage Anderson cascade impactor with an air-flow 
rate of 28.3 L/min. The nebulizer produced an aqueous mist of fine droplets with sizes 
ranging between 1 and 4 µm, which falls within the optimal size range of 1-5 µm for 
effective aerosol delivery into the deep lung after inhalation [52]. The aerodynamic 
parameters of the aerosols are summarized in Table 4.2. The TED of aerosolized 
HPβCD-ITZ solution and URF-ITZ colloidal dispersion were 22.04 and 21.78 mg, 
respectively out of the total of 27 mg ITZ available for nebulization. Their corresponding 
fine particle doses were 11.58 and 11.93 mg. Fine particle dose was defined as TED × 
FPF, the amount of aerosol droplets entering the impactor that was less than 4.7 μm, 
representing the dose delivered to the deep lung. The MMAD of the aerosol droplets 
from nebulized HPβCD-ITZ solution and URF-ITZ colloidal dispersion were 3.19 and 
2.80 μm, respectively with GSD of 2.28 and 2.83, respectively, indicating their suitability 
for deep lung delivery.  
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4.4.4 Pharmacokinetic Study of Single Dose Inhalation in Mice  
The mice were exposed to the single dose aerosols of the nebulized HPβCD-ITZ 
solution and URF-ITZ colloidal dispersion (equivalent to 27 mg of ITZ total) for a 
duration of 18 and 11 min, respectively. The longer nebulization time of the HPβCD-ITZ 
solution was due to its higher viscosity. The concentration-time profile of ITZ in lung 
tissue obtained from the single dose 24-hr pharmacokinetic study is illustrated in      
Figure 4.6. Immediately upon finishing nebulization of the compositions (0 hr post 
dosing), a Cmax of 3.38±1.16 and 4.86±2.67 μg/g wet lung weight of ITZ was measured in 
lungs from the HPβCD-ITZ solution and URF-ITZ colloidal dispersion dosing groups, 
respectively. The elimination of ITZ from lungs appeared to be 2-phased with an initial 
rapid elimination/distribution phase from 0 to 4 hr with Kdistribution rate constants of 0.143 
and 0.238 hr−1 and  corresponding t1/2s of 4.87 and 2.91 hr for HPβCD-ITZ and URF-
ITZ, respectively. This was followed by slow elimination from 6 to 24 hr with Kelimination 
rate constants of 0.022 and 0.025 hr−1 and the corresponding t1/2 of 30.9 and 28.0 hr for 
HPβCD-ITZ and URF-ITZ, respectively (Table 4.3.). The fast elimination of ITZ from 
lung tissue coincided with absorption into the systemic circulation. At 24 hr post dosing, 
their corresponding ITZ levels in the lungs were 0.98±0.40 and 0.65±0.29 μg/g wet lung 
weight, respectively, probably due to slow elimination. Their AUC0–24 values were 
calculated to be 32.0 and 27.2 μg·hr/mL, respectively. The Cmax of deposited ITZ in lung 
after a single dose inhalation of nebulized HPβCD-ITZ solution and URF-ITZ colloidal 
dispersion were not statistically different, although the latter exhibited a higher mean 
value. This could partly be attributed to variation in rodent behavior within the dosing 
apparatus and breathing patterns since the two formulations demonstrated comparable 
MMADs (both within the 1- 4 μm range). 
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The drug concentration-time profiles of ITZ and its main metabolite hydroxyl-
itraconazole (HyITZ) in serum are illustrated in Figures 4.7. and 4.8., and the 
pharmacokinetic parameters of ITZ and HyITZ are listed in Table 4.4. The Cmax of ITZ 
for the HPβCD-ITZ solution and URF-ITZ colloidal dispersion dosing groups were 
0.48±0.11 and 0.55±0.084 μg/mL measured at 1.5 and 3 hr after dosing, respectively. 
Their corresponding K01 absorption and K10 elimination rate constants were 0.679 and 0.718 hr-1, 
and 0.144 and 0.168 hr-1, respectively, indicating a much faster absorption and slower 
elimination of ITZ from HPβCD-ITZ solution as compared to URF-ITZ nanoparticle 
dispersion. The corresponding AUC0–∞ values were 3.26 and 4.17 μg·hr/mL.  
 
Upon absorption into systemic circulation, ITZ is primarily metabolized in the 
liver by a large number of pathways producing more than 30 metabolites. The major 
metabolite, HyITZ, has considerable antifungal activity similar to that of ITZ and 
contributes to the overall potent antifungal properties of ITZ [53, 54]. In this study, the 
Cmax of HyITZ for HPβCD-ITZ and URF-ITZ dosing group were 0.49±0.14 and 
0.64±0.17 μg/mL at 2 and 4 hr post dosing, respectively, exhibiting a lag-time between 
30 to 60 minutes with respect to the tmax of the parent compound. The K01 and K10 rate 
constants of HyITZ in serum are very similar to those of ITZ. Their AUC0–∞ values were 
3.98 and 5.26 μg·hr/mL, respectively. HyITZ reached higher plasma concentrations than 
the parent compound, in agreement with the literature [55]. However, HyITZ levels in 
lung tissues were not quantifiable because they were below the detection limit of the 
HPLC method. This is because drug-metabolizing enzymes exist in much lower 
concentrations in the lungs than the liver and gastrointestinal tract [56]. 
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The pharmacokinetic profile of inhaled HPβCD-ITZ in the lungs and blood 
differed substantially from the findings by Tolman and coworkers [33] who administered 
a single dose (6.25 mg/mL, 5 mL) of nebulized voriconazole solubilized in SBEβCD 
solution (prepared by diluting the Vfend® I.V. aqueous solution) to mice. The rapid 
absorption of voriconazole into systemic circulation was observed with tmax values of 20 
to 30 min in plasma after completion of dosing, similar to pharmacokinetics following 
intravenous drug administration [33]. Moreover, elimination of voriconazole from lung 
tissue was relatively fast such that the drug level was undetectable after 6–8 hr while the 
plasma levels remained quantifiable for up to 24 hr post dosing. In contrast, inhalation of 
HPβCD-ITZ aerosols resulted in ITZ tmax of 1.6 hr in blood and ITZ levels in lung were 
still high at about 1 μg ITZ/g wet lung weight at 24 hr post dosing. This is a notable 
finding since both of the triazoles were solubilized in solutions of βCD derivatives and 
the in vivo experiment conditions were similar. 
 
Literature regarding the pulmonary applications of cyclodextrin in formulating 
poorly-water soluble drugs is limited, despite increasing interest in pulmonary delivery of 
therapeutics. Little has been reported about the pharmacokinetics of drugs and CDs 
following pulmonary administration. The most significant barrier to absorption of inhaled 
drug is the pulmonary epithelium [57]. Cabral Marques et al. [58] studied the absorption 
of several cyclodextrin derivatives themselves following  intratracheal instillation into 
rabbits.  Interestingly, the bioavailabilities of intratracheal instilled βCD, dimethyl-βCD 
and HPβCD were found to be as high as 66, 74 and 80%, respectively. These values were 
considerably higher than CD absorption following oral administration. The systemic 
absorption of CD molecules from the gastrointestinal tract is limited because of their 
bulkiness and hydrophilicity [59]. However, CDs can permeate the pulmonary Calu-3 
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cells, suggesting the ability of HPβCD to be absorbed into systemic circulation from the 
lungs [60]. The tmax in plasma for HPβCD was reported to be about 113 min as compared 
to 20-30 min for βCD and dimethyl-βCD, and the plasma elimination of the three CDs 
seemed to be independent of the route of administration [58]. In our study, the 
pharmacokinetic profile of nebulized HPβCD-ITZ in serum showed an initial lag phase 
prior to reaching Cmax at about 90 min and a prolonged post-peak decline such that ITZ 
levels were still detectable at 24 hr. These features were well matched with the reported 
pharmacokinetic profile of pure HPβCD following lung administration [58]. Therefore, it 
appears that the pharmacokinetics of ITZ from the inhaled HPβCD-ITZ formulation 
seemed to have been modified to follow the pharmacokinetics of HPβCD.  
 
However, the present findings contradict previous reports which had 
demonstrated the absence of influence of CD on pharmacokinetics of drugs. Previous 
researchers attempted to use HPβCD as a carrier to modify pulmonary absorption of 
small, hydrophobic molecules, with a hypothesis that inclusion of a guest molecule 
within HPβCD that can also be absorbed would present a larger entity for absorption. 
Marques et al. [58] made an HPβCD-salbutamol complex, with the intent of slowing the 
pulmonary absorption of salbutamol in rabbits. Unexpectedly, the pulmonary absorption 
of salbutamol was not significantly extended by HPβCD complexation. The authors 
suggested that drug-HPβCD complexes with larger stability constants may display 
extended absorption profiles with a decrease in the apparent rate of drug absorption. A 
subsequent study [61] employed HPβCD for delaying the absorption of rolipram and 
testosterone (with stability constants of 260 and 12 000 M-1, respectively, versus 60-70 
M-1 for salbutamol) in rats. It was also observed that HPβCD exerted little effect on 
rolipram absorption and no effect on testosterone absorption in vivo. The authors 
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suggested that rapid dissociation of the drugs from HPβCD may be occurring in vivo due 
to the potential competition of endogenous cholesterol with these drugs for the CDs.  
 
To explore the potential reasons for the discrepancy in pharmacokinetics observed 
between the above reported studies and our current work, the movement of the inhaled 
HPβCD-ITZ aerosols from deposition into alveoli to absorption into systemic circulation 
was examined mechanistically.  
 
Each droplet of the nebulized aerosol of HPβCD-ITZ contains many ITZ 
molecules predominantly encapsulated inside HPβCD as demonstrated in vitro. The 
inhaled aerosol deposited mainly in lung alveoli as characterized by their MMAD. In the 
alveoli, the nebulized droplets containing HPβCD-ITZ coalesced into the thin layer of 
lung lining fluid. Total alveolar fluid volume for mice was estimated to be 10 μL, based 
on the alveolar surface area of 680 cm2 for mice [62] as compared to a total alveolar 
surface area of 1,022,000 cm2 and average alveolar surface fluid volume of 15 mL in a 
human [56, 63]. Moreover, based on the lung drug deposition of 3.38 μg ITZ/g wet lung 
weight upon completing nebulization and an average mouse lung weight of 0.16 g, an 
estimated mass of 0.54 μg ITZ (equal to 0.1 μL of the HPβCD-ITZ solution used) was 
deposited in each mouse lung. The deposition of inhaled HPβCD-ITZ has insignificant 
influence on the volume of lung lining fluid. Therefore ITZ concentration in the lung 
lining fluid is estimated to be 54 μg/mL (i.e. 0.54 μg ITZ/10 μL total alveolar fluid 
volume), which is dramatically higher than the equilibrium solubility of ITZ of about 10 
ng/mL in simulated lung fluid as previously reported [29]. Meanwhile, the inhaled 
HPβCD-ITZ was diluted 100-times following lung deposition. HPβCD-ITZ is present as 
dynamic inclusion complexes without irreversible covalent bonds. The ITZ molecules 
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contained within the HPβCD cavities were in equilibrium with free ITZ molecules in the 
lining fluid. The major driving force for drug release from these dynamic inclusion 
complexes is simple dilution [64, 65]. Only at rare occasions when the binding stability 
constants are greater than 105 M-1, the persistence of the drug and CD interaction was 
probable despite dilution. Generally, the stability constant values are found within the 
range of 10 − 1×103 M-1 while values of 1×104 M-1 were seen occasionally. With reported 
binding stability constants of ITZ/HPβCD 1:1 complexes of 1000-2000 M-1 at pH 7 [6, 
66], dissociation of ITZ from the inclusion complexes may presumably occur easily 
owing to the significant concentration decrease of free ITZ molecules. 
 
Once ITZ was released from the host HPβCD, it followed its inherent 
pharmacokinetics and was absorbed across the mucosal membrane [67, 68]. For drugs 
with low solubility, the mass transport of the drugs across the GI tract mucosal absorption 
surface was proposed to be equal to the solubility times the permeability [69]. Applying 
this equation to lung epithelium, the systemic absorption rate of a drug deposited within 
the lungs is determined by the product of its membrane permeability (P), the available 
surface area over which it is spread (A), and the drug concentration in the fluids (C), i.e. 
absorption rate = P × A × C. The drug concentration in blood is assumed to be 
insignificant as compared to the lung concentration and the transfer from lung to blood is 
irreversible [70]. Since the inhaled aerosol droplets mainly deposited in the lung alveoli 
where the barrier is the thinnest [56],  the value for A is fixed. Since HPβCD-ITZ in the 
lung lining fluid was still effectively solubilized, solubilization was not a rate-limiting 
step any more. Thus, permeability of ITZ through lung epithelium seemed to be the factor 
controlling the rate of molecular transport. It is widely accepted that small, mildly 
hydrophobic molecules can show extremely rapid absorption kinetics from the lungs [57]. 
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Typical drug molecules with a log P value (octanol–water partition coefficient) greater 
than 1 are expected to be absorbed, with absorption half-lives (i.e., the time required for 
half of the total number of molecules deposited in the lungs to disappear from the tissue) 
of approximately 1 minute or so [71]. According to this principle, with a molecular 
weight of 349.3 and moderate lipophilicity (log P =1.8) [72], voriconazole was well 
matched with the criteria for high permeability across mucosal membranes. This may 
explain the rapid and high extent distribution of voriconazole from lung to systemic 
circulation after its delivery to the deep lung. In contrast, ITZ molecule is larger (MW: 
705.6) and has a calculated log P value of 6.2 [6] suggesting its poor permeability. 
Classified as a BCS class II drug, ITZ was deemed to have high membrane permeability. 
However, this is relative to its extremely low solubility. In the absence of poor solubility, 
permeability seems to have emerged as the primary factor that hindered drug absorption 
across the mucosal membrane. 
 
Tolman et al. [33] used an approximation of the drug partition coefficient (based 
on the lung-to-plasma ratios of Cmax and AUC0–6) with the calculated values between 1.4 - 
1.6 to explain the fast absorption and distribution of voriconazole across lung mucosal 
surfaces to systemic circulation with minimal drug retained in lung tissue. Accordingly, 
after inhalation of the nebulized aerosols of HPβCD-ITZ, the calculated partition 
coefficients for Cmax and AUC were 9.7 and 12.7, respectively, suggesting a relatively 
poor transport of ITZ from lung to systemic circulation. The calculated partition 
coefficients for the inhaled URF-ITZ colloidal dispersion were 9.9 and 7.3, respectively, 
falling into the same range. Therefore, it was apparent that the calculated partition 
coefficient of ITZ was independent of the formulations used in this study.  
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Based on the dynamic equilibrium between free ITZ and the inclusion complexes, 
there should still be a considerable portion of ITZ remaining as HPβCD-ITZ complexes 
in the lung lining fluid. It could be possible that ITZ was carried across the lung 
epithelium together with HPβCD by paracellular diffusion due to the hydrophilicity of 
HPβCD [57]. However, the apparent permeability coefficient of HPβCD is rather low, 
based on the typical measured permeabilities of molecules with similar sizes and 
hydrophilicities in lung cell culture, which range from 10-7 to 10-8 cm/s [73]. Thus, 
HPβCD-ITZ inclusion complexes may move across the lung epithelium fairly slowly. It 
is reported that the time required for HPβCD to reach the maximum plasma level was 
113 min (1.9 hr) in rabbit after intratracheal instillation [58], which approximate the ITZ 
Tmax of 1.5 hr in serum in the present study. Absorption of ITZ as HPβCD-ITZ inclusion 
complexes from lung epithelium could be one of the potential mechanisms contributing 
to the total transport of ITZ from lung to blood after inhalation of nebulized HPβCD-ITZ 
solution.  
 
In comparison, upon deposition of the inhaled aerosol droplets containing URF-
ITZ (ITZ:mannitol:lecithin=1:0.5:0.2, weight ratio) nanoparticles in the lung lining fluid, 
they underwent rapid dissolution and were able to attain and maintain high magnitude of 
supersaturation, as indicated in simulated lung fluid in vitro [29]. The rate and extent of 
dissolution, as well as permeability across mucosal membrane influenced the absorption 
rate of ITZ through the lung epithelium to reach systemic circulation. Worthy to note is 
the role of lecithin which contains mainly dipalmitoylphosphatidylcholine (DPPC), the 
primary component of endogenous human lung surfactant [74]. Besides playing an 
important role in improving the wettability of the nanoparticles containing ITZ, lecithin 
also acted as a permeation enhancer. It could induce changes in the cytoskeleton which 
 154
affect tight junctions and accelerate paracellular passages of drugs [75], resulting in 
enhanced permeation of ITZ molecules through lung epithelium into systemic circulation. 
In the present study, the higher Cmax and AUC of ITZ in serum of mice inhaled nebulized 
URF-ITZ colloidal dispersion, compared to mice inhaled HPβCD-ITZ solution, may be 
attributed to the permeation enhancement of lecithin in the URF-ITZ composition.  
 
Since ITZ in HPβCD-ITZ solution is effectively solubilized, it was immediately 
available for absorption. The elimination of the phase-to-phase transition which limited 
bioavailability [37], rendered HPβCD-ITZ about 1.3 hr faster in reaching tmax as 
compared to URF-ITZ colloidal dispersion that required a prior dissolution step of the 
nanoparticle matrices. 
 
In our previous report, where mice inhaled a nebulized URF-ITZ colloidal 
dispersion at a single dose of 100 mg ITZ equivalent (5 mL × 20 mg ITZ/mL dispersion), 
an ITZ Cmax of 21.19 μg/g wet lung weight and 1.64 μg/mL in serum was achieved [29]. 
In this study, under the identical in vivo experimental conditions, except for the reduction 
of ITZ dosage to about one-fourth of the previously used dose, very similar drug 
concentration-time curves in lung and serum were observed with Cmax values of 4.86 μg/g 
wet lung weight and 492 ng/mL, respectively. Those values were almost proportional to 
the dose reduction, suggesting non-saturable absorption of inhaled URF-ITZ colloidal 
dispersion from lung to systemic circulation over a wide concentration range. This 




An aqueous solution containing 5.3 mg/mL of ITZ in inclusion complex with 
HPβCD suitable for deep lung delivery using the Aeroneb® micropump nebulizer was 
made of amorphous ITZ without other excipients. Inhalation of nebulized aerosols of the 
aqueous ITZ solution and a nanoparticulate ITZ colloidal dispersion produced similar 
ITZ lung depositions due to comparable aerodynamic properties of the aerosols. 
Solubilized ITZ exhibited faster systemic absorption than the nanoparticulate ITZ 
colloidal dispersion due to the elimination of phase-to-phase transition that required for 
ITZ release from nanoparticulates. Permeability of ITZ across the lung epithelium 
becomes the rate-limiting factor that hindered the solubilized ITZ from achieving rapid 
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Table 4.1. XPS analysis of surface elemental content of the physical mixture, and 
lyophilized powders of HPβCD/ITZ inclusion complexes sampled at 1,  
24 and 48 hr after dispersion of amorphous ITZ in 15% (w/v) HPβCD. 
 
Tested Powder Atomic Concentration % 
 C 1s O 1s N 1s Cl 2p 
Physical Mixture 64.78 29.58 4.99 0.65 
HPβCD/ITZ Inclusion Complex-1 hr 61.92 36.98 0.98 0.12 
HPβCD/ITZ Inclusion Complex-24 hr 63.11 36.83 0.06 0 





Table 4.2. Andersen Cascade Impactor data for nebulized HPβCD-ITZ solution 
(ITZ:HPβCD = 5.3:150, weight ratio) and URF-ITZ (ITZ:mannitol:lecithin = 
1:0.5:0.2, weight ratio) colloidal dispersion (equivalent to 5.3 mg/mL of ITZ) 
using the Aeroneb® Professional micropump nebulizer with an airflow rate of 
28.3 L/min. 
 
  HPβCD-ITZ URF-ITZ 
Total Emitted dose (mg) 22.04 21.78 
Respirable Fraction# (%) 82.52 82.41 
Fine Particle Fraction* (%) 52.56 54.77 
Available Dose  (mg/min) 1.07 1.68 
Mass Median Aerodynamic Diameter (MMAD) (µm) 3.19 2.80 
Geometric Standard Deviation (GSD) 2.28 2.83 
 
# Defined as the % mass of drug in aerosol droplets < 9 µm  
* Defined as the % mass of drug in aerosol droplets <4.7µm  
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 Table 4.3. Pharmacokinetic parameters of ITZ deposited in mice lung after inhalation of 
nebulized aerosols of HPβCD-ITZ solution (ITZ: HPβCD = 5.3:150, weight 
ratio) and URF-ITZ (ITZ:mannitol:lecithin = 1:0.5:0.2, weight ratio) 
colloidal dispersion (equivalent to 5.3 mg/mL of ITZ) in a whole-body 
exposure dosing apparatus.  
   
Pharmacokinetic Parameter HPβCD-ITZ URF-ITZ 
Cmax (μg/g) 3.38±1.16 4.87±2.67 
Tmax (hr) 0 0 
Kdistribution (hr-1) 0.143 0.238 
T1/2 distribution (hr) 4.87 2.91 
Kelimination (hr-1) 0.022 0.025 
T1/2 elimination (hr) 30.9 28 







Table 4.4. Pharmacokinetic parameters of ITZ and HyITZ in mice serum after inhalation 
of nebulized aerosols of HPβCD-ITZ solution (ITZ: HPβCD = 5.3:150, 
weight ratio) and URF-ITZ (ITZ:mannitol:lecithin = 1:0.5:0.2, weight ratio) 
colloidal dispersion (equivalent to 5.3 mg/mL of ITZ) in a whole-body 
exposure dosing apparatus. 
 
  ITZ  HyITZ  
Pharmacokinetic Parameters HPβCD-ITZ URF-ITZ HPβCD-ITZ URF-ITZ 
Cmax (μg/mL)  0.48±0.11 0.55±0.084 0.49±0.14 0.64±0.17
Tmax (hr)  1.5 3.0 2.0 4.0 
K01 (/hr) 0.679 0.718 0.973 0.858 
K10 (/hr) 0.144 0.168 0.166 0.151 
T1/2 K01 (hr)  1.02 0.97 0.71 0. 81 
T1/2 K10 (hr)  4.83 4.13 4.18 4.58 
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Figure 4.2. Time-concentration profiles for crystalline and amorphous ITZ in 15% 






Figure 4.3. Differential Scanning Calorimetry (DSC) thermograms of bulk crystalline 
ITZ, bulk HPβCD, Physical Mixture (ITZ:HPβCD= 5.3:150, weight ratio), 




















Figure 4.4. Fourier transform infrared spectroscopy (FTIR) spectra of pure crystalline 
ITZ, pure HPβCD, Physical Mixture (ITZ:HPβCD= 5.3:150, weight ratio), 
















Figure 4.5. Photographs of HPβCD-ITZ solution (ITZ: HPβCD = 5.3:150, weight ratio) 
and URF-ITZ (ITZ:mannitol:lecithin = 1:0.5:0.2, weight ratio) colloidal 
dispersion (equivalent to 5.3 mg/mL of ITZ) employed for in vivo 




































Figure 4.6. Concentration-time profile of ITZ in mice lung after inhalation of nebulized 
aerosols of HPβCD-ITZ solution (ITZ: HPβCD = 5.3:150, weight ratio) and 
URF-ITZ (ITZ:mannitol:lecithin = 1:0.5:0.2, weight ratio) colloidal 
dispersion (equivalent to 5.3 mg/mL of ITZ) in a whole-body exposure 
dosing apparatus. Data are presented as mean with standard deviation (n=6) 































Figure 4.7.  Concentration-time profile of ITZ in mice serum after inhalation of nebulized 
aerosols of HPβCD-ITZ solution (ITZ: HPβCD = 5.3:150, weight ratio) 
and URF-ITZ (ITZ:mannitol:lecithin = 1:0.5:0.2, weight ratio) colloidal 
dispersion (equivalent to 5.3 mg/mL of ITZ) in a whole-body exposure 
dosing apparatus. Data are presented as mean with standard deviation (n=6) 




































Figure 4.8. Concentration-time profile of HyITZ in mice serum after inhalation of 
nebulized aerosols of HPβCD-ITZ solution (ITZ: HPβCD = 5.3:150, 
weight ratio) and URF-ITZ (ITZ:mannitol:lecithin = 1:0.5:0.2, weight 
ratio) colloidal dispersion (equivalent to 5.3 mg/mL of ITZ) in a whole-
body exposure dosing apparatus. Data are presented as mean with standard 




Appendix A: Prophylaxis Study of Inhaled Itraconazole against 
Invasive Pulmonary Aspergillosis  
 
A.1 INTRODUCTION  
The ultimate aim of developing new itraconazole (ITZ) formulation and 
alternative administration route compared to the conventional formulations is to improve 
bioavailability of drug and thereby therapeutic effect.  For treating invasive aspergillosis, 
survival in fungal infected animal model is probably the most meaningful difference can 
be shown between the control and the fungal infected group.  
 
As characterized in previous chapters, aqueous colloidal dispersion of URF-ITZ 
nanostructured aggregates (URF nanotechnology processed ITZ:mannitol:lecithin 
=1:0.5:0.2 by weight ratio) has demonstrated excellent in vitro properties for deep lung 
deliver by nebulization. Furthermore, single-dose inhalation of the nebulized aerosols of 
the URF-ITZ aqueous colloidal dispersion produced considerable lung deposition (more 
than 20 μg/g wet lung tissue) and systemic ITZ level (1.64 μg/mL) in mice [1]. Based on 
the promising pharmacokinetic profiles of the inhaled URF-ITZ and prophylaxis studies 
of previously developed pulmonary ITZ formulations [2, 3], we are therefore interested to 
see the preventing effect of inhaled URF-ITZ against invasive fungal infections on 
Aspergillus fumigatus inoculated immunosuppressed mouse model.  
 
A.2 ANIMAL MODEL  
An established murine model of invasive pulmonary aspergillosis was used as 
previously described [2, 4]. Female ICR mice (Harlan Sprague Dawley, Inc., 
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Indianapolis, IN) were immunosuppressed by intraperitoneal cyclophosphamide (250 
mg/kg) and subcutaneous cortisone acetate (250 mg/kg) two days prior to inoculation. 
Both cyclophosphamide (200 mg/kg intraperitoneal) and cortisone acetate (250 mg/kg 
subcutaneously) were re-administered on day 3 post-inoculation, and mice received 
antibiotic prophylaxis with ceftazidime 50 mg/kg/day. This study was approved by the 
Institutional Animal Care Use Committee at the University of Texas Health Science 
Center at San Antonio, and all animals were handled in accordance with the American 
Association for Accreditation of Laboratory Animal Care.  
 
For inoculation, mice were placed inside an acrylic chamber, and A. fumigatus 
conidia were introduced by aerosolizing the conidial suspension with a small particle 
nebulizer (Hudson Micro Mist, Hudson RCI, Temecula, CA) driven by compressed air 
[4]. A standard exposure time of 1 hour was used to allow for complete aerosolization of 
the conidial suspension. Starting inocula were assessed by colony forming unit (CFU) 
enumeration from mice one hour post-inoculation.  
 
A.3 ANTIFUNGAL THERAPY  
Mice were assigned to three treatment groups: inhaled nebulized aerosol of URF-
ITZ (ITZ:mannitol:lecithin=1:0.5:0.2 by weight ratio) colloidal dispersion (20 mg/mL × 
10 mL, twice daily), amphotericin B deoxycholate (1 mg/kg interperitoneally daily; 
Apothecon, Princeton, NJ), or aerosolized purified water as control in a whole-body 
exposure dosing chamber [5] using a Aeroneb® Pro micropump nebulizer with air-flow 
of 1 L/min to blow the aerosol into the chamber. Prophylaxis was begun two days prior to 
pulmonary inoculation and continued for a total of 10 days (day 7 post-inoculation). 
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Animals that appeared moribund prior to the end of the study were euthanized by 
halothane and death was recorded as occurring the next day.  
 
The prophylaxis study of inhaled URF-ITZ colloidal dispersion in fungal infected 
mice model was performed by Dr. Nathan Wiederhold in the University of Texas Health 
Science Center at San Antonio.  
 
A.4 SURVIVAL RESULTS 
The prophylaxis study results are presented in Figure A.1. URF-ITZ dosing group 
showed similar survival rate compared to mice dosed amphotericin B in both short term 
(8 days) and long term (12 days). However, both of the antifungal treatment groups 
demonstrated lower percent survival than the control group which inhaled nebulized 
water. The 8 days survival on therapy in control group was 75%, which may indicate the 
fungal infection mouse model was not successful. The URF-ITZ and amphotericin B 
administration groups were 55 and 50%, respectively. This may imply possible toxic side 
effects associated with the antifungal agents used in this study. Further investigation of 
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Figure A.1. Survival curves for immunosuppressed mice that inhaled nebulized aerosol of 
URF-ITZ (ITZ:mannitol:lecithin=1:0.5:0.2 by weight ratio) colloidal 
dispersion (20 mg/mL × 10 mL, twice daily), amphotericin B deoxycholate, 
or control (aerosolized purified water) and challenged by pulmonary 




Appendix B: Study of Interaction of Cyclophosphamide and Inhaled 
Itraconazole 
 
B.1 INTRODUCTION  
Aqueous colloidal dispersion of URF-ITZ (URF nanotechnology processed 
ITZ:mannitol:lecithin=1:0.5:0.2) has demonstrated excellent in vitro properties for deep 
lung deliver by nebulization. Furthermore, single-dose inhalation of the nebulized 
aerosols of the URF-ITZ aqueous colloidal dispersion produced considerable lung 
deposition and systemic itraconazole (ITZ) level (1.64 μg/mL) in mice [1]. Because of 
the promising pharmacokinetic profiles of the inhaled URF-ITZ, prophylaxis studies of 
inhaled URF-ITZ on fungi inoculated immunosuppressed mice were conducted in the 
University of Texas Health Science Center at San Antonio. However, the prophylaxis 
study showed no significant improvement of the survival rate in mice administered ITZ 
compared to the control. 
 
To establish the immunosuppressed mouse model, a combination of cortisone 
acetate and cyclophosphamide (CY) were employed. CY is a phosphoramide form of 
nitrogen mustard commonly used in cancer treatment. In addition, its toxicity to 
lymphocytes has made it an important immunosuppresent agent in hematopoietic stem 
cell transplant therapies [2], and more recently in treatment of inflammatory conditions 
such as systemic lupus erythematosis and rheumatoid arthritis, etc. [3]. The parent drug 
itself is not cytotoxic. It must be activated by hepatic cytochrome P450 (CYP) enzymes 
and undergoes three metabolic pathways: (1) urinary elimination as unchanged CY, 
which account for about 25-30% of the drug metabolism; (2) detoxification via CYP 
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3A4/5 to dechloroethyl-cyclophosphamide (DCCY), which account for about 5-10%; and 
(3) the major metabolic pathway---activation via CYP 2A6, 2B6, 3A4, 3A5, 2C9, 2C18, 
and 2C19 to 4-hydroxycyclophosphamide (HCY) [4]. HCY is then converted by beta-
elimination to toxins acrolein, which is primarily responsible for urothelial toxicity, and 
phosphoramide mustard (PM), responsible for antineoplastic activity. Other metabolites 
include o-carboxyethyl-phosphoramide mustard (CEPM), 4-keto-cyclophosphamide 
(ketoCY), and hydroxypropyl-phosphoramide mustard (HPPM) [3, 5]. The schematic of 
CY metabolic pathways is shown in Figure B.1. 
 
Antifungal azole drugs function by inhibiting the fungal CYP enzyme 14-α-sterol-
demethylase which is involved in cell membrane biosynthesis [6]. ITZ is a known potent 
inhibitor of CYP 3A4 and has many clinically significant drug interactions associated 
with this enzyme inhibition [7]; whereas fluconazole is a relatively potent inhibitor of 
CYP 2C9 [8]. 
Published toxicity data from a randomized trial comparing fluconazole with ITZ 
as antifungal prophylaxis in hematopoietic cell transplant recipients demonstrated a 
disequilibrium in CY metabolites, and renal and hepatic toxicities in patients who 
received the azole drugs concurrent with CY-containing regimens [9, 10]. 
Coadministration of high-dose fluconazole (400 mg daily) with CY was associated with 
greater exposure to CY and DCCY, whereas ITZ (2.5 mg/kg 3 times daily) was 
associated with greater exposure to HCY, ketoCY, and CEPM [9]. In addition, concurrent 
fluconazole was associated with less renal and hepatic toxicity, and a trend to improved 
survival at day 20 [11]. Recipients of ITZ demonstrated higher exposure to toxic 
metabolites than recipients of fluconazole, suggesting differential inhibition of hepatic 
CYP450 isoenzymes can affect CY metabolism and conditioning-related toxicities [12]. 
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We therefore suspect that drug interaction between CY and ITZ occurred in the 
prophylaxis studies, and the resultant toxic metabolites lead to the unexpected lower 
survival rate of the fungal infected immunosuppressed mice with ITZ therapy. This study 
is designed to confirm this hypothesis.  
 
To quantify the metabolites of CY, LC-MS need to be used. However, HCY and 
AldoCY are very unstable (t1/2 = ~4 min). Moreover, PM and acrolein are toxic and 
unstable; they might bind to protein or react with tissue, hard to extract out, and easily 
decompose [13, 14]. CEPM is the only chemically stable major CY metabolite formed 
between the activation of CY to HCY and the ultimate formation of glutathione 
conjugates of acrolein and PM. ITZ can inhibit P4503A4, then the inactivation pathway 
product DCCY may be decrease [15]. Based on these, CEMP and DCCY were selected 
as markers to monitor the change of CY toxic metabolites with concomitant ITZ therapy.   
 
B.2 MATERIALS AND METHODS  
B.2.1 Materials 
CY is produced by Baxter Health Corporation (Deerfield, IL). CEPM and DCCY 
were purchased from Eno Research Chemicals and Custom Synthesis Eno Research & 
Consulting Services, LLC (Hillsborough, NC). Cortisone acetate was purchased from 
Sigma. Ceftazidime is manufactured by Sandoz GmbH for Hospira Worldwide Inc., 
(Lake Forest, IL). ITZ was purchased from Hawkins Chemical (Minneapolis, MN). 
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B.2.2 In vivo study design  
The immunosuppressed mouse model will be established as follows. Mice 
(weighing between 18 - 22 g, female) with access to sterile food and water ad libitum, 
will be rendered immunosuppressed by intraperitoneal CY (250 mg/kg) and subcutaneous 
cortisone acetate (250 mg/kg) on Day-1. Both CY (200 mg/kg intraperitoneally) and 
cortisone acetate (250 mg/kg subcutaneously) were re-administered on Day-6. The mice 
will inhale ITZ aerosols from Day-1 for 10 days, 100 mg ITZ equivalent in 5 mL × 2 
each time, twice per day.  The immunosuppressed mice need housing in the barrier 
facility to ensure the health and safety. In addition, mice will receive a daily dose of the 
antibiotic ceftazidime (50 mg/kg) subcutaneously (0.2 mL/mouse) to prevent bacteria 
infection from Day-1. The mice will be divided into 5 groups as following. 
Group 1: Aerosolized ITZ + Cyclophosphamide & cortisone acetate (same 
immunosuppression regimen used in the prophylaxis study)  
Group 2: Aerosolized ITZ + cortisone acetate (no Cyclophosphamide)  
Group 3: Cyclophosphamide + cortisone acetate (no aerosolized ITZ)  
Group 4: Cortisone acetate alone 
Group 5: Normal mice without any treatment 
The treatment of the mice listed schematically in Figure B.2. 
 
B.2.3 Sampling of blood 
Blood samples will be taken by cardiac puncture and place into tubes containing 
EDTA (ethylenediaminetetraacetic acid), mixed and centrifuged immediately after 




B.2.4 Analysis of CY metabolites by using mass spectrometry-HPLC (LC-MS)   
The Applied Biosystems 4000 Q Trap LC-MS/MS system with ESI, APCI and 
nanospray sources coupled with Shimadzu LC-20AD HPLC system (Shimadzu, 
Columbia, MD) located in the Analytical Instrumentation Facility Core (PHR 1.110) at 
The University of Texas at Austin was employed for quantitation of CY stable 
metabolites DCCY and CEPM, as well as ITZ. The LC-MS/MS method development 
was performed by Dr. Herng-Hsiang Lo in the CRED Analytical Instrumentation Facility 
Core supported by NIEHS center grant ES07784.  
 
B.2.5 Bioassays of mice plasma and organ histology  
Plasma creatinine, BUN, bilirubin (total and indirect), alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), Alkaline phosphatase (ALP) will be analyzed 
by IDEXX for toxicity analysis. 
Livers and kidneys will be collected and fixed in formaldehyde; Tissue slices may 
be prepared by IDEXX when necessary for histology study. 
 
B.3 RESULTS  
LC-MS methods for determining the amount of ITZ, DCCY and CEPM have 
been established by Dr. Stony Lo. The standard curves are presented in Figures B.3, B.4, 
and B.5. For ITZ, there is a good linearity in the range of 50-1000 picogram (pg) can be 
detected by the LC-MS system used. DCCY and CEPM demonstrated good linearity in 





1. W. Yang, J. Tam, D.A. Miller, J. Zhou, J.T. McConville, K.P. Johnston, and R.O. 
Williams. High bioavailability from nebulized itraconazole nanoparticle 
dispersions with biocompatible stabilizers. Int J Pharm. 361:177-188 (2008). 
 
2. M.E. de Jonge, A.D.R. Huitema, S. Rodenhuis, and J.H. Beijnen. Clinical 
pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 44:1135-1164 
(2005). 
 
3. T.F. Kalhorn, S. Ren, W.N. Howald, R.F. Lawrence, and J.T. Slattery. Analysis of 
cyclophosphamide and five metabolites from human plasma using liquid 
chromatography-mass spectrometry and gas chromatography-nitrogen-
phosphorus detection. J Chromatogr B. 732:287-298 (1999). 
 
4. S.M. Yule, D. Walker, M. Cole, L. McSorley, S. Cholerton, A.K. Daly, A.D.J. 
Pearson, and A.V. Boddy. The effect of fluconazole on cyclophosphamide 
metabolism in children. Drug Metab Dispos. 27:417-421 (1999). 
 
5. G.J. Pass, D. Carrie, N. Boylan, S. Lorimore, E. Wright, B. Houston, C.J. 
Henderson, and C.R. Wolf. Role of hepatic cytochrome P450s in the 
pharmacokinetics and toxicity of cyclophosphamide: Studies with the hepatic 
cytochrome P450 reductase null mouse. Cancer Res. 65:4211-4217 (2005). 
 
6. G.P. Bodey. Azole Antifungal Agents. Clin Infect Dis. 14:S161-S169 (1992). 
 
7. D.E. Colburn, F.J. Giles, D. Oladovich, and J.A. Smith. In vitro evaluation of 
cytochrome P450-mediated drug interactions between cytarabine, idarubicin, 
itraconazole and caspofungin. Hematology. 9:217-221 (2004). 
 
8. T. Kantola, J.T. Backman, M. Niemi, K.T. Kivisto, and P.J. Neuvonen. Effect of 
fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin 
Pharmacol. 56:225-229 (2000). 
 
9. K.A. Marr, W. Leisenring, F. Crippa, J.T. Slattery, L. Corey, M. Boeckh, and 
G.B. McDonald. Cyclophosphamide metabolism is affected by azole antifungals. 
Blood. 103:1557-1559 (2004). 
 
10. I. Oren, J.M. Rowe, H. Sprecher, A. Tamir, N. Benyamini, L. Akria, A. Gorelik, 
N. Dally, T. Zuckerman, N. Haddad, R. Fineman, and E.J. Dann. A prospective 
randomized trial of itraconazole vs fluconazole for the prevention of fungal 
infections in patients with acute leukemia and hematopoietic stem cell transplant 
recipients. Bone Marrow Transplantation. 38:127-134 (2006). 
 186
 
11. A. Upton, J.S. McCune, K.A. Kirby, W. Leisenring, G. McDonald, A. Batchelder, 
and K.A. Marr. Fluconazole coadministration concurrent with cyclophosphamide 
conditioning may reduce regimen-related toxicity postmyeloablative 
hematopoietic cell transplantation. Biol Blood Marrow Transplant. 13:760-764 
(2007). 
 
12. G.B. McDonald, J.T. Slattery, M.E. Bouvier, S. Ren, A.L. Batchelder, T.F. 
Kalhorn, H.G. Schoch, C. Anasetti, and T. Gooley. Cyclophosphamide 
metabolism, liver toxicity, and mortality following hematopoietic stem cell 
transplantation. Blood. 101:2043-2048 (2003). 
 
13. S. Ren, T.F. Kalhorn, G.B. McDonald, C. Anasetti, F.R. Appelbaum, and J.T. 
Slattery. Pharmacokinetics of cyclophosphamide and its metabolites in bone 
marrow transplantation patients. Clin Pharmacol Ther. 64:289-301 (1998). 
 
14. U. Schuler, P. Waidelich, H. Kolb, T. Wagner, and G. Ehninger. 
Pharmacokinetics and Metabolism of Cyclophosphamide Administered after 
Total-Body Irradiation of Bone-Marrow Transplant Recipients. Eur J Clin 
Pharmacol. 40:521-523 (1991). 
 
15. L. Yuand D.J. Waxman. Role of cytochrome P450 in oxazaphosphorine 
metabolism - Deactivation via N-dechloroethylation and activation via 4-
hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450. Drug 







Figure B.1. Partial metabolic pathways of cyclophosphamide (CY). Chloroacetaldehyde 
(CAA), acrolein, and phosphoramide mustard (PM) are cytotoxins, but 
acrolein and PM are the major toxins because of the abundance of their 
formation. HCY (4-hydroxy-cyclophosphamide) is formed primarily in the 
liver but circulates in blood, entering cells as its tautomer 
aldocyclophosphamide (AldoCY). Acrolein and PM are formed from 
AldoCY when it decomposes through beta-elimination. Other metabolites 
include o-carboxyethylphosphoramide mustard (CEPM), deschloroethyl-
cyclophosphamide (DCCY), 4-ketocyclophosphamide (KetoCY), 







Figure B.2. Flowchart of timeline for the animal experiment 
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ITZ standard curve (50-1000 pg)




























DCCY standard curve (100-2000 pg)



























CEPM standard curve (50-1000 pg)



































Appendix C: Detection Recrystallization of Amorphous Formulation by 
Transmission Electron Microscopy 
 
C.1 INTRODUCTION  
Amorphous formulations have been developed in our laboratory to increase the 
aqueous solubility of poorly water-soluble drugs (i.e. itraconazole (ITZ)), thereby 
enhance the bioavailability which is limited by the low aqueous solubility [1, 2]. Due to 
the metastable character of amorphous form, it may automatically transfer to lower 
energy level of crystalline form during storage. Because of the instability of amorphous 
state, the supposed improvement of dissolution rate and extent will be affected. 
Conventionally, powder X-ray diffraction (XRD), differential scanning calorimetry 
(DSC) and dissolution test can be used to detect recrystallization of amorphous 
pharmaceutical products. However, they all have limitations in detecting low percentage 
of morphological change. It is generally accepted that only when the content of crystal is 
higher than 5%, it can be differiented by XRD [3]. For the nanomaterials, the sensitivity 
is even lower, due to the weaker diffraction by the smaller particles of crystal. DSC is 
relatively more sensitive, it can quantify the amount of recrystallized material based on 
the energy change in a thermal event. However, it is too complicated to predict for 
systems with more than two components. 
 
Solid state NMR can determine molecular structure and Intermolecular packing, 
therefore has been reported to use to monitor recrystallization. However, it has not been 
reported to detect the recrystallization of pharmaceutical amorphous nanomaterials. The 
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application in detecting small amount of crystal in amorphous nanomaterials will be 
another research focus.  
 
With advancements in spatial and temporal resolution, instruments such as 
transmission electron microscopes (TEM), scanning transmission electron microscopes 
(STEM) have been developed with the ability to observe the evolution of material 
microstructure and properties [4]. We therefore explored the application of TEM in 
detecting small amount of recrystallization of an amorphous nano-structured aggregate of 
ITZ made by URF technology (i.e. URF-ITZ). 
              
C.2 METHODS 




The crystallinity of freshly made URF-ITZ powder and URF-ITZ powder stored 
for 12-month was examined using wide angle XRD as described in previous chapters. 
 
C.2.2 TEM 
The freshly made URF-ITZ powder and URF-ITZ powder stored for 6-month 
were examined using TEM. The dry sample powder was placed on a Holey Carbon 
Support Film with 200 Mesh Copper Grids (Jed Pella, Inc., Redding, CA) and viewing on 
a JEOL 2010F transmission electron microscope (JEOL USA, Inc., Peabody, MA). 
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The TEM images were taken by Dr. Paulo Ferreira in the Materials Science and 
Engineering Program at The University of Texas at Austin.  
 
C.3 RESULTS  
C.3.1 XRD profiles 
From the XRD patterns shown in Figure C.1., the freshly prepared URF-ITZ 
powder exhibited broad, diffuse haloes in absence of the characteristic crystalline peaks 
of ITZ and mannitol, indicating its amorphous nature [5]. The URF-ITZ powder that 
stored for 6 months also demonstrated no appreciable characteristic crystalline peaks, 
suggesting its amorphousness.  
 
C.3.2 TEM in detecting recrystallization 
The TEM image in Figure C.2. illustrated a disordered mass of the freshly 
prepared URF-ITZ powder, indicating its complete amorphous state. In contrast, for the 
URF-ITZ powder that stored for 6 months as shown in Figure C.3., some areas at the 
edge of the powder displayed ordered morphology. Within the blue circle, regular crystal 
plates can be seen, compared to the disordered area within the red frame, indicating 
recrystallization at a few nm level. TEM can “see” the morphological difference at few 
nm. Compared to XRD and other techniques, TEM is highly sensitive to detect trace 
amount of recrystallization of amorphous product.  
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Figure C.1. XRD patterns of Bulk ITZ, URF-ITZ powder freshly prepared, URF-ITZ 




























Appendix D: scanning Electron Microscopy images of lyophilized dry 
powders of itraconazole formulations 
 
 
D.1 INTRODUCTION  
 
To make biocompatible and biodegradable ITZ nanoparticle formulations for pulmonary 
delivery, various sugars, sugar alcohols, bovine serum albumin (BSA), lecithin and 
polysorbate 20 (Tween 20) were tested with different weight ratios. ITZ and excipients 
were first dissolved in a mixed solvent; the formed solution was then applied to URF 
process, lyophilized to obtain dry powders. The samples were mounted onto an aluminum 
stage using conductive carbon tape. Samples were coated using a model K575 sputter 
coater (Emitech Products, Inc., Houston, TX) with gold/palladium for 20 sec in a high 
vacuum evaporator. Scanning Electron Microscopy (SEM) was performed using a 
Hitachi S-4500 field emission scanning electron microscope (Hitachi High-Technologies 
Corp., Tokyo, Japan) operating at an accelerating voltage of 10-15 kV. SEM images are 























Figure D.4. SEM images of URF processed dry powder of 
ITZ/BSA/Lecithin=1/0.063/0.2 (w/w/w). 
 





































Figure D.10. SEM images of URF processed dry powder of 
ITZ/Trehalose/Lecithin=1/0.5/0.1 (w/w/w). 
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Figure D.13. SEM images of URF processed dry powder of 
ITZ/Xylitol/Lecithin=1/0.3/0.1 (w/w/w). 
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Figure D.14. SEM images of URF processed dry powder of 
ITZ/Erythritol/Tween20=1/5/0.0038 (w/w/w). 
 
Note: the critical micelle concentration (CMC) of Tween 20 is 7.6×10-5 g/mL. When the 
powder dispersed into water to form a dispersion of 20 mg ITZ/mL equivalent, 







Figure D.15. SEM images of URF processed dry powder of 
ITZ/Glucose/Tween20=1/5/0.0038 (w/w/w). 
 
Note: the critical micelle concentration (CMC) of Tween 20 is 7.6×10-5 g/mL. When the 
powder dispersed into water to form a dispersion of 20 mg ITZ/mL equivalent, 





Figure D.16. SEM images of URF processed dry powder of 
ITZ/Lactose/Tween20=1/5/0.0038 (w/w/w). 
 
Note: the critical micelle concentration (CMC) of Tween 20 is 7.6×10-5 g/mL. When the 
powder dispersed into water to form a dispersion of 20 mg ITZ/mL equivalent, 
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